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Summary 
Myosins are molecular nanomachines that produce mechanical force from ATP 
hydrolysis by cyclically interacting with actin filaments. They are implicated in wide 
variety of diseases such as cancer, loss of neurosensory functions, nephritis, and 
familial hypertrophic cardiomyopathy. In this thesis, small molecule effectors were 
used to elucidate the molecular mechanisms underlying the function of disease-
related myosin motors such as human nonmuscle myosin-2C and class-1 myosins 
and myosin-14 from apicomplexan parasites. X-ray crystallographic approaches 
were used to determine the first structure of human nonmuscle myosin-2.  
 
The natural compound pentachloropseudilin (PClP) was identified as a reversible 
and allosteric inhibitor of myosin ATPase and motor activities. In mammalian cells, 
PClP selectively inhibits myosin-1c function. To elucidate the structural basis for 
PClP-induced allosteric coupling and isoform-specific differences in the inhibitory 
potency of the compound, a multifaceted approach combining assays probing 
myosin kinetics and motor function, X-ray crystallography, and in silico modeling 
studies was used. The results indicate that allosteric inhibition by PClP is mediated 
by the combined effects of global changes in protein dynamics and direct 
communication between the catalytic and allosteric sites via a cascade of 
conformational changes along a conserved communication pathway.  
Ammosamides, another class of natural compounds produced by marine 
microorganisms, were used for the structural dissection of allosteric inhibition of 
myosin. Crystal structures of myosin motor domains in complex with ammosamides 
revealed two allosteric binding sites. The first site is identical to the ‘pseudilin-binding’ 
pocket. The second one is a novel-binding site near the helix-loop-helix region. Both 
binding sites undergo no major conformational changes upon ammosamide binding.  
Work targeted at the structural and functional characterization of human nonmuscle 
myosin-2 isoforms led to determination of the crystal structure of the nonmuscle 
myosin-2c motor domain in the pre-power stroke state. The structure was solved to a 
resolution of 2.25 Å. Dissection of the structure provides novel insights about the 
molecular mechanisms underlying allosteric coupling in the myosin motor domain, 
which were further extended by the detailed analysis of nonmuscle myosin-2A 
mutant A454S. 
 
Homology modeling of Toxoplasma MHC-MLC complexes showed that 
TgMLC1:MyoA and TgMLC2:MyoD form tight clamp like structures. Special features 
in both the light and heavy chains contribute to the compactness and uniqueness of 
the MLC-MHC interface. These structural features of the MLC-MHC interface make it 
an attractive drug target for the development of anti-apicomplexan drugs.  
Key words:  
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Zusammenfassung 
Myosine sind molekulare Nanomaschinen, welche die Energie der ATP-Hydrolyse in 
mechanische Kraft umsetzen, indem sie zyklisch mit Aktinfilamenten interagieren. Myosine 
sind an der Entstehung einer Vielzahl von Krankheiten, beispielsweise Krebs, Nephritis und 
hypertropher Kardiomyopathie beteiligt. In der vorliegenden Arbeit wurden niedermolekulare 
Effektoren eingesetzt, um die molekularen Mechanismen von krankheitsrelevanten Myosin 
Motoren, wie beispielweise nichtmuskulärem Myosin-2 sowie Myosinen der Klasse-1 des 
Menschen und des Myosins-14 von Apicomplexa Parasiten zu analysieren. In diesem 
Zusammenhang wurde mittels Röntgenstrukturanalyse die erste Struktur eines humanen 
Myosins, des nichtmuskulären Myosins-2C, bestimmt.  
Der Naturstoff Pentachloropseudilin (PClP) wurde als reversibler, allosterischer Inhibitor der 
Myosin ATPase und Motoraktivität identifiziert. In Säugerzellen konnte gezeigt werden, dass 
PClP selektiv die Funktion des Myosins-1c inhibiert. Um die strukturelle Grundlage der PClP-
induzierten allosterischen Mechanismen und isoform spezifischen Unterscheide in der 
inhibitorischen Aktivität zu erforschen, wurde eine Kombination aus direkt funktionalen, 
kristallographischen und in silico Modeling Techniken eingesetzt. Die Ergebnisse dieser 
Studien deuten darauf hin, dass die allosterische Inhibition durch PClP aus einer 
Kombination von globalen Veränderungen in der Proteindynamik sowie der direkten 
Kommunikation zwischen katalytischem und allosterischem Zentrum, vermittelt durch eine 
Kaskade aus Konformationsänderungen entlang eines konservierten Kommunikationswegs, 
entsteht.  
 
Ammosamide, eine Naturstoffklasse produziert durch marine Mikroorganismen, wurden für 
die strukturelle Analyse der allosterischen Inhibition von Myosin eingesetzt. Die 
Kristallstrukturen von Myosin-Motordomänen im Komplex mit Ammosamiden zeigen zwei 
allosterische Bindungsstellen. Eine dieser Bindungsstellen ist die “Pseudilin-Bindungsstelle” 
während die zweite eine bisher unbekannte Bindungsstelle in räumlicher Nähe der Helix-
Schleife-Helix Region darstellt. Beide Bindungsstellen zeigen keine prominenten 
Ammosamid-induzierten Konformationsänderungen im Proteinrückgrat. 
Studien zur strukturellen und funktionalen Charakterisierung von Isoformen des humanen 
nichtmuskulären Myosins-2 resultierten in der Bestimmung der ersten Kristallstruktur der 
Motordomäne des humanen nichtmuskulären Myosins-2C im pre-power stroke Zustand mit 
einer Auflösung von 2.25 Å. Die Strukturanalyse gibt neue Einsichten in die Allosterie der 
Myosin-Motordomäne, welche durch die funktionale Analyse des nichtmuskulären Myosins-
2A und dessen Mutante A454S erweitert wurde.  
Homologiemodellierung von Toxoplasma MHC-MLC zeigte, dass die Komplexe 
TgMLC1:MyoA und TgMLC2:MyoD klammerartige Strukturen ausbilden. Ausgeprägte 
Merkmale sowohl in den leichten Ketten als auch der schweren Kette tragen zur 
Kompaktheit sowie der Spezifität der MLC-MHC Kontaktregion bei. Niedermolekulare 
Verbindungen können in diesem Kontext neue Einblicke in die Strukturdynamik von 
molekularen Motoren und damit in die Funktionsweise und molekulare Kopplung 
ermöglichen. Die einzigartige Zusammensetzung der engen MLC-MHC Kontaktfläche macht 
diese zu einer attraktiven Zielstruktur für die Entwicklung von Anti-Apicomplexa Wirkstoffen. 
Schlüsselwörter: 
Myosine, Allosterie, und energetische Kopplung  
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1. INTRODUCTION 
1.1 Molecular Motors 
Various forms of motion in the cell are driven by molecular motors, which convert 
the chemical energy of nucleoside triphosphate (NTP) hydrolysis into mechanical 
force (Bourne et al, 1991; Lymn & Taylor, 1971). Most forms of directed 
movement are powered by cytoskeletal molecular motors from the dynein, 
kinesin and myosin superfamilies (Vale, 2003) (Figure 1.1). Members of the 
myosin superfamily can traffic towards the plus-end or the minus-end of actin 
filaments. Kinesins move in the plus or minus-end direction of microtubule tracks, 
and all dyneins move to the minus-end of microtubule tracks (Kolomeisky & 
Fisher, 2007).  
The multitude of cellular functions driven by molecular motors is possible 
because the structure and regulation of the particular motors in each family can 
vary considerably, despite strong similarities in their catalytic cores (Veigel & 
Schmidt, 2011). It is therefore not surprising that defects in motor-dependent 
transport are associated with a wide range of diseases, including 
neurodegeneration, tumorigenesis and developmental defects (Afflitto & Inchiosa, 
1979; Hirokawa et al, 2009). Basic principles of motor design and mechanism 
have been derived, and an understanding of their complex cellular roles is 
emerging rapidly (Schliwa & Woehlke, 2003).  
Studies on the eukaryote-specific molecular motors and their diversification 
within the cytoskeleton have proved to be particularly useful for understanding 
phylogenetic patterns, domain evolution and functional traits. Gene families with 
numerous paralogues, such as myosins, are often considered unfavorable for 
rebuilding ancient evolutionary relationships because of their very complexity. 
However, Richards et al. has shown that domain architecture of myosins is one 
of the criteria for sufficient taxon sampling and reliable mapping of ancient 
molecular motors evolution (Richards & Cavalier-Smith, 2005). 
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Figure 1.1: Overview of selected cytoskeletal motor proteins. The motor catalytic domains are 
displayed in blue, mechanical amplifiers in light blue, and tail domains implicated in cargo 
attachment are shown in purple. Tightly associated motor subunits (light chains) are shown in 
green. This figure is adapted from Vale R. D, Cell (Vale, 2003). 
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1.2 Myosin Super Family 
Myosins are molecular nanomachines that produce mechanical force from ATP 
hydrolysis by cyclically interacting with actin filaments (Geeves et al, 2005). As 
ATPases, they convert the free energy obtained from ATP hydrolysis into 
mechanical work and force production, thereby carrying out essential functions 
ranging from the movement of entire cells to intracellular structural dynamics and 
transport, muscle contraction, and mechanical signal transduction (Mermall et al, 
1998; Veigel & Schmidt, 2011; von Delius et al, 2010). 
The first myosin found was the double-headed skeletal muscle myosin, which 
was discovered in the 19th century (Kühne, 1864). A hundred years after the 
discovery of muscle myosin, Pollard and Korn discovered myosins consisting of a 
single myosin heavy chain in Acanthamoeba (Pollard & Korn, 1973). Following 
their discovery, Korn and colleagues termed these myosins class-1 myosins in 
contrast to the conventional myosins comprising two myosin heavy chains, each 
associated with two light chains (Hammer et al, 1986). However, it soon became 
clear that this is not a valid basis for the classification of the members of the 
myosin superfamily. Therefore, class numbers were assigned later in the order in 
which the novel myosin sequences were first described in the scientific literature 
(Mooseker & Foth, 2008).  
All myosin classes observed today are likely to be derived from a single 
progenitor molecule by a process involving gene duplications and diversification 
(Hodge & Cope, 2000). Members of the myosin superfamily consist of a ‘generic’ 
motor domain attached to a variety of unique and functionally specialized tail 
domains anchored by a neck domain. Myosin heavy chains have been 
categorized into 24 classes, based on comparisons and phylogenetic analysis of 
the ‘generic’ motor domain (Foth et al, 2006). Figure 2 embraces the 
phylogenetic tree of all different myosin classes identified so far. As 
schematically depicted in figure 2, the myosin class-2 family comprises the 
largest number of known members (Figure 1.2) including the classical two 
headed, filament forming dimeric myosins found in skeletal muscle, cardiac 
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muscle, smooth muscle and virtually all non-muscle cells (Korn et al, 1988). 
Conventional myosins are solely represented by members of myosin class-2 
family, whereas all other myosins are classified as unconventional (Redowicz, 
2007).  
In this thesis, different myosins from classes-1, -2, -5 and -14 over a vast range 
of organisms from D.discoideum, mammals and Apicomplexans have been used. 
Therefore, selected myosins of classes-2 and -14 are presented in more detail in 
the following sections. 
 
Figure 1.2: Unrooted phylogenetic tree of myosin superfamily (Hodge & Cope, 2000). 
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1.2.1 Nonmuscle Myosin-2 
Nonmuscle myosin-2s are members of the class-2 myosin family. The term 
nonmuscle myosin is a misnomer because nonmuscle myosins can be 
expressed in both muscle and nonmuscle cells. They represent a branch of the 
myosin superfamily that is closely related to skeletal and smooth muscle myosins 
(Buxton et al, 2003) (Figure 1.3). 
 
Figure 1.3: Phylogenetic tree of the human class-2 myosin heavy chains based on the sequence 
analysis of the motor domain. The y-axis displays the scale of amino acid sequence identity. 
Members of the nonmuscle myosin subclass are highlighted in brown and smooth muscle myosin 
in teal. Cardiac and skeletal muscle myosins are highlighted in blue and grey, respectively.  
Figure adapted and modified after Golomb et al, JBC (Golomb et al, 2004). 
Three types of nonmuscle myosin-2 isoforms are identified so far: nonmuscle 
myosin heavy chain-2A (NMHC-2A), nonmuscle myosin heavy chain-2B (NMHC-
2B) and nonmuscle myosin heavy chain-2C (NMHC-2C). The genes encoding 
the nonmuscle myosin-2 isoforms are designated MYH9, MYH10 and MYH14. At 
protein level, nonmuscle myosins follow classical domain architecture of myosin-
2 molecules consisting of an N-terminal motor domain, a neck domain and an 
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adjacent α-helical coiled coil terminating in a short non-helical tail. The coiled coil 
region forms the rod-like domain and enables the dimerization of two myosin 
heavy chains (Sellers, 2000b). The assembly allows the interaction between the 
myosin filament and adjacent actin filaments. Remarkably, these filaments are 
substantially (20-30 fold) shorter than those of skeletal or cardiac muscle myosin 
and comprise around 28 myosin molecules (Rosenfeld et al, 2003); (Verkhovsky 
& Borisy, 1993). To date, there is no evidence about the formation of co-filaments 
between different nonmuscle myosin-2 isoforms (Golomb et al, 2004; Vicente-
Manzanares et al, 2009b).  
Nonmuscle myosin-2 isoforms show > 85% sequence similarity in their 
catalytically active motor domain. Alternative splicing is the major source of 
functional diversity among the nonmuscle myosin-2 isoforms (Kondrashov & 
Koonin, 2003). Alternate splicing of the MYH14 gene leads to the production of 
different splice variants in humans (Golomb et al, 2004; Jana et al, 2009; Leal et 
al, 2003). The putative amino acid sequences between the NMHC-2C motor 
domains of the transcript variants are well conserved with an identity of 96-99% 
(Heissler & Manstein, 2011). Isoforms 2C1 differs only by an 8 amino acid 
extension of loop-1. Isoform 2C2 has the same extension of loop-1 and an 
additional 33 amino acid extension in loop-2 and isoform 2C0 represents the 
shortest isoform without loop extensions (Heissler & Manstein, 2011).  
The function of nonmuscle myosins is diverse, ranging from cell adhesion, cell 
division to cell migration (Vicente-Manzanares et al, 2009b). In smooth muscles, 
nonmuscle myosins are required for maintaining tension whereas in skeletal 
muscles they are important for muscle development and differentiation (Vicente-
Manzanares et al, 2009). Due to the universal expression pattern and their 
participation in fundamental cellular processes, it is not surprising that mutations 
in nonmuscle myosins are associated with a large range of diseases, such as 
macrothrombocytopenia, deafness, nephritis and many more (Donaudy et al, 
2004). MYH9-related diseases include giant-platelet disorders like May-Hegglin 
anomaly and Fetchner syndrome (Althaus & Greinacher, 2009; Hu et al, 2002). 
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MYH14 is implicated in autosomal dominant nonsyndromic neural hearing loss 
(Donaudy et al, 2004).  
1.2.2 Toxoplasma Myosins 
The phylum Apicomplexa comprises protozoan parasites of several medically 
and veterinary relevant obligate intracellular parasites such as Plasmodium 
(malaria), Toxoplasma (toxoplasmosis), Cryptosporidium (cryptosporidiosis), 
Babesia (babesiosis) and Eimeria (coccidiosis). Parasitic infections with 
Apicomplexans lead to considerable economic losses by infecting livestock 
(Homer et al, 2000; Morris, 1843; Wolf et al, 1939). Members of the Apicomplexa 
are morphologically unified by a common set of apical structures, including the 
conoid, the polar ring complex, sub-pellicular microtubules and secretory 
organelles including micronemes, rhoptries and dense granules (Morrissette & 
Sibley, 2002). The pellicle of the invasive forms of these parasites consists of the 
plasma membrane and the two membranes of the inner membrane complex 
(IMC), a continuous layer of flattened vesicles underlying the plasma membrane. 
In the absence of locomotive organelles such as cilia or flagella, the invasive 
forms of these parasites have an unusual form of substrate-dependent motility 
that is essential for host cell invasion (Sibley et al, 1998). Like most 
Apicomplexans, the invasive stages of T.gondii enter host cells by an active 
process dependent on gliding motility. T.gondii tachyzoites exhibit three distinct 
modes of locomotion: circular gliding, upright twirling and helical rotation 
(Hakansson et al, 1999), and all three are powered by the parasite actomyosin 
system (Opitz & Soldati, 2002). Among the Apicomplexans, the T.gondii genome 
comprises the largest known myosin repertoire of 11 myosin heavy chains 
(TgMyoA to TgMyoK) allocated to different classes, including class XIV (Foth et 
al, 2006). 
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Figure 1.4: Schematic architecture of the glideosome in T.gondii. T.gondii comprises the motor 
complex [myosin A (TgMyoA), the myosin light chain (TgMLC), TgGAP45 and TgGAP50], which 
is anchored to the outer membrane of the IMC and connected via F-actin and the aldolase to the 
hexameric micronemes protein complex (TgMIC2-TgM2AP), which, in turn, interacts with host-
cell receptors. Adopted from Keeley A and Soldati D. 2004, Trends in Cell Biol. (Keeley & Soldati, 
2004) ]. 
TgMyoA and TgMyoD belong to class XIVa myosins (Foth et al, 2006; Hettmann 
et al, 2000). T.gondii MyoA orthologues have been found in other Apicomplexan 
genomes, including Neospora caninum, Cryptosporidium parvum and Eimeria 
tenella. TgMyoA is associated to the myosin light chain MLC1 (also called 
myosin A tail interacting protein (MTIP)) in Plasmodium species (Bergman et al, 
2003; Herm-Gotz et al, 2002) and plays an essential role in parasite motility and 
invasion (Meissner et al, 2002). This motor was previously shown to be part of a 
large complex composed of the gliding-associated proteins GAP45 and GAP50 
(Gaskins et al, 2004). This complex initially described as the “glideosome” (Opitz 
& Soldati, 2002) is located to the pellicle, in the space between the plasma 
membrane (PM) and the IMC (Keeley & Soldati, 2004) (Figure 1.4).  
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Depletion of TgMyoA impairs both host cell invasion and parasite egress 
(Meissner et al, 2002). As the inhibitors of actin filament polymerization 
(cytochalasin D) and the myosin ATPase (butanedione monoxime (BDM)) disrupt 
the three forms of T.gondii gliding motility (Hakansson et al, 1999), parasite 
movement suggests the involvement of more than one myosin. TgMyoD is the 
shortest T.gondii myosin identified so far, with a size of 91-kDa (Herm-Gotz et al, 
2006). TgMyoD is a motor found only in coccidians and shown to be dispensable 
for tachyzoites (Herm-Gotz et al, 2006). Since TgMyoD is more prominently 
expressed in bradyzoites, it may fulfill an important function in the invasive stage. 
Recently, Toxoplasma myosin light chain 2 (TgMLC2) was identified as the 
interaction partner of TgMyoD. TgMLC2, only found in coccidians, is associated 
with TgMyoD via its calmodulin-like domain and anchored to the plasma 
membrane of T.gondii via its N-terminal extension (Polonais et al, 2011).  
1.3 Myosin-2 Structure 
Skeletal muscle myosin-2 is the conventional myosin prototype responsible for 
producing muscle contraction. It is a hexamer with a total molecular weight of 
520 kDa. It is composed of two heavy chains and four light chains. Each of the 
two heavy chains has a molecular weight of 220 kDa and is characterized by a 
globular head domain at the N-terminus and a α-helix at the C-terminus. The C-
terminal tail region is periodically interspersed with hydrophobic residues to give 
a “coiled coil” type rod. The tails are connected to the heads at the neck, which is 
the location of the hinge region or the pliant region (Geeves & Holmes, 1999; 
Gourinath et al, 2003). The four light chains weigh about 20 kDa each and are 
paired into two regulatory chains and two essential light chains. Each head of the 
protein has one chain of each type.  
The proteolytic fragment S1 comprises the first 843 residues of the heavy chain 
together with the two light chains. Myosin S1 is a fully competent actin-activated 
ATPase that transports actin in in vitro motility assays.  Further limited proteolysis 
breaks the S1 into three fragments named after apparent molecular masses; the 
N-terminal 25 kDa domain, the 50 kDa middle domain [divided into 50 kDa upper 
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and lower sub-domains] and the C-terminal 20 kDa domain (Geeves & Holmes, 
1999) (Figure 1.5). The first X-ray crystal structure of a myosin motor was of 
obtained using S1 from chicken pectoralis muscle without nucleotide but with a 
sulfate ion in place of the γ-phosphate in the active site (Rayment et al, 1993). 
The structure shows the S1 to be tadpole-like in form. All three proteolytic 
fragments (25 kDa, 50 kDa, and 20 kDa) contribute to the central 7-stranded β-
sheet. The α-helices that surround this central β-sheet form a deep cleft 
extending from the nucleotide-binding site to the actin-binding region. 
 
Figure 1.5: Crystal structure of myosin S1 from scallop striated adductor muscle (pdb-code: 
1QVI). The proteolytic fragments are labeled as follows: 25 kDa (N-terminal), 50 kDa (middle) and 
20 kDa (C-terminal). The 50 kDa fragment actually spans two domains, called as the 50 kDa 
upper subdomain and the 50 kDa lower subdomain. The ATP-binding site is in this large domain 
near the 25 kDa – 50kDa fragment boundary and contains a characteristic P-loop similar to that 
found in many ATPases and G-proteins. S1 has an elongated head consisting of a seven-
stranded β-sheet and a C-terminal a-helical tail or ‘neck’, which carries two calmodulin-like light 
chains - the regulatory chain and the essential light chain. The C-terminal tail with its associated 
light chains has been called the “neck” or the “lever arm”. 
1.3.1 Myosin Motor Domain and its Key Structural Features 
In several structural studies, myosin head fragments (761 residues) from 
Dictyostelium discoideum were generated genetically by terminating the myosin 
heavy chain in the long α-helix that forms the backbone of the light chain-binding 
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motif (Fedorov et al, 2009; Fisher et al, 1995; Gulick et al, 2000). This truncated 
myosin head retains a limited ability to move and crystallizes readily without the 
need for chemical modification. High-resolution crystal structures of the myosin 
head with and without nucleotides bound have provided detailed structural 
analysis of the motor domain (Gulick et al, 1997; Reubold et al, 2003).  
 
Figure 1.6: Topological representation of myosin motor domain. Helices are shown as cylinders 
and β-strands as arrows. The core of the myosin motor domain is formed by central, seven-
stranded β-sheet and surrounding α-helices. Figure adapted from Preller et al (Preller & Manstein, 
2011). 
Comparison of these structures has shown that the motor domain (MD) is most 
simply described as comprising four major subdomains that are linked by three 
major structural elements, so-called joints that are highly conserved in sequence 
(Figure 1.6). A first joint, switch-2, links the upper and lower 50 kDa subdomains 
near the γ-phosphate pocket. The other two joints, the relay and the SH1 helix, 
link the converter to the lower 50 kDa and the N-terminal subdomains, 
respectively. 
1.3.2 Nucleotide Binding Pocket 
The nucleotide binding pocket is located at the interface between the 50 kDa and 
N-terminal subdomains. It is composed of four major loops that are highly 
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conserved not only among myosins but also among the G-proteins (Vale, 1996). 
The nucleotide binding pocket comprises the purine-binding loop or adenine 
binding loop [A-loop] (NPxxxxxxY) on one side and the switch-1 (NxxSSR), P-
loop (GESGAGKT) and switch-2 (DIxGFE) elements that sandwich the 
polyphosphate moiety of the nucleotide on the other side (Figure 1.7A).  
 
Figure 1.7: (A) Cartoon representation of the active site of myosin-2 motor domain. Key elements 
in the active site are color coded and labeled accordingly. (B) Schematic representation of the 
coordination of the MgATP in the nucleotide-binding pocket of myosin-2 motor domain. This 
figure adapted from Preller & Manstein, 2011. 
The purine ring of the nucleotide is in anti-conformation relative to the ribose, 
which exhibits a C3’-endo ring pucker. The binding site for the purine ring is 
formed almost exclusively from residues in the N-terminal subdomain (Rayment 
et al, 1996). The P-loop, the switch-1 and -2 loops together form the so-called 
“phosphate tube” around the phosphate moieties of ATP. The P-loop is a glycine 
rich element that binds to the γ-phosphate end of the nucleotide. The two switch 
loops obtained their names from the observation that they can adopt different 
conformations and thereby serve as a switch for information transduction by 
changing their conformation (Koppole et al, 2006); (Reubold et al, 2003).  
Several high-resolution motor domain structures have shown that the Mg2+ ion 
shows hexacoordination with surrounding structural elements in the nucleotide-
binding pocket (Figure 1.7B). These elements include two oxygens of the γ- and 
the β-phosphates of ATP, the side chains of S237 and T186, and two water 
Introduction 
 
13 
 
molecules. Mutational studies have shown crucial roles of residues K185 of the 
P-loop, R238 of switch-1 and G457 as well as E459 of switch-2 in the ATP 
hydrolysis reaction. Mutation of these residues resulted in a loss or substantial 
decrease of the myosin ATPase activity (Sasaki et al, 1998; Shimada et al, 1997). 
Residues R238 and E459 form a salt-bridge between switch-1 and switch-2. 
Myosin motor domains with mutations E459R or R238E, blocking salt-bridge 
formation, show defects in nucleotide-binding, reduced rates of ATP hydrolysis, 
and a 10-fold reduction in actin affinity (Furch et al, 1999). Further, these results 
have shown that the salt-bridge between switch-1 and switch-2 is required to 
support efficient ATP hydrolysis, normal communication between different 
functional regions of the myosin head, and motor function (Furch et al, 1999). 
1.3.3 Relay Helix and Converter Domain 
The relay helix is one of the longest helices in the motor domain of myosin, which 
joins the lower and upper 50kDa subdomains through switch-2 loop (Figure 1.7). 
Adjacent to relay helix, β-sheet-3 (β3) from the seven-stranded β-sheet is 
followed by a turn and a broken helix containing two reactive thiols (SH1 707 and 
SH2 697). Comparison with other structures shows that the distal part of the 
SH1-SH2 helix forms the hinge for the ensuing lever. Further, these two helices 
are followed by a small compact domain generally referred to as the “converter”. 
The converter domain functions as a communication hub and socket for the C-
terminal α-helical tail (Rayment et al, 1993).  
The converter domain is tightly coupled to the relay helix. A kink that can form in 
the relay helix induces a rotation of the converter domain through 600, which is 
one of the key structural events during the power stroke (Figure 1.8). In the rigor-
like state, in the absence of nucleotide, the relay helix is straight. In the pre-
power stroke state, which mimics the ADP•Pi state, the relay helix is kinked 
(Coureux et al, 2003; Fedorov et al, 2009) (Figure 1.8A).  
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Figure 1.8: (A) Rearrangements of key structural elements in the nucleotide binding pocket of 
myosin-5 motor domain in the rigor-like state [nucleotide-free] (1OE9) and myosin-2 motor 
domain (2JJ9) in the pre-power stroke state [ADP•VO3]. (B) Large movements of converter 
domain are shown for the rigor-like myosin-5 motor domain (1OE9) and the pre-power stroke 
state of myosin-2 motor domain (2JJ9) structures. 
 
It was observed in different myosin-2 isoform motor domain structures that the 
ATP analogue, ADP•VO3 or ADP•VO4, forms strong interactions with the switch-1 
residues in the active site, inducing switch-1 to close (moving towards the β- and 
γ-phosphates of the bound nucleotide (Figure 1.8A). Concomitant changes occur 
as switch-2 closes by moving back the lower part of β-strand 5 into the plane of 
the seven-stranded β-sheet (Gourinath et al, 2003; Kliche et al, 2001). 
Furthermore, switch-2 closing induces formation of the kink in the relay helix, 
causing a 60° rotation of the converter domain and the neck helix into the up 
position (Figure 1.8B) (Fedorov et al, 2009).  
1.3.4 Surface Loops and their Functional Importance 
The myosin motor domain comprises several surface loops, which were proven 
to be of functional importance (Figure 1.6). The solvent-exposed, proteolytically 
sensitive surface loops of myosin that join the proteolytically defined myosin 
subdomains are highly variable in their sequences, both in length and 
composition.  Furthermore, many myosin isoforms differ in these surface loops 
as a result of alternative splicing. The splice variants are differentially expressed 
in various tissues. Among these are vertebrate cardiac, smooth muscle, skeletal 
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myosin, catch muscle myosins and nonmuscle myosins (Kondrashov & Koonin, 
2003; Murphy & Spudich, 2000; Perreault-Micale et al, 1996).  
One of these surface loops, loop-1 or the so-called 25-50 kDa loop, is situated 
near the nucleotide binding site. The length and composition of loop-1 has a 
considerable influence on the binding of nucleotides. Biochemical studies have 
shown that loop-1 affects the affinity of actomyosin for ADP, the ADP release 
from actomyosin, the in vitro motility and Vmax of the actin-activated Mg2+-ATPase 
activity, possibly through Pi release (Uyeda et al, 1994).  
Structural and biochemical studies have shown that loop-2, a highly positive 
surface segment of the myosin motor domain, interacts with the negatively 
charged amino-terminal part of F-actin, and this electrostatic interaction is mainly 
responsible for the weak binding of the myosin head to F-actin (Ponomarev et al, 
2000; Schröder et al, 1993). Molecular genetic manipulations of loop-2 have 
been shown to alter myosin’s affinity for F-actin and its actin-activated ATPase 
activity (Furch et al, 1998). Three-dimensional reconstructions of electron-
microscopy images and solution experiments performed on the actomyosin 
complex suggest that loop 3, in addition to loop-2, is involved in electrostatic 
contacts with F-actin (Holmes et al, 2003; Lorenz & Holmes, 2010). Cross-linking 
experiments have shown that loop-3 mediated interaction with F-actin occurs in 
striated muscle myosin isoforms but is apparently not essential for the formation 
of a high-affinity actin-myosin interface or modulation of actomyosin ATPase 
activity (Van Dijk et al, 1999).  
Furthermore, loop-4 of the upper 50 kDa subdomain, the cardiomyopathy loop 
[CM-loop] and the helix-loop-helix motif of lower 50 kDa subdomain contribute to 
F-actin binding. The CM-loop lies at the apex of the motor domain, in close 
proximity of the entrance of the large cleft that separates the lower and upper 50 
kDa subdomains (Geeves et al, 2005). A point mutation at position R403Q in 
human β-cardiac myosin was the first one to be identified as the cause of familial 
hypertrophic cardiomyopathy (Geisterfer-Lowrance et al, 1990). The strut loop is 
one of the three loops that connect the upper and lower 50 kDa subdomains 
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(Figure 1.6). This loop is strongly conserved among the myosin superfamily, and 
mutagenesis studies have shown that the residue D590 plays an important role 
in maintaining the disposition of the upper and lower 50 kDa subdomains (Fujita-
Becker et al, 2006; Sasaki et al, 2000).  
1.3.5 The ATPase Cycle 
Myosin is a product-inhibited ATPase that is strongly stimulated by F-actin, which 
is a nucleotide exchange factor for myosin. This mechanism was first established 
by Lymn&Taylor (Lymn & Taylor, 1971). At present, a more detailed modified 
version of this method known as ‘swinging lever hypothesis’ is in practice (Anson 
et al, 1996a; Holmes, 1997; Rayment et al, 1993) (Figure 1.9). This hypothesis 
suggests that rather than the bulky head region of the molecule swing about that 
only the smaller tail portion moves relative to the filament axis.  
On account of the number of experimentally solved high-resolution X-ray 
structures, electron microscopy experiments with the isolated proteins, and 
solution kinetics, this chemomechanical cycle was further refined by assigning 
chemical states, which are defined by the nucleotide bound at the active site, to 
experimentally observed structural states (Figure 1.9). Starting with a nucleotide-
free myosin or apo-state and the lever arm in the post-rigor position, the motor 
protein is tightly bound to the F-actin filament [A·M]. Binding of ATP to myosin 
initiates the dissociation of the actomyosin complex, due to the negative 
cooperativity between F-actin and ATP, converting the motor to a state that is 
referred to as near-rigor or pre-hydrolysis state. 
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Figure 1.9: The acto-myosin ATPase cycle. Figure adapted from Preller et al, (Preller & Manstein, 
2011). The abbreviations are indicated as M=Myosin, A=F-Actin, D=ADP and Pi= inorganic 
phosphate. The asterisk symbol represents different conformational states of the myosin motor 
domain. 
Conformational changes in the motor domain lead to the repositioning of the 
lever arm and the formation of the hydrolysis competent post-recovery stroke 
state [M*·T]. In this detached state, the hydrolytic cleavage of the ATP to ADP·Pi 
takes place. The equilibrium constant for the hydrolysis step is close to 1 for most 
myosins examined. Subsequently, myosin rebinds to the actin filament takes 
place, initially resulting in the formation of the weak affinity, metastable pre-
powerstroke state [A·M*·D·Pi] and progressing to the post-hydrolysis state with 
moderate actin-affinity [A·M*·D+Pi]. Isomerization steps concurrent with strong 
binding to actin, swinging of the lever arm, and force generation are coupled to 
the release of inorganic phosphate (Pi) [A·M·D] and subsequently ADP [A·M]. 
Except for the rigor state most of the states described in this scheme are difficult 
to approach experimentally. Electron density maps of the actomyosin complex 
obtained by cryoEM are still of comparatively low resolution and crystal 
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structures of the myosin head were only obtained in the absence of F-actin. 
Nevertheless, it is possible to ascribe individual X-ray structures to certain states 
of the ATPase cycle. As its name implies, F-actin was early on recognized to 
serve not only as the passive track on which myosins move but to play an active 
role in catalysis. Myosin displays poor ATPase activity in the absence of F-actin 
and requires the interaction with F-actin for fast release of the products of the 
hydrolysis reaction, Pi and ADP (Preller & Manstein, 2011). 
1.4 Allosteric Regulation  
Over the years, static pictures of allosterically-regulated proteins indicated a 
change in the shape of the substrate binding site between the On/Off states 
depending on whether the effector molecule is bound or absent at the allosteric 
site. This has led to the paradigm that allostery involves conformational change. 
The two classical models, the Monod-Wyman-Changeux (MWC model) (Monod 
et al, 1965)  and the Koshland-Nemethy-Filmer (KNF) (Koshland et al, 1966) 
described allostery as a binding event at one site altering protein activity via a 
conformational change at the second site. The MWC model emphasized that the 
conformational transition is a concerted action between two co-existing, distinct 
states (relaxed and tense, or R and T); on the other hand, the KNF model 
formulated it as a sequential, induced conformational change by the binding at 
the first site. In contrast to the “old” view, Gunasekaran et al stated that the native 
states are ensembles of pre-existing populations; thus, an allosteric effector 
leads to an equilibrium shift of pre-existing conformational and dynamic states 
(Gunasekaran et al, 2004). Proteins such as G protein-coupled receptors, 
hemoglobins, serine proteases, and cyclin-dependent kinases use allostery to 
mediate function.  Recent studies indicate that even if there is no visual change 
in the shape of the protein backbone at the allosteric binding site upon binding of 
the effector, there may still be an associated change in the substrate binding site 
and hence in protein activity (Daily & Gray, 2007; Popovych et al, 2006; Tsai et al, 
2008). 
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1.4.1 Allosteric Communication in Myosin Motor Domains 
In the crowded environment of a typical eukaryotic cell, any object larger than 50 
nm is effectively immobile and cannot rely on diffusion to arrive at its destination. 
As a result, myosin motors evolved to generate force for the transport of cargoes, 
cell motility, and cell division, processes that are critical for life itself. These 
motors convert chemical free energy by changing shape in a controlled manner 
while bound to actin filaments. A fundamental feature of all motor proteins is that 
their movements are carefully coordinated, so that the motor travels through a 
specific sequence of coupled biochemical and mechanical states. The nature of 
this coordination remains obscure, but it is clearly essential for proper motor 
function. The recent recognition that each myosin class has evolved specific 
structural and kinetic features allows for the comparison of different coordination 
mechanisms across the myosin super family.  
Recently, it was reported that myosin motors use intrinsic allostery to mediate 
their functions (Cecchini et al, 2008; Tang et al, 2007). Remote sites in the motor 
domain communicate through pathways that connect distant sites, trigger large 
conformational changes, and induce 10,000-fold and greater affinity changes in 
F-actin and nucleotide binding during the normal ATPase cycle (Conibear et al, 
2003; Reubold et al, 2003). X-ray crystallography and biochemical experiments 
have identified the following major myosin motor conformations that correspond 
to discrete stages of the actomyosin cycle.  
a) The structure of the pre power-stroke state is characterized by 
hydrolyzed ATP in the catalytic site, an open 50 kDa cleft between the 
catalytic site and the actin binding site, and the lever arm in its cocked, 
or “up” position.  
b) During the power stroke the lever arm swings to its “down” position. 
c) Release of phosphate and ADP results in the rigor state, characterized 
by a closed 50kDa cleft, strong binding to F-actin, and the lever arm in 
the “down” position.  
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d) When the catalytic site is reoccupied by ATP, myosin releases from F-
actin and the molecule reaches its post-rigor conformation 
characterized by its lever arm still in the “down” position and the cleft is 
open.  
In addition to the above changes, opening and closing of the active site elements, 
bending and straightening of relay helix and the communication between the 
active site and the converter domain, play a crucial role in different stages of the 
ATPase cycle. The mechanochemical properties indicate that these 
nanomachines inherently possess different intrinsic allosteric mechanisms. 
Understanding all or some of these mechanisms in detail will need the 
application of different methodologies. In this thesis, small molecule effectors 
were used for dissecting the allosteric mechanisms in the myosin motor domain. 
1.4.2 Small Molecule Effectors  
Cytoskeletal proteins, including microfilaments, microtubules, and intermediate 
filaments, play a pivotal role in the treatment of cancer, as their regulation by 
small molecules arrests progression through the cell cycle (Reayi & Arya, 2005). 
Natural compounds are valuable tool for searching more potent and highly 
specific compounds against a wide variety of diseases ranging from cancer to 
malaria (Bai et al, 2010; Martin et al, 2009b; Shang et al, 2010; Shen et al, 2010). 
The role of myosins for a wide range of diseases has been established in 
numerous instances (Anan et al, 1994; Anderson et al, 2000; Liang et al, 1998; 
Melchionda et al, 2001; Probst et al, 1998). Due to their rapid, conditional, and 
reversible mode of action, small molecule modulators of protein function are 
useful tools in cell biological research and can serve as lead compounds in the 
development of therapeutic agents (Lehar et al, 2008; Walsh & Chang, 2006).  
Several small molecule allosteric effectors of myosin motor have been reported 
in the last two decades. In 1989, the first myosin inhibitor, 2,3-butanedione 2-
monoxime (BDM) was reported (Higuchi & Takemori, 1989) (Figure 1.10). Initially, 
it was identified as well-characterized, low-affinity, no-competitive inhibitor of 
skeletal muscle myosin-2. It has been widely used at millimolar concentrations in 
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cell biological experiments with the assumption that it is an ATPase inhibitor of 
the class-2 myosins. Kinetic studies showed that BDM decreases the ATPase 
rate and force production by inhibiting Pi release and stabilizing the weakly actin-
bound MyosinADPPi state (Herrmann et al, 1992).  
 
Figure 1.10: Schematic representation of the 2,3-butanedione 2-monoxime (BDM). 
BDM not only inhibits some myosins but also has shown highly non-specific 
inhibitory action against non-myosin proteins like acetylcholinerase, 
serine/threonine phosphorylation in kinases and lot of other proteins (Sellin & 
McArdle, 1994). Cheung et al. reported N-benzyl-p-toluene sulphonamide (BTS) 
as a specific inhibitor of the actin-stimulated ATPase activity of rabbit muscle 
myosin-2 S1 (Cheung et al, 2002) (Figure 1.11). 
 
Figure 1.11: Schematic representation of the N-benzyl-p-toluenesulfonamide (BTS) 
Although BTS does not compete for the nucleotide-binding site of myosin, it 
weakens myosin's interaction with F-actin, leading to dissociation of myosin in 
the presence of ADP. BTS reversibly suppressed force production in skinned 
skeletal muscle fibers from rabbit and frog skin at micro molar concentrations 
(Cheung et al, 2002). The mode of action and the binding-site of the inhibitor in 
the myosin motor domain are unknown at present.  
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The phenothiazine, trifluoperazine (TFP) has long been known to be a potent 
antagonist of calmodulin action (Levin & Weiss, 1976) (Figure 1.12). At millimolar 
concentrations, TFP has also been reported to remove the regulatory light chain 
subunits from both vertebrate smooth muscle (Trybus et al, 1994) and scallop 
muscle myosin-2 (Patel et al, 2000). Patel et al. demonstrated that TFP inhibits 
the actin-activated MgATPase activity of scallop adductor muscle myosin-2 
without bound regulatory light chains at concentrations of 100-200 µM (Patel et al, 
2000). Sellers et al. has shown that TFP inhibits the actin-activated MgATPase of 
a proteolytic fragment of myosin-5 that contains not only the motor domain and 
no calmodulin, suggesting that the site of action of TFP is on the myosin heavy 
chain (Sellers et al, 2003).   
 
Figure 1.12:  Schematic representation of the Trifluoperazine (TFP). 
Blebbistatin, a 1-phenyl-2-pyrrolidinone derivative, represents an effective 
inhibitor of some class-2 myosins with IC50 values ranging from submicromolar 
(IC50~0.5 µM) to nearly 100 µM (Limouze et al, 2004). Blebbistatin has been 
shown to potently inhibit nonmuscle myosin-2B, rabbit skeletal muscle myosin-2, 
and Dd myosin-2, but does not inhibit smooth muscle myosin-2, or myosins from 
classes-1, -5, or -10. The structural basis for the mode of action of blebbistatin 
was reported for the Dd myosin-2 motor domain (Allingham et al, 2005). 
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Figure 1.13:  (A) Schematic representation of the (S)-(-) blebbistatin (B) Blebbistatin binding site 
in Dd myosin-2 motor domain (1YV3). Color-coding has been done according to the secondary 
structure of the myosin motor domain. 
  
Blebbistatin binds in a hydrophobic pocket at the apex of the 50 kDa cleft, close 
to the γ-phosphate-binding pocket (Figure 1.13). Allingham et al. proposed that 
the inhibitor is complementary to the metastable state; consistent with proposition 
that blebbistatin inhibits Pi release in MgADP-Pi complex by stabilizing this 
conformation (Kovács et al, 2004). Blebbistatin binding doesn’t induce any major 
conformational changes in the myosin motor domain (rmsd of Cα is 0.407 Å only). 
This fact supports the newly proposed allostery mechanism by Tsai et al:  Even if 
there is no visual change in shape of backbone at the substrate binding site upon 
binding of the allosteric effector, there could be still an allosteric change in the 
substrate binding site, and in protein activity (Tsai et al, 2008). 
The use of small molecule effectors of myosin function such as N-benzyl-p-
toluenesulfonamide (BTS) and blebbistatin help to provide important new insights 
in a range of cellular functions that require the active participation of at least one 
member of the myosin family. Compounds like blebbistatin and BTS display 
preferred interactions with selected members of myosin class-2 (Cheung et al, 
2002; Limouze et al, 2004). However, there is a requirement for developing 
specific small molecule inhibitors of other classes of myosins.  
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Recently, the total synthesis of halogenated pseudilins; natural products 
containing a 2-arylpyrrole moiety and their synthetic analogues have been 
described (Martin et al, 2009a). Pentabromopseudilin (PBP) was shown to inhibit 
myosin-2 dependent processes such as isometric tension development and 
unloaded shortening velocity in muscle cells. PBP was subsequently identified as 
a potent inhibitor of vertebrate myosin-5 motor activity (Figure 1.14). An IC50 of 
400 nM was determined for the inhibition of vertebrate myosin-5 ATPase activity 
by PBP (Fedorov et al, 2009).  
The novel allosteric binding pocket of PBP is about 16 Å away from the 
nucleotide-binding pocket and is close to the actin-binding cleft, at the apex of 50 
kDa cleft (Fedorov et al, 2009). Based on this finding, related compounds to 
identify myosin effectors with altered selectivity for the members of different 
myosin classes were screened.  
 
Figure 1.14: (A) Schematic representation of pentabromopseudilin (PBP) (B) Crystal structure of 
Dd myosin-2 complexed with PBP in the presence of MgADPVO3. 
Pentachloropseudilin (PClP), a chemical and structural analogue of PBP, was 
identified in this screening as a potent inhibitor of class-1 myosins. The main aim 
of this thesis is to dissect the molecular and structural basis of inhibiton of PClP 
on myosin motor domains.   
Ammosamides structural scaffold is similar to the microbial product ‘lymphostin’ 
(Aotani et al, 1997) and several sponge-derived pyrroloiminoquinone natural 
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products, including ‘batzelline A’, isobatzelline D, and makaluvamine A (Antunes 
et al, 2005) [Figure 1.15].  Ammosamide A and B exhibited significant in vitro 
cytotoxicity against HCT-116 colon carcinoma, each with IC50=320 nM. These 
compounds also demonstrated pronounced selectivity in a diversity of cancer cell 
lines with values ranging from 20 nM to 1 µM, indicating a specific target 
mechanism of action. To explore the intracellular target of the ammosamides, 
ammosamide B was converted to a highly fluorescent molecule by conjugation 
(Hughes et al, 2009a). Treatment of HCT-116 colon carcinoma or HeLa cells with 
this fluorescent molecule produced immediate and irreversible labeling of a 
specific protein in the cellular cytosol. By using cell biology studies, the target of 
the ammosamides was identified as a member of the myosin family, important 
cellular proteins that are involved in numerous cell processes, including cell cycle 
regulation, cytokinesis, and cell migration (Hughes et al, 2009a).   
The main ammosamide derivatives, Ammosamide A and Ammosamide B, differ 
only in one functional group. The fact that the ammosamides are highly colored 
(ammosamide A: λmax=580 nm; ammosamide B: λmax=530 nm), yet lack quinone 
or iminoquinone functionalities, leads to speculation about the electronic 
character and reactivity of these metabolites (Hughes et al, 2009b). The 
functionality within the ammosamide structure was very important for targeting 
myosin and has been proved (Hughes et al, 2009a).  
 
Figure 1.15: Related metabolites from bacteria and sponges. These compounds have similar 
structural scaffold as ammosamides. This figure is taken from Hughes et al (Hughes et al, 
2009b). 
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This thesis focuses on myosin motor domains, whose function and structure was 
dissected using an approach that involves the use of small molecules and 
different combinations of biochemical and biophysical techniques. Furthermore, 
this thesis will address critical questions about the underlying inhibitory 
mechanisms of myosin motor domains using small molecule inhibitors. 
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2. Material and Methods 
2.1 Materials  
Table 1: List of equipment 
Equipment Company 
Centrifuge 5415 D Eppendorf 
Centrifuge Avanti Centrifuge J-20 XP 
with rotors JLA 16.250, JA 25.50 
Beckman Coulter 
Centrifuge J-HC with rotor JS4.2 Beckman Coulter 
Centrifuge Megafuge 1.0R Heraeus 
Econo Column chromatography  Bio-Rad 
Fluorescence microscope CK 40 Olympus 
Fluorescence microscope IX70 Olympus 
FPLC Äkta-Purifier 10 Amersham Biosciences 
Gel filtration column Highload 26/60 
Superdex 200 PG 
Amersham Biosciences 
Incubator, E.coli Heraeus 
Incubator, Sf9 Sanyo 
Laboratory refrigerator and freezer Liebherr 
Laboratory water bath GFL 
Laminar flow cabinet COJAIR 
Linbro plates Hampton Research 
Magnetic stirrer MR Hei-Standard Heidolph 
Micro scale Sartorius 
Microwave Daewoo 
Mini-PROTEAN 3 cell Bio-Rad 
Molecular Imager ChemiDoc Bio-Rad 
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Orbital shaker, E.coli and D.discoideum Thermo 
Orbital shaker, Innova 44, Sf9 New Brunswick 
pH-meter 3520 Jenway 
Photometer DU800 Beckman Coulter 
Pipettes 2-1000 µl Gilson 
Plate reader, Multiscan FC Thermo 
Power pack EV265 Consort 
Sample Loop 7.8 ml Amersham Biosciences 
Semi-dry blotting chamber PHASE 
Sonifier Sonoplus HD2200 Bandelin 
Stopped-flow SF-61SX2 Hi-Tech Scientific 
Thermostat plus Eppendorf 
Ultracentrifuge Optima LE-80K with 
rotors 45Ti, 70Ti 
Beckman Coulter 
Ultracentrifuge Optima Max with rotor 
TLA 120.1 
Beckman Coulter 
Vortex-Genie 2 Scientific Industries 
2.1.1 Consumables 
Table 2: List of consumables used and the corresponding companies 
Consumable Company 
Bottle top filter, 22 µM and 45 µm PES   Nalgene 
Cell culture flasks, T25-T175 Sarstedt 
Cell culture plate, 6 well Nunc 
Cell scraper Greiner 
Cryotubes Sarstedt 
Cover slip (22 mmx22mmx22mm, 
thickness 0.01 mm) 
Roth 
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Dialysis tubing Serva 
Falcon tubes, 15 and 50 ml Sarstedt 
Flasks with vent cap, sterile, 125-1000 
ml  
Corning 
Microscope slide Roth 
Microtiter plate, 96 well, UV transparent, 
half-size area 
Corning 
Petri dish Sarstedt 
Pipette tips, 10-1000 µM Sarstedt 
Pipette tips, sterile 2-1000 µM Star Lab 
Reaction tubes, 1.5 and 2 ml Sarstedt 
Serological pipettes, 2-50 ml Sarstedt 
Sterile filter, 22 µM and 45 µM PES Millipore 
Storage bottles, 200-500 ml Corning 
Syringe Omnifix, 2-50 ml Braun 
Ultrafiltration unit, Vivaspin, PES 4 ml 
and 20 ml, MWCO 50000 Da 
Vivascience 
PVDF membrane Millipore 
Whatman paper Whatman 
2.1.2 Chemicals  
Table 3: List of chemicals and corresponding companies 
Chemicals  Company 
Acetone J.T.Baker 
Acrylamide: Bisacrylamide  Merck 
ADP     Sigma-Aldrich 
Agar                         Serva 
Agarose, LE GQ                  Fermentas 
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Ampicillin                                         Sigma-Aldrich 
Amylacetate  Sigma-Aldrich 
Ammonium Peroxide Sulfate  Merck 
ATP, sodium salt  Sigma-Aldrich 
Beta-Mercaptoethanol              Sigma-Aldrich 
Bovine Serum Albumin, BSA  Sigma-Aldrich 
Bromophenol blue                        Sigma-Aldrich 
2,3 Butanediol  Sigma-Aldrich 
Calcium chloride                           Calbiochem 
Casein      Serva 
Chloramphenicol                          Fluka 
Calcium acetate       Sigma-Aldrich 
Caccodylic acid                          Sigma-Aldrich 
2’-desoxy-mantADP    BIOLOG 
2’-desoxy-mantATP     Jena Biosciences 
Dipotassiumhydrogenphosphate (K2HPO4)  Merck 
Dithiothreitol (DTT)   Sigma-Aldrich 
Dimethylsulfoxide (DMSO) > 99 %  Sigma-Aldrich 
EDTA, Triplex II                 Merck 
EGTA, Triplex VI                         Merck 
Ethanol, absolute >99%             J.T.Baker 
Ethanol                                       J.T.Baker 
Ethidium Bromide     Fluka 
Gentamicin                          PAA 
Glucose   Sigma-Aldrich 
Glycerine                                          Merck 
Glycerol                                             Sigma-Aldrich 
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Glycine     Sigma-Aldrich 
HiFi Extract               Serva 
HEPES, 4-(2-Hydroxyehtyl)-piperazine-1- 
ethanesulfonic acid     
Sigma-Aldrich 
 
Imidazole               Sigma-Aldrich 
Inhibitor tablets, Complete Mini, EDTA free                Roche 
IPTG, Isopropyl-b-D-1-
thiogalactopyranoside  
Fermentas 
Isopropanol, 2-Propanol J.T.Baker 
Kanamycin    Merck 
Lithium Citrate                              Sigma-Aldrich 
Lithium hydroxide                  Jena Bioscience 
Magnesium Chloride (MgCl2.6H2O)  Calbiochem 
Manganese Chloride  Sigma-Aldrich 
mantADP     Jena Biosciences 
mantATP         Jena Biosciences 
Methanol      J.T.Baker 
Microloops MiTeGen 
MOPS, 3-(N-Morpholino)-propansulfonic 
acid  
J.T.Baker 
N-(1-prenyl) iodoacetamide (Pyrene)   Fluka 
NADH, Disodium salt   Roche 
Nickel-Nitrilotriacetate-column material,  
Ni2+-NTA-superflow  
QIAGEN 
 
Nitrocellulose  Sigma-Aldrich 
PageBlue stain Fermentas 
PEP, Phosphoenolpyruvate   Roche 
Peptone      Serva 
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Phosphoric acid    J.T.Baker 
Potassium Chloride    Merck 
Potassium Dihydrogen Phosphate 
(KH2PO4) 
Merck 
Potassium Hydroxide (KOH)   Merck 
Sodium Azide (NaN3) Merck 
Sodium Carbonate (Na2CO3)   J.T.Baker 
Sodium Chloride     Merck 
Sodium-Dodecyl Sulfate, SDS            Merck 
Sodium hydrogen Carbonate (NaH2CO3)  Merck 
Sodium Hydroxide (NaOH)   Merck 
TEMED, N,N,N’,N’-
Tetramethylehtylendiamine        
Merck 
Tetracycline      Sigma-Aldrich 
Tetramethyl-Rhodamine-iso-Thiocyante 
(TRITC)-phalloidin          
Sigma-Aldrich 
Trehalose     Fluka 
Tri Chloro Acetic Acid (TCA)  Fluka 
Triton-X-100      Sigma-Aldrich 
Tryptone      Serva 
Vanadate, Sodium salt     Sigma-Aldrich 
X-Gal       Fermentas 
Xylene Cyanol FF     Merck 
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2.1.3 Enzymes  
Table 4: List of enzymes used. 
Enzymes Company 
CIAP, calf intestine alkaline phosphatase 
(1U/ml)  
Fermentas 
Glucose Oxidase               Sigma-Aldrich 
Catalase Sigma-Aldrich 
Lactate dehydrogenase (LDH)                            Roche 
Phusion High Fidelity (Hot Start) DNA-
Polymerase     
 Finnzymes 
Pyruvate Kinase (200 U/mg)                                               Roche 
Quick T4 DNA Ligase   NEB  
T4 DNA Ligase                Fermentas 
Taq Polymerase                QIAGEN 
2.1.4 Reagent Kits 
Table 5: Kits used in this thesis. 
Kit          Company 
Cellfectin® Reagent             Invitrogen 
JCSG++ Suite                     Jena Biosciences 
NeXtal DWBlock AmSO4 Suite         QIAGEN 
NeXtal DWBlock Anions Suite                    QIAGEN 
NeXtal DWBlock Cations Suite                    QIAGEN 
NeXtal DWBlock Classics Suite                    QIAGEN 
NeXtal DWBlock MPD Suite                    QIAGEN 
NeXtal DWBlock PEGs Suite             QIAGEN 
NeXtal DWBlock pHClear Suite                                           QIAGEN 
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2.1.5 Vectors 
Table 6: Vectors used for cloning. 
Vector                              Company 
pDEST8 Invitrogen 
pDONR201 Invitrogen 
pDXA-3H      Lab made 
pGEM®-T Easy     Promega 
pFastBac1 TM                  Invitrogen 
pFASTBac TM Dual     Invitrogen 
  
2.1.6 Protein Standards 
PageRulerTM Protein Ladder, Fermentas, (Bands : 170, 130, 100, 70, 55, 40, 35, 
25, 15, 10 kDa) 
2.1.7 Antibodies 
Penta-His Antibody, BSA-free, QIAGEN 
2.1.8 Microorganisms 
Following microorganisms have been used for cloning, plasmid amplification and 
the generation of recombinant bacmid. 
Table 7: Chemically competent E.coli cells used for the amplification and production of plasmid 
DNA and bacmid DNA, respectively. 
E.coli Strain Genotype Company 
DH5α Φ80d, lacZ∆M15, recA1, endA1, gyrA96, thi-1, 
hsdR17, (rk – mK+), supE44, relA1, deoR, 
∆(lacZYA-argF), U169, F- 
Invitrogen 
DB3.1 F-, gyr A462, endA1, ∆(sr1-recA), mcrB, mrr, 
hsdS20(rB-,mB-), supE44, ara14, galK2, lacY1, 
proA2, rpsL20(Smr), xyl5, ∆leu, mtl1 
Invitrogen 
DH10Bac F- mcr A D( mrr-hsdRMS-mcrBC) f80lacZDM15 
DlacX74 recA1 endA1 araD139 D(ara,leu) 7697 
galU galK I-rpsL nupG / bMON14272 / pMON7214 
Invitrogen 
NEB 10-beta araD139∆(ara-leu)7697, fhuA, lacX74, galK, (Φ80 
∆ (lacZ)M15), mcrA, galU, recA1, endA1, nupG, 
NEB 
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rpsL, ∆(mrr-hsdRMS-mcrBC) 
XL1-Blue recA1, endA1, gyrA96, thi-1, hsdR17, supE44, 
relA1, lac[F’ proABlacIqZ∆M15 Tn10 (Tetr)] 
Stratagene 
 
2.1.9 Cell culture 
Table 8: List of cellculture media and other accessories. 
Material      Company 
Dulbecco’s PBS  (no Ca2+ & Mg2+)  PAA 
HL-5c Medium FORMEDIUM 
Luria Broth USB 
Sf9 cells (SFM adapted)    Invitrogen 
Trypan Blue      Invitrogen 
 
2.2 METHODS 
2.2.1 Protein Preparation from Sf9 Cells 
The purification of His8-tagged recombinant myosin constructs from Sf9 insect 
cells was either carried out from frozen or fresh cell material. All purification steps 
were carried out at a temperature of 4°C and all bu ffers and solutions were 
prechilled to 4°C prior to use. Cell pellets from 5 -10 litres Sf9 suspension culture 
were resuspended in 600 ml Lysis-Buffer and sonicated (power setting: 40%, 
duty cycle: 50%) on ice for 3 x 30 seconds with 30 second cooling periods 
between the burst periods. The lysate was ultracentrifuged (13000 × g, 30 min, 
4°C, rotor 45Ti). In order to prepare the Ni-NTA ma trix for the affinity purification 
of His8-tagged myosin construct under native conditions, 10 ml of a 50% Ni-NTA 
(Ni-NTA-super flow, QIAGEN) slurry was added to 120 ml Column Buffer and 
centrifuged (700 × g, 5 min, 4°C). The cleared lysate was added to the resin and 
mixed gently by shaking at 4°C for 150 minutes. Aft er a centrifugation step (700 
× g, 5 min, 4°C), the resin was resuspended in 300 ml ATP Buffer and incubated 
for 15 minutes. The slurry was centrifuged (700 × g, 5 min, 4°C), resuspended in 
Material and Methods 
 
36 
 
Low Salt Buffer and again centrifuged (700 × g, 5 min, 4°C). The pellet was 
resuspended in 300 ml High Salt Buffer and the mixture was transferred into an 
empty column. The flowthrough was collected and the His8 fusion protein was 
eluted with Elution Buffer. The eluent was collected and analyzed by SDS-PAGE. 
Fractions containing myosin were pooled and dialyzed over night against 3 l 
Dialysis Buffer. The protein solution was concentrated through ultracentrifugation 
(MWCO 50 kDa, 3000 × g, 4°C) to a final volume of 2.5 ml. The concentrate d 
protein solution was sterile filtered (0.22 µm) and loaded on a preequilibrated 
Superdex 26/60-200 prep grade gel filtration column with a flow rate of 0.5 
ml/min. The sample was eluted with Dialysis Buffer (flow-rate: 0.5 ml/min, 
maximal pressure: 0.5 MPa) and the eluent was collected in 1 ml fractions. The 
fractions were analyzed by SDS-PAGE and myosin-containing fractions were 
pooled and concentrated up to 4-18 mg/ml via ultrafiltration (MWCO 50 kDa, 
3000 × g, 4°C). Aliquots of the protein samples were flash frozen in liquid 
nitrogen and stored at -80°C for future usage. 
Table 9: Buffers for the preparation of His8-tagged myosin motor domain constructs from Sf9 
insect cells 
Lysis Buffer Column Buffer ATP Buffer Low Salt Buffer 
50 mM HEPES  
pH 7.3 
25 mM HEPES  
pH 7.3 
25 mM HEPES  
pH 7.3 
25 mM HEPES  
pH 7.3 
300 mM NaCl 300 mM NaCl 600 mM NaCl 300 mM NaCl 
3 mM MgCl2  0.5 mM ATP 0.1 mM EGTA 
2 mM ATP  0.1 mM EGTA 3 mM MgCl2 
10 mM β-
Mercaptoethanol 
 3 mM MgCl2 40 mM Imidazole 
4 mM Imidazole  20 mM Imidazole  
6 Complete-Tablets  7 mM β-
Mercaptoethanol 
 
   1 % Triton X-100  
High Salt Buffer Elution Buffer Dialysis Buffer Storage Buffer 
25 mM HEPES  
pH 7.3 
25 mM HEPES  
pH 7.3 
25 mM HEPES  
pH 7.3 
25 mM HEPES  
pH 7.3 
500 mM NaCl 400 mM NaCl 400 mM NaCl 400 mM NaCl 
0.1 mM EGTA 0,2 mM EGTA 1 mM EGTA 1 mM EGTA 
3 mM MgCl2 3 mM MgCl2 1 mM EDTA 1 mM EDTA 
65 mM Imidazole 100-850 mM 
Imidazole 
1 mM DTT 1 mM DTT 
  3 % Trehalose 10 % Trehalose 
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2.2.2 Actin Preparation 
F-actin is required for the functional, biochemical and kinetic characterization of 
myosin. The preparation of G-and F-actin was carried out according to a two-step 
protocol. In the first step, actin acetone powder was extracted from rabbit muscle. 
The powder was the starting material for the second step, in which monomeric 
and filamentous actin was prepared. All steps were carried out at a temperature 
of 4°C and all buffers and solvents were prechilled  to 4°C prior to use.  
2.2.2.1 Preparation of Actin Acetone Powder 
For the preparation of actin acetone powder four New Zealand white rabbits 
(Oryctolagus cuniculus) were sacrificed and the dorsal lateral skeletal muscles 
and the hind leg muscles are excised and chilled on ice. The muscles were freed 
from tendons and fat, sliced and minced in a prechilled meat grinder. The mince 
is extracted by stirring for 10-20 minutes in 3 volumes Guba Straub Buffer. 
Further, the solution was supplemented with 12 volumes of cold water and stirred. 
The extract was filtered through two layers of cheesecloth. Later, the filtered 
muscle mince was resuspended in 5 volumes Carbonate Buffer A (w/v) and 
stirred for 30 minutes. The extract was filtered through 2 layers of cheesecloth 
and the filtered residue was resuspended in the same volume (w/v) Carbonate 
Buffer B. The extract was stirred for 10 minutes and diluted with 5 volumes of 
warm water and this was filtered through 2 layers of fine meshed cheesecloth. 
The filtered residue was resuspended in 2.5 l (per kg of rabbit meat) cold acetone 
and stirred for 30 minutes and filtered through the fine meshed cheesecloth. This 
procedure was repeated once and the final pellet was spread on filter paper and 
allowed to dry overnight in the chemical hood. The acetone powder was stored at 
-20°C.  
Table 10: Buffers for the preparation of actin acetone powder 
Guba Straub Puffer Carbonate Buffer A Carbonate Buffer B 
0.3 M KCl 47.6 mM NaHCO3 10 mM NaHCO3 
0.1 M KH2PO4 0.1 mM CaCl2 10 mM Na2CO3 
0.05 M K2HPO4  0.1 mM CaCl2 
pH 6.5   
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Around 225 g dry acetone powder could be obtained from 2.5 kg rabbit meat. 
The actin acetone powder was the starting material for the preparation of G- and 
F-actin. 
2.2.2.2 Preparation of G- and F-actin from Acetone Powder 
Actin acetone powder was prepared from the rabbit muscle as described above. 
5 g of actin acetone powder was mixed with 80-100 ml Actin Buffer and stirred at 
4°C for 30 minutes. The extract was filtered throug h 2 layers of filter paper 
through a vacuum tank filter. The filter paper was washed 4 times with Actin 
Buffer to increase the protein yield. After filtration, the volume of the extract was 
typically 120 ml. The solution was then ultracentrifuged (70,000 × g, 60 min, 4°C, 
rotor 70Ti). The volume of the actin containing supernatant was measured and 
supplementing the solution with 100 mM KCl and 2 mM MgCl2 induced the 
polymerization of monomeric G-actin to filamentous F-actin. The solution was 
kept at room temperature for 2 hours and subsequently ultracentrifuged (70,000 
× g, 180 min, 4°C, rotor 70Ti). The sediment was homog enized in 50 ml 
Depolymerization Buffer by using a hand held glass homogenizer and dialyzed 
over night against 5 l Depolymerization Buffer.  
The G-actin solution was clarified by centrifugation (70,000 × g, 60 min, 4°C, 
rotor 70Ti). The volume of the supernatant was measured and the actin 
concentration determined by measuring the absorption at 280 nm (ε280 = 46 000 
cm-1M-1, MW = 41.7 kDa). The actin concentration was adjusted to 1-2 mg/ml by 
adding Depolymerization Buffer and G-actin polymerization was induced by 
supplementing the solution with KCl and MgCl2 to 100 mM and 2 mM, 
respectively. The solution was kept at room temperature for 1 h. The F-actin 
containing solution was ultracentrifuged (70,000 × g, 60 min, 4°C, rotor 70Ti) and 
the sediment was either stored at 4°C or directly r esuspended. For resuspension, 
the pellet was removed with a stainless steel spatula by scraping it into 1-2 ml 
Homogenisation Buffer and transferred it into a hand held glass homogenizer, 
gently homogenized and the concentration of the F-actin solution was measured. 
The typical yield was approximately 50 mg F-actin from 5 g actin acetone powder. 
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Table 11: Buffers for the preparation of G- and F-actin 
Actin Buffer Depolymerization Buffer Homogenization Buffer 
10 mM HEPES pH 8.0 5 mM HEPES pH 7.5 5 mM HEPES pH 7.5 
0.5 mM ATP 0.2 mM CaCl2 2 mM MgCl2 
0.2 mM CaCl2 1 mM NaN3 100 mM KCl 
1mM DTT 0.5 mM ATP 0.02 % NaN3 
2.2.2.3 Preparation of Pyrene-Labeled Actin 
Pyrene (N-(1-pyrene)iodoactamide) labeled F-actin was required for the transient 
kinetic studies of the interaction between myosin and F-actin. Site-specific 
labeling of Cys374 with pyrene was carried out as described by Kouyama et al 
(Kouyama & Mihashi, 1981). The strong fluorescence of the reporter moiety in 
combination with the quench in fluorescence makes this label an ideal tool for 
transient kinetic study (Criddle et al, 1985). Further, the labeling reaction was 
carried out by slowly mixing F-actin with pyrene in a ratio of 1:5 (w/w) and the 
solution was stirred for 16 hours protected from light. The solution was 
centrifuged (4700xg, 15 min, 4°C, rotor 70Ti) to pe llet the precipitated dye and 
denatured protein. In addition, the F-actin containing supernatant was centrifuged 
(7000xg, 180 min, 4°C, rotor 70Ti) and the sediment  was resuspended in 
Homogenization Buffer (Table 11). Later, concentration of pyrene actin was 
determined under consideration of the absorbance of pyrene at a wavelength of 
280 nm. The pyrene concentration was determined photometrically at 344 nm 
(ε=23000 cm-1M-1) and the contribution of pyrene (ε=22000 cm-1M-1) to the total 
absorption of the sample at 280 nm was determined and subtracted from the 
total absorption at 280 nm. The extent of labeling degree was typically 60-90%. 
2.2.2.4 Preparation of TRITC-Phalloidin Actin 
TRITC (Tetramethylrhodamine-B-isothiocyanate)-labeled actin was required for 
the visualization of actin filaments in the in vitro motility assay (Bereiter-Hahn & 
Kajstura, 1988). TRITC-phalloidin is a fluorescent rhodaminyl-coupled phalloidin 
derivative that selectively interacts and stabilizes filamentous actin and prevents 
F-actin depolymerization to G-actin. F-actin was labeled with TRITC-phalloidin by 
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incubating 2 µM F-actin and 3 µM TRITC-phalloidin in the appropriate assay 
buffer for at least 12 hours protected from light. 
2.2.3 The Baculovirus/Sf9-System 
Recombinant baculoviruses are widely used to produce heterologous genes in 
cultured insect cells. Baculoviruses are double-stranded, circular, supercoiled 
DNA molecules in a rod-shaped capsid. For the recombinant production, isolates 
of the Autographa californica multiple nuclear polyhedrosis virus (AcMNPV) are 
used. In the baculovirus expression system, the naturally occurring polyhedrin 
gene is replaced with a recombinant gene or cDNA and produced under the 
control of the naturally occurring polyhedrin promoter. Usually, the recombinant 
proteins are processed, modified and targeted to the appropriate cellular 
locations (Smith et al, 1983).  
2.2.3.1 Transformation 
In order to generate recombinant bacmid for the heterologous production of 
recombinant human myosin motor domains, the transfer vectors containing the 
cDNA encoding the expression construct (from Sarah Heissler, Institute of 
Biophysical Chemistry, Hannover Medical School) were transformed in 
chemically competent DH10Bac cells. The composite bacmid can be isolated 
and transfected into Sf9 insect cells as described under section 2.2.3.2. 
For the transformation procedure, competent DH10Bac cells (100 µl) were 
thawed on ice and 100 ng of transfer vector was added. The cell suspension was 
gently mixed and incubated on ice for 30 minutes. To heat-shock the cells, the 
suspension was heated 45 seconds in a 42°C thermost at and incubated on ice 
for two minutes. 900 µl S.O.C. medium was added and the cell suspension was 
incubated at 37°C for 4 hours with a shaking speed of 225rpm. After the 
incubation, the reaction mix was diluted 1:10 and 1:100 with S.O.C. medium and 
150 µl of the suspension were spread on LB agar plates (supplemented with 50 
µg/ml kanamycin sulfate, 7 µg/ml tetracycline, 10 µg/ml gentamicin, 300 µg/ml X-
gal and 40 µg/ml IPTG) and incubated for 18 hours at 37°C. 
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Colonies containing the composite bacmid appeared as white colonies on the 
selective medium. These transformants were selected and grown at 37°C 
overnight in 3 ml LB broth (225 rpm) containing 50 µg/ml kanamycin sulfate, 7 
µg/ml gentamicin and 10 µg/ml tetracycline for the bacmid preparation (see 
section 2.2.3.2).  
Table 12: Medium for the cultivation of E.coli 
LB brotha LB agara S.O.C. medium 
10 g/l Tryptone 10 g/l Tryptone 20 g/l Peptone 
10 g/l Casein 10 g/l Casein   5 g/l Yeast extract 
10 g/l Yeast extract 10 g/l Yeast extract 10 mM NaCl 
  5 g/l NaCl    5 g/l NaCl  2,5 mM KCl 
 15 g/l Agar 10 mM MgCl2 
  10 mM MgSO4 
  20 mM Glucose 
a The media was supplemented with additives after autoclaving at temperatures below 
37°C.  
2.2.3.2 Bacmid Preparation 
Composite bacmid was prepared from 3 ml selective LB medium after incubating 
for approximately 16 hours at 37°C with the buffers  supplied with the QIAGEN 
Plasmid Midi Kit. The cells were harvested by centrifugation (2000xg, 5 min, RT) 
and resuspended in 300 µl buffer P1. After the addition of 300 µl buffer P2, the 
cell suspension was incubated for 5 minutes at RT. 300 µl buffer P3 were added 
and the sample was mixed immediately by inverting 5 times prior to 10 minutes 
incubation on ice. The solution was centrifuged (14000 × g, 10 min, RT) and the 
cleared lysate was isolated and centrifuged (14000 × g, 10 min, RT) again. The 
supernatant containing the bacmid DNA was precipitated by adding 800 µl of 
room-temperature isopropanol and incubated for 10 minutes on ice. The DNA 
was pelleted (14000 × g, 15 min, RT), washed with 500 µl of 70% ethanol and 
centrifuged (14000 × g, 5 min, RT). The pellet was air-dried for 10 minutes and 
the bacmid DNA was dissolved in 40 µl buffer EB or water and either stored at -
20°C or directly transformed in Sf9 insect cells.   
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2.2.3.3 Insect Cell Culture 
2.2.3.3.1 Cell Line and Cell Growth 
In this thesis, Sf9 insect cells were used for the recombinant production of human 
myosin motor domain constructs using the baculovirus expression system. Sf9 
cells are a clonal isolate originated from the IPLB-Sf21-AE cell line, derived from 
the pupal ovarian tissue of the armyworm Spodoptera frugiperda (Smith et al, 
1983) . The morphology of typical Sf9 cell is round and short spindle-shaped. Sf9 
insect cells have a doubling time of 72 hours. Sf9 cells were maintained under 
sterile conditions in monolayer and suspension culture. The insect cells grow 
optimally at 27°C in serum-free suspension as well as in adhesion culture and do 
not require CO2 supplement. Insect cell medium was equilibrated to room 
temperature prior to use. Handling of Sf9 cells was carried out in a laminar flow 
hood.  
2.2.3.3.1.2 Initiation  
A vial of frozen cells was removed from liquid nitrogen and thawed on ice. The 
cells were directly added to 10 ml medium and centrifuged (1000 × g, 5 min, 4°C). 
The cell pellet was resuspended in fresh medium and transferred to an 
Erlenmeyer flask. The cells were maintained between 0.8⋅106 cells/ml and 2⋅106 
cells/ml for a time period of 10 days.  
2.2.3.3.1.3 Cultivation of Sf9 Cells in Adhesion- and Suspension Culture 
Sf9 insect cells need to be sub-cultured by diluting the cells back to a density that 
is required to maintain logarithmic growth and provides maximum viability. 
Subculture procedure for adherent cultures: Adherent cultures were passaged at 
confluence and diluted 1:5 in fresh media. The conditioned media was removed 
from the cells and replaced with fresh media. The cells were dislodged from the 
culture with a cell scraper. One fifth of the cell suspension was transferred into a 
new culture flask and diluted to the original volume with fresh media. The cells 
were incubated at 27°C until they reach confluency.  The following table 
summarizes parameters for the cultivation of Sf9 cells in monolayer culture. 
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Table 13: Flask sizes and medium volumes 
 
 
Alternatively, Sf9 insect cells were maintained in suspension culture. Cells were 
grown in sterile Erlenmeyer flasks in a 27°C consta nt-temperature incubator with 
an orbital shaker platform. For shaker cultures, the working volume was 
maximum 50% of the indicated volume for adequate aeration. Suspension 
cultures were diluted before they reached a maximum density of 4⋅106 cells/ml 
and diluted back with fresh medium to a minimum of 0.8⋅106 cells/ml. This 
procedure maintains the cells in the logarithmic growth phase. 
2.2.3.3.1.3 Cryoconservation 
Sf9 insect cells were frozen when they doubled regularly and were >95% viable 
at as low passage number as possible. This was typically after 10-14 days after 
the initiation of a new culture. The cells density was determined and the cells 
were centrifuged (1000 × g, 5 min, 4°C). The conditioned medium was removed 
and saved in order to prepare the freezing medium (Table 14). The cells were 
resuspended to a density of 1.5-2⋅107 cells/ml in Freezing-Medium. One milliliter 
of the cell suspension was transferred to sterile cryovials and incubated on ice for 
30 minutes. The vials were placed at -20°C for 1 ho ur in a Styrofoam box, 
transferred to -80°C for 24 hours and finally store d in liquid nitrogen.  
Table 14: Medium for cryoconservation 
Freezing-Medium  
50% Conditioned medium 
42.5% Fresh medium 
 7.5% DMSO 
 
Flask Size [cm2] Cell density at confluency Volume [ml] 
9.6 (6-well plate) 1.2⋅106  2 
T-25 4.0⋅106  4 
T-75 1.2⋅107  13 
T-175 2.7⋅107  35 
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2.2.3.3.1.4 Cell Density and Viability 
The number of viable cells per milliliter cells and the relative amount of viability 
can be determined with a hemocytometer. For determining cell viability and cell 
number, 10 µl of Sf9 suspension culture are mixed with 10 µl trypan blue dye. 10 
µl of the solution are infused in a hemocytometer. Dead cells appear blue in the 
since their membranes are no intact and they take up the dye. Live cells have 
intact membranes that exclude the dye. The total amount of cells as well as the 
amount of dead cells is determined over 25 squares of the hemocytometer. The 
number of living cells was calculated from the counted number of cells multiplied 
with the dilution factor of the solution as well as the factor 104. The viability of the 
Sf9 cells should be at least 98%. 
2.2.3.4 Transfection 
The transfection of Sf9 insect cells was carried out with the cationic lipid reagent 
Cellfectin II according to the manufacturer. 0.8 x 105 cells in 2 ml medium were 
seeded in each well of a 6-well plate and the cells were allowed to attach for 30 
minutes. Meanwhile, 8 µl Cellfectin II were diluted in 100 µl medium and 
combined with a solution containing 1-2 µg bacmid in 100 µl medium. The 
combined transfection mixture was incubated for 15-30 minutes at room 
temperature. After the incubation, the transfection mixture was added drop-wise 
onto the cells. The cells were incubated for 3-5 hours before the transfection 
mixture was removed and replaced with 2 ml medium. The cells were incubated 
for 4 days or until they showed signs of viral infection. Baculovirus containing 
medium was harvested as described under section 2.2.3.3.1.3. 
2.2.3.5 Amplification and Isolation of Recombinant Baculovirus 
Recombinant baculovirus stocks were amplified from low passage seed stocks in 
order to produce larger volumes of virus and high titer stocks. This step is 
necessary to generate a viral stock for the large-scale production is recombinant 
myosin motor domain constructs in Sf9 insect cells.  
To amplify recombinant baculovirus in monolayer culture, cells were infected at 
70% confluency with 1/50 - 1/100 (volume of virus/final volume of medium) with 
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recombinant baculovirus (Table 13). The cells were incubated for 4 days prior to 
harvesting the supernatant from the plate. Cellular debris was removed by 
centrifugation (1000 × g, 5 min, 4°C). The virus containing supernatant was  
sterile filtered (0.22 µM) and stored in a sterile container at 4°C protected from 
light.  
To amplify recombinant baculovirus from suspension culture, cells were infected 
at a maximal density of 1.6⋅106 cells/ml with 1/50 or 1/100 volume of virus/final 
volume of medium with recombinant baculovirus. The cell suspension was 
cultivated for 4 days and cells and cell debris were isolated by centrifugation 
(1000 × g, 5 min, 4°C). The supernatant was isolated, steril e filtered and stored 
at 4°C, protected from light.  
2.2.3.6 Protein Production and Isolation of Expressing Cells 
For the recombinant production of human myosin motor domain constructs in Sf9 
insect cells, cells in suspension cultures were inoculated at a cell density of 
1.6⋅106 cells/ml with 1/10 volume of recombinant virus/final volume of medium. 
The cells were grown for 72 hours in suspension culture and harvested by 
centrifugation (1000 × g, 5 min, 4°C). The cell pellet was resuspended in 1 /10 of 
the initial volume PBS, centrifuged (1000 × g, 5°C, 4°C) and stored at -80°C 
upon usage.  
2.2.4 Dictyostelium discoideum Cell Culture 
Dictyostelium discoideum’s (D.discoideum) ability to be easily cultivated in the 
lab adds to its appeal as a model organism. They can be grown in liquid culture 
and also in petri dishes best at 20 to 22 0C. AX-2 and AX-4 cells of D.discoideum 
were used in this study for cell culture and also for recombinant protein 
production. 
2.2.4.1 Recombinant Protein production In D.discoideum 
The eukaryotic organism Dictyostelium discoideum (D.discoideum) is one of the 
preferred organisms of choice for the overproduction of recombinant myosins 
and myosin fragments (Manstein & Hunt, 1995).  
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The expression vectors used in this work are derivatives of the D.discoideum 
pDXA vector (Manstein & Hunt, 1995). The vectors comprise the origin of 
replication (ori) of the D.discoideum high-copy-number plasmid Ddp2. The 
expression cassette of all vectors contain the strong, constitutive actin promoter 
act15, a start codon upstream of the multiple cloning site (MCS) as well as C- or 
N-terminal sequences for affinity tags. They also have the act6 neoR Tn5 
cassette for resistance to G418 for selection of positive transformants. 
Downstream of the MCS, polyadenylation and termination signals are present. In 
this work, the vector pDXA-3H was used, which comprises the DNA sequence 
coding for a C-terminal histidine octamer downstream of the MCS (Manstein et al, 
1991). The incorporation of cDNA sequence encoding for D.discoideum myosin-2 
motor domain into the MCS of the vector results in the recombinant production of 
His8 tagged protein, which can be purified by Ni2+-NTA-affinity chromatography. 
2.2.4.2 Analytical Preparation of Recombinant Myosin Motor Domains 
Expressed in D.discoideum 
The recombinant production of myosin motor domain constructs was carried out 
according to the protocol for transformation and selection of positive 
transformants as described (Manstein et al, 1989). The selected transformants 
were picked and used for the production of His8-tagged motor domain construct 
of Dd myosin-2, which was fused to single strand binding protein tail (SSB tail). 
Initially, the expression of myosin-2 motor domain proteins was carried out in the 
petri plate (9 cm plate) until the cells reach confluency (2-5x107 cells). For the 
analytical test of protein expression, the attached cells were scraped from the 
plate, resuspended in Lysis Buffer 1and transferred to a reaction tube. After 
centrifugation (5,000 rpm, 2min, 4°C), the pellet w as washed in 1 ml Extraction 
Buffer. The pellet was resuspended in 500µl Lysis Buffer 2 and cells were lysed 
by adding the same volume of Lysis Buffer 3. The cells were incubated (1 hour 
on ice) and centrifuged (13000 rpm, 30 min, Eppendorf 5415C). The pellet was 
washed with 500µl Lysis Buffer 1 and centrifuged (13000 rpm, 25 min, 
Eppendorf 5415C). The pellet contains the insoluble actomyosin complex, which 
is extracted in the presence of Mg2+-ATP by homogenizing the pellet in 50-70µl 
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Lysis Buffer 4. The extract was centrifuged (13000 rpm, 20 min). The 
supernatant was removed and mixed with 50-70 µl SDS Loading Buffer for the 
qualitative and quantitative analysis of the extracted protein via SDS-PAGE. 
Routinely, more than 90% of the protein in the soluble fraction correspond to 
actin, myosin, and the recombinant myosin fragments. Therefore, it is easy to 
detect any differences in expression levels between individual myosin constructs 
via SDS-PAGE analysis. Furthermore, the presence of a band corresponding to 
the recombinant protein indicates that the overexpressed protein has at least 
some of the functional properties that are characteristic for a myosin motor 
(Manstein & Hunt, 1995). 
Table 15: Buffers and inhibitor mixes for the analytic preparation of myosin motor domain 
constructs from D.discoideum.  
Lysis Buffer 1 Lysis Buffer 2 Lysis Buffer 3 
50 mM Tris/HCl pH 8.0 Lysis Buffer 1 Lysis Buffer 1 
2.5 mM EDTA 1 U CIAP/sample (freshly 
prepared) 
1% (v/v) Triton-X 100 
0.2 mM EGTA   
Protease-Inhibitor Mix 1 
(freshly prepared) 
  
1x Protease-Inhibitor Mix 
2 (freshly prepared) 
 
  
Lysis Buffer 4 100x Protease-Inhibitor 
Mix 1 
1000x Protease-Inhibitor 
Mix 2 
Extraction Buffer 10 mg/ml TAME 100 mM PMSF, in 
absolute ethanol 
12 mM MgCl2 8 mg/ml TPCK  
10 mM ATP (freshly 
prepared) 
0.2 mg/ml Pepstatin A 
 
0.5 mg/ml Leupeptin, 
absolute Ethanol 
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2.2.4.3 Overexpression and Purification of Dd Myosin-2 Motor Domain 
Once the expression of the motor domain is confirmed by analytical preparation 
(see section 2.2.4.2), the volume of the cells can be scaled up for the preparative 
protein purification. In principle, the protocol for the preparative protein 
purification is similar to the analytical minipreparation. The two procedures differ 
only in the amount of cells processed, and by an affinity chromatography step 
following the extraction of the myosin motor domain construct (Manstein and 
Hunt, 1995).  
If not stated otherwise, all steps were carried out at a temperature of 4°C and all 
buffers and solvents were prechilled to 4°C prior t o use. In this work, 18 l of cells 
were harvested at a cell density of 6 x 106-1 x 107 cells/ml. The cells were 
pelleted (4200 rpm, 5 min, 4°C, rotor JS-4.2), wash ed with 0.5 l of cold PBS 
Buffer and pelleted (4200 rpm, 5 min, 4°C, rotor JS -4.2) again. The wet weight of 
the pellet was determined. The washed cells (10-25 g) were resuspended in 5-
vol/g cell of Lysis Buffer 1 and transferred to a glass flask. After adding the same 
volume of Lysis Buffer 2, the suspension was sonicated for 1-2 minutes with a 30 
s pause (¾’’ tip, 50% power setting, 40% duty cycle). The suspension was 
incubated for further cell lysis for 45 minutes with gentle stirring at 4 ° C.  The 
lysate was ultracentrifuged (40000 rpm, 1h, 4°C, ro tor 45Ti). After centrifugation, 
the supernatant was discarded and the pellet was washed with 60-100 ml of 
Wash Buffer and centrifuged (45000 rpm, 45 min, 4°C , rotor 45Ti). The 
supernatant was discarded and the solid pellet, containing the myosin motor 
domain construct, was extracted by resuspension in 1.6 vols./g cells of Extraction 
Buffer supplemented with 10 mM ATP. The cell extract was centrifuged (60000 × 
g, 1h, 4°C, rotor 70Ti) and the supernatant was appl ied in the following Ni2+-NTA 
affinity chromatography step. 
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Table 16: Buffers for the preparative production of myosin motor domain constructs from 
D.discoideum.  
Lysis Buffer 1 Lysis Buffer 2 Wash Buffer Extraction Buffer 
50 mM Tris.HCl, pH 8.0 Lysis Buffer 1 50 mM Tris.HCl, pH 
7.3 
50 mM HEPES, 
pH 7.3 
2.5 mM EDTA 1% (v/v) Triton-X 
100 
30 mM Potassium 
acetate 
30 mM 
Potassium 
acetate 
0.2 mM EGTA 15 µg/ml 
Ribonuclease A 
15 mM Magnesium 
acetate 
15 mM 
Magnesium 
acetate 
1 mM DTT (freshly 
prepared) 
100 U CIAP, 
absolute (freshly 
prepared) 
7 mM β-mercapto 
ethanol (freshly 
prepared) 
0-300 mM KCl 
5 mM benzamidine 
(freshly prepared) 
 
5 mM benza- 
midine (freshly 
prepared) 
7 mM β-mercapto 
ethanol (freshly 
prepared) 
40 µg/ml TLCK   5 mM 
benzamidine 
(freshly prepared) 
Protease-Inhibitor Mix 1 
(Table 15) 
  
15 g ATP 
(freshly prepared) 
Protease-Inhibitor Mix 2 
(Table 16) 
   
2.2.4.4 Ni2+-NTA affinity chromatography 
The myosin-containing supernatant was filtered through a sterile filter with the 
pore size of 45 µm. By using the Äkta FPLC system, the filtrate was applied on to 
a Ni-NTA affinity chromatography column (2 x 20 cm) via a super-loop (capacity 
150 ml). Before loading the sample, the column was pre-equilibrated with 10 
column volumes (CV) of Low Salt Buffer. Once, the sample was loaded 
completely, the column was washed with 10 CV Low Salt Buffer, 5 CV of High 
Salt Buffer followed by a wash with Low Salt Buffer containing 25mM imidazole 
was used for removal of non-specific proteins. The elution of the protein was 
realized by a gradient of 3 to 100% Ni-NTA imidazole buffer containing the 
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NiNTA Low Salt Buffer (6 CV at 2 ml/min flow rate). The elution profile of the 
myosin-2 motor domain was followed on the OD280nm trace. Appropriate fractions 
were collected and analyzed by SDS-PAGE. The fractions containing the myosin 
motor domain were pooled and dialyzed against 2L Storage Buffer. The pure 
protein was concentrated by ultracentrifugation using Vivaspin devices.   
Table 17: Buffers for the Ni2+-NTA affinity chromatography of myosin motor domain constructs 
from D.discoideum.  
Low Salt Buffer High Salt Buffer Imidazole Buffer Storage 
Buffer 
50 mM HEPES, pH 
7.3 
50 mM HEPES, pH 
7.3 
1 M Imidazole, 
pH 7.3 
50 mM 
HEPES-KOH, 
pH 7.4 
30 mM Potassium 
acetate 
300 mM Potassium 
acetate 
3 mM 
benzamidine 
(freshly prepared) 
0.5 mM 
EDTA 
3 mM benzamidine 
(freshly prepared) 
3 mM benzamidine 
(freshly prepared) 
 1 mM DTT 
   1 mM MgCl2 
   
1 mM benza- 
midine 
(freshly 
prepared) 
   
3% (w/v) 
sucrose and 
150 mM KCl 
2.2.4.5 Gel Filtration  
In order to attain high purities of the recombinant myosin motor domain 
constructs, impurities were removed by gel filtration. Hence, the concentrated 
protein solution was sterile filtered (0.22 µM) and loaded on a pre-equilibrated 
Superdex 26/60-200 prep grade gel filtration column with a flow rate of 0.5 
ml/min. The sample was eluted with Storage Buffer (Table 17) (flow-rate: 0.5 
ml/min, maximal pressure: 0.5 MPa) and the eluate was collected in 1 ml 
fractions. The fractions were analyzed by SDS-PAGE and myosin containing 
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fractions were pooled and concentrated up to 10-20 mg/ml. Aliquots of the 
protein samples were flash-frozen in liquid nitrogen and stored at -80°C for future 
usage. 
2.2.4.6 Protein Quantitation 
Since proteins contain tryptophan, tyrosine or cysteine-cysteine disulfide bonds 
that absorb in the UV range (280 mm), purified proteins can be directly quantified 
by determining the UV absorbance at 280 nm in a UV-visible spectrophotometer. 
The Lambert-Beer equation was used to correlate the absorbance at 280 mm 
with the protein concentration. 
 
Where A, is the absorbance, ε is the molar extinction coefficient (M-1⋅cm-1), c is 
the protein concentration (M=moles/liter) and d is the path length in centimeters. 
The molar extinction coefficient was determined, based on the protein sequence, 
by using the online tool ‘Protparam’ (Gasteiger et al, 2005). 
2.2.4.7 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
SDS-PAGE is a method to separate proteins according to their size using a 
denaturing and discontinuous method developed by Laemmli (Laemmli, 1970). 
For the determination of the purity and size of prepared proteins from Sf9 and 
D.discoideum cells, precast 4-20% gradient gels (Pierce) were used. The protein 
samples were supplemented with 3x SDS Loading Buffer and boiled (10 min, 
95°C). The samples were loaded on the gel together with an appropriate protein 
marker.  
Table 18: Buffers for the SDS-PAGE  
HEPES-Running Buffer 3x Loading Buffer  
0.1 M Tris pH 8.0 0.2 M Tris/HCl pH 6.8 
0.1 M HEPES 33 % Glycerol 
3 mM SDS 3% SDS 
 3.2 % β-Mercaptoethanol 
 0.0016 % Bromphenol Blue 
A = ε⋅ c⋅ d
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The gel was run at a constant current of 30 mA for a time period of one hour in 
HEPES-Running Buffer. After the separation of the protein samples, the gel was 
subsequently stained with PageBlue solution.  
2.2.4.8 PageBlue-Staining 
Subsequent to the SDS-PAGE, the gel was transferred into a plastic container, 
covered with deionized water and microwaved for 2 minutes on high power. The 
water was discarded and the gel was covered with PageBlue solution, heated in 
the microwave for 30 seconds on high power and subsequently shaken for 15 
minutes at room temperature. The staining solution was discarded. The gel was 
destained by washing with water and microwaving for 5-10 minutes.  
2.2.5 Biophysical Methods 
2.2.5.1 Steady-State ATPase Assay 
The myosin steady-state ATPase activity in the presence or absence of F-actin 
was assayed in a spectrophotometric assay, which is based on the regeneration 
of hydrolyzed ATP, coupled to the oxidation of NADH. This coupled enzymatic 
assay, as schematically depicted in figure 2.1 is based on the ADP dependent 
conversion of phosphenolpyruvate (PEP) to pyruvate, catalyzed by the enzyme 
pyruvate kinase (PK). Subsequently, pyruvate is converted to L-lactate by the 
enzyme lactate dehydrogenase (LDH). This step requires NADH, which is 
oxidized to NAD+. NADH oxidation is accompanied with a decrease in NADH 
absorbance at 340 nm, which is directly proportional to the rate of the myosin 
steady-state ATP hydrolysis.  
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Figure 2.1: Schematic representation of the myosin steady-state ATPase assay. 
The steady-state ATPase activity in the presence or absence of F-actin was 
performed at 25 °C. Typically 0.2-0.5 µM myosin was  mixed with either 30, 40 or 
140 µM F-actin (depends upon the type of myosin) in a total volume of 100 µl 
ATPase Buffer.  
Measurements of the steady-state ATPase activity were either performed in UV-
transparent microtiter plates (96 well, half area, flat bottom) or quartz cuvetts in a 
spectrophotometer. In 96 well plates (Corning half area UV transparent), a 
standard reaction volume of 100 µl corresponds to a path length of 0.56 cm. Data 
acquisition was performed with the software SkanIt 2.5.1 (Thermo Scientific). The 
change in absorbance was detected at a wavelength of 340 nm, a temperature of 
25°C and a time period of max. 10 minutes. The data  acquisition interval was 4-5 
second. Analysis of the time series was performed with ORIGIN 8 (OriginLab). 
The rate of ATP hydrolysis (kATPase) is calculated from the following equation: 
[ ]sinmin60
/min
)340(
1
myods
Absk
nmNADH
ATPase
⋅⋅⋅⋅
∆−
=
− ε  
Where, εNADH(340nm) is the molar absorption coefficient of NADH at a wavelength 
of 340 nm and equals 6620 cm-1M-1. ∆Abs/min is the time-dependent change of 
the absorption signal; d is the path length of the well/cuvette and [myosin] is the 
myosin concentration. 
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Table 19: Buffers for the steady-state ATPase assay. 
ATPase Buffer   
25 mM HEPES pH 7.4 0.2 mM NADH 2 mM ATP 
0-25 mM KCl 0.05 mg/ml PK 0-140 µM F-Actin 
5 mM MgCl2 0.5 mM PEP 0.2-0.5 µM Myosin 
0.5 mM DTT (fresh) 0.02 mg/ml LDH  
2.2.5.2 Transient kinetics 
Transient kinetic analysis defines the elementary steps along the pathway of an 
enzyme catalyzed reaction. The methods rely on rapidly mixing a substrate with 
a sufficient concentration of enzyme to allow a direct observation of 
intermediates and products formed at the active site during a single enzyme 
cycle. Stopped-flow methods afford observation of reactions by monitoring 
changes in optical signals (i.e., absorbance, fluorescence, and light scattering) as 
a function of time after mixing. Analysis of the substrate concentration 
dependence of the rates and the amplitudes of observable species can define 
the sequence of events that occur after substrate binding (Johnson, 1998; 
Johnson & Porter, 1982). 
2.2.5.3 Stopped-flow techniques 
Stopped-flow techniques were used to study the kinetics of myosin in the 
presence of nucleotides and F-actin in solution. Figure 2.2 shows the scheme of 
a typical stopped-flow apparatus. A Stopped-flow spectrophotometer contains 
two syringes with reactant solutions that are rapidly mixed and pushed in a 
mixing chamber and then in an observation cell. The flow fills the stop syringe, 
which hits the trigger. The trigger switch stops the flow and starts data acquisition 
by monitoring an optical signal.  
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Figure 2.2: Schematic representation of a stopped-flow spectrophotometer.   (Scheme was 
adapted and modified from this reference link: http://porpax.bio.miami.edu/ 
<cmallery/255/255enz/ecb3x28.jpg). 
In the present work, transient kinetic assays were performed with a SF-61SX2 
stopped-flow system (Hi-Tech Scientific) equipped with a 75W Hg/Xe lamp. The 
performance of the instrument is limited by the dead time, which is ∼ 1 ms. 
To study the interaction between myosin, F-actin and nucleotides either the 
intrinsic tryptophan fluorescence signal or the light scattering signal was detected. 
Mant-fluorophores (N-methylanthraniloyl) (Figure 2.3B) or the fluorescent label 
pyrene (Figure 2.3A) enabled the detection of extrinsic fluorescence signals. 
Usage of fluorescent probes like mant-nucelotides is a valuable tool to determine 
the kinetic properties of the myosin motor domain (Batra et al, 1999; Ritchie et al, 
1993; Stewart et al, 2010). Since the mant moiety is very compact and its 
attachment position on the ribose ring of nucleotides result in minimal 
perturbations of the nucleotide-protein interaction. Furthermore, the fluorescence 
is polarity-sensitive and enables the direct detection of the nucleotide-myosin 
interaction (Batra & Manstein, 1999; Friedman et al, 1998).  
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Figure 2.3: A (right panel): Pyrene is a UV excitable thiol-reactive fluorophore that can be used to 
monitor the reaction between myosin and F-actin. B (left panel): MantATP has an 
excitation/emission maximum at 355/448 nm. The quantum yield of the fluorophore is highly 
environmental sensitive and increases significantly upon binding to myosin motor domains. B (left 
panel): Pyrene is a UV excitable thiol-reactive fluorophore that can be used to monitor the 
reaction between myosin and F-actin.  
The interaction between myosin and F-actin can be assayed directly by using the 
flourescently labelled pyrene-actin. The strong fluorescence of the pyrene moiety 
in combination with the strong quench in fluorescence (up to 70%) upon myosin 
binding makes pyrene and ideal marker for the transient kinetic studies of the 
actin-myosin interaction (Criddle et al, 1985). 
When assaying the interaction between myosin and nucleotides, the intrinsic 
protein fluorescence was excited at 297 nm and the emitted light was detected 
after the passage of a WG320 cut-off filter. The WG320 filter eliminates the 
emission light (wavelength of 348 nm) from the excitation light. When using 
mant-nucleotides, the fluorescence was excited at a wavelength of 365 nm and 
the fluorescence emission was monitored through a KV389 filter. Alternatively, 
the FRET signal, arising from the radiation less transition from myosin to the 
mant-moiety, was excited at a wavelength of 297 nm and the fluorescence 
emission was monitored after passage through a KV389 filter. Pyrene-
fluorescence was excited at a wavelength of 365 nm and the emitted light was 
detected after the passage of a KV389 cut-off filter.  
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If not stated otherwise, given concentrations are final concentrations after mixing 
the reactants in a 1:1 ratio in the stopped-flow apparatus. The reaction volume 
was 50 µl per shot. Each experimental condition was at least assayed 3 times to 
optimize the signal-to-noise ratio. Data acquisition and evaluation was performed 
with the software Kinetic Studio 1.12 (TgK Scientific). The time-dependent 
change of the spectroscopic signal was approximated with single or double 
exponential regressions. If not stated otherwise, all assays were carried out at a 
constant temperature of 20°C in MOPS-Buffer with a fixed MgCl2 concentration 
of 5 mM. Before usage, the buffer was sterile filtered (0.22 µm) and degassed. 
Table 20: Buffer for the stopped-flow assays. 
MOPS-Buffer 
20 mM MOPS pH 7.0 
100 mM KCl 
0-20 mM MgCl2 
2.2.5.4 In vitro Motility assay 
The in vitro motility assay is a simplified model of force and motion generation by 
myosin motors (Warshaw et al, 1990a; Warshaw et al, 1990b). In the present 
work, the assay was performed with recombinant myosin motor domain 
constructs fused to an artificial lever arm in order to study the interaction of the 
myosins with small molecule effectors. 
Preparation of flow cells: For the preparation of the flow cells, 1% (w/v) 
nitrocellulose was incubated in amyl acetate overnight at a temperature of 4°C. A 
1.5 µl drop of this solution was placed on a coverslip and spread over the surface 
with a 10 µl tip. The coverslip was dried for 10 minutes at room temperature. Two 
parallel strips of double-sided tape were placed 4 mm apart from each other on a 
microscope slide. The coated coverslip was placed up side down on a 
microscope slide. This generates flow cells with a volume of approximately 10 µl. 
The flow cells were constructed and stored up to 3 days at 4°C.  
To ensure a good quality of movement, inactive motors were separated from 
active motors via an actin-purification step. Therefore, 0.4-0.5 mg/ml myosin was 
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mixed 1:1 (mass ratio) with unlabelled F-actin in the presence of 3.5 mM ATP in 
AB Buffer and sedimented (70000 rpm, 20 min, 4°C, r otor 120.1) in an 
ultracentrifuge.  TRITC-phalloidin actin was prepared as described under section 
2.2.2.4. 
For the preparation of the flow cell, 10µl penta-histidine-antibody (0.025 mg/ml 
antibody dissolved in water) was filled in the flow cell and allowed to remain in 
the cell for 5 minutes. The flow cell was washed with 10 µl Buffer 1 in order to 
prevent unspecific binding. 10 µl myosin solution was filled in the flow cell. After 
incubation for 2 minutes, the flow cell was washed with 10 µl Buffer 1, followed 
by the infusion of 10 µl fragmented F-actin solution (approx. 20 nM). The 
chamber was incubated for 2 minutes in order to block non-specific binding. The 
flow cell was subsequently washed with 10 µl Buffer-4 and 10 µl Buffer 1. 10 µl 
TRITC-phalloidin labelled F-actin (approx. 20 nM) were perfused and incubated 
for 2 minutes. The flow cell was washed with 10 µl Buffer 1 and 10 µl Buffer-2. 
After the addition of Buffer 2, the decoration of the myosin with TRITC-labelled F-
actin was checked under the microscope. The assay was started with the 
addition of 10 µl Buffer 3. 
The movement of actin filaments over the myosin-decorated nitrocellulose 
surface was determined with an Olympus IX70 microscope equipped with an 60x 
oil-immersion objective (PLAPO/TIRF) in an in enclosed box at a temperature of 
30°C. The pixel size was defined by the reaction se tup: When a camera-binning 
of 2x2, a microscopic magnification of 1 or 1.5 together with a 60-fold objective 
magnification was used, calibration with an object micrometre resulted in a pixel 
size of 0.215 µM and 0.144 µM, respectively.  TRITC-fluorescence was excited 
at a wavelength of 545 nm and the fluorescence emission was detected at a 
wavelength of 570 nm. The corresponding filters were implemented in the 
microscope. 
In a standard assay, 100 images were acquired with a 1394 Orca-ERA CCD-
camera (Hamamatsu Photonics). The exposure time of the fluorophore was 230 
ms. The interval between two images was 300 or 600 ms. The resulting movie is 
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a split screen image of actin filaments over a myosin- decorated nitrocellulose 
surface.  The images were converted to ‘TIFF’ images with the program CellR 
(Olympus). Actin sliding velocities were determined by an automatic tracking 
system (DiaTrack 3.01, Semasopht). The software determines the mean sliding 
velocity of the centre of single actin filaments along trajectories. For the 
evaluation of the mean sliding velocities, the data was exported in ORIGIN 8 
(OriginLab) and up to 10 individual data were merged. The sliding velocities were 
graphed as histogram and the mean velocity was calculated with a Gaussian 
function according to the following equation: 
y = 1
σ 2pi
e
−
1
2
x−µ
σ
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In this equation, the parameter µ equals the statistical average and σ equals the 
standard deviation.
 
Table 21: Buffers for the in vitro motility assay. 
AB Buffer Buffer 1 Buffer 2 Buffer 3 Buffer 4 
25 mM 
Imidazole 
10 mM 
DTT 
5 mg/ml Glucose 5 mg/ml Glucose 4 mM 
ATP 
25 mM KCl 0.5 mg/ml 
BSA 
0.1 mg/ml 
Glucose oxidase 
0.1 mg/ml Glucose 
oxidase 
in AB 
Buffer 
0.5-10 mM 
MgCl2 
in AB 
Buffer 
0.02 mg/ml 
Catalase 
0.02 mg/ml 
Catalase 
 
1 mM EGTA  in AB Buffer 4 mM ATP  
pH 7.4   in AB Buffer  
2.2.6 Crystallographic Methods 
2.2.6.1 Crystallization  
To determine the structure of proteins and protein-effector complexes, highly 
purified protein was used in all the instances. To form crystals, proteins had to 
attain an ordered arrangement. Since this formation of crystals is influenced by 
different factors such as homogeneity, concentration, temperature, pH, salt and 
many other factors, one has to initially consider these factors before starting any 
crystallization setups.  
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For crystallization purpose, the most common and effective vapour diffusion 
method “hanging drop” and “sitting drop” were used. Both entail a droplet 
containing protein, buffer, and precipitant being allowed to equilibrate with a 
larger reservoir containing similar buffer and precipitant. In the hanging drop 
method; the protein solution is placed on a siliconised glass cover slide. An 
aqueous buffered solution with precipitant, known as mother liquor, is mixed with 
the protein drop at a concentration just below that necessary to precipitate the 
protein (Figure 2.4). Usually, the protein solution and the mother liquor are mixed 
in a 1:1 ratio such that the reagents of the resulting drop have half of their original 
concentration. The cover slide is then inverted over a reservoir containing the 
crystallization solution (500 µl) and sealed with grease. Since the reagents in the 
reservoir solution have double the concentration to those in the drop, water 
gradually evaporates from the drop. When the precipitating condition or 
supersaturated state is reached; protein crystals may form. In the sitting drop 
method; the protein solution is placed in a post inside the well of a 24 well Linbro 
plate. Equal volume (1:1) mixing of mother solution with protein solution has 
been done in all cases. The same procedure of vapour diffusion principles 
applies in this method also. 
 
Figure 2.4: Phase diagram of macromolecule crystallization. This figure adapted from, Neer 
Asherie (Asherie, 2004). 
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2.2.6.2 Screening of Crystallization Conditions 
In order to find a proper crystallization condition, different commercial sparse-
matrix and grid screens were tested. For initial crystallization conditions, the 
crystallization screens MFS (myosin fusion screen, in house prepared), JCSG++ 
suite, PEGs suite, Ammonium Sulfate suite, MPD suite, pH suite, Anion & Cation 
suite and Classics suite were employed. Conditions containing hints of crystal 
formation were optimized by individually devised screens around the initial 
condition by altering buffer, precipitant, and additive concentrations and identities, 
as well as altering the temperature of crystallization (12 °C, 8 °C and 4°C) and 
protein concentration. Therefore, 500 µl of precipitant solution were filled into a 
Linbro crystallization plate containing 24 wells. 2 µl of mother liquor was mixed 
with 2 µl of protein solution on a siliconised cover slide. The cover slide 
containing the drop hanging upside down was sealed with grease (hanging drop 
vapour diffusion method). In most cases, crystals grew in 2 weeks but the biggest 
and best diffracting crystals took 3-4 weeks to grow.  
2.2.6.3 Crystallization of Pentachloropseudilin with Dd Myosin-2 
The Dd myosin-2 motor domain construct M761 was used for crystallization in 
the presence of pre-incubated (1 hour, 4 °C) mixtur e of sodium meta-vanadate (2 
mM), ADP (2 mM), and PClP (0.5 mM). A mother liquor of 50 mM HEPES pH 7.4, 
140 mM NaCl, 11% w/v PEG8000, 2% (v/v) MPD, 5 mM MgCl2, 5 mM DTT, and 
1 mM EGTA was mixed in 1:1 ratio with the pre-incubated protein solution. 
Hanging-drop method was used.   
2.2.6.4 Crystallization of Ammosamides with Dd Myosin-2 
The Dd myosin-2 motor domain construct M761 was used for crystallization. 
Initial trials of sparse and grid matrix as well as attempts of co-crystallization 
Ammosamides with the Dd myosin-2 motor domain failed. However, Dd myosin-2 
motor domain crystals grew at 4°C in a mother liquo r containing 50 mM HEPES 
pH 7.6, 140 mM NaCl, 11% (w/v) PEG5K-MME, and 2% (v/v) MPD. Prior to 
crystallization, the protein was preincubated (1 hour, 4 °C) with a mixture of 
sodium ortho-vanadate (2 mM) and ADP (2 mM). Dd myosin-2 crystals were 
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grown in 3 weeks in the absence of any effector to a size of 500-600 µm. The 
crystals were used for soaking with the effectors Ammosamide A, Ammosamide 
B, Ammosamide 272 and Deschloroammosamide B. The crystals were soaked in 
gradually increasing concentrations of Ammosamides up to a final concentration 
of 2 mM. For each step of incubation, the crystals were incubated for 10 minutes 
in the presence of Ammosamides.   
2.2.6.5 Crystallization of Human Nonmuscle Myosin-2C Motor Domain 
Fused to Alpha Actinin Repeats (2R) from Dictyostelium discoideum  
The nonmuscle myosin-2C motor domain fused with two spectrin like alpha actin 
repeats (2R) was crystallized in the pre-power stroke state (Mg2+ADPVO4). 
Crystallization conditions were: 50mM Tris pH 8.2, 10 % PEG 5K MME, 1 % 
MPD and 200 mM NaCl. Protein and mother solution were mixed in a 1:1 ratio. 
Rectangular plate shaped crystals of the motor domain construct of nonmuscle 
myosin-2C grew in hanging drops using vapour diffusion at 8 °C by mixing 2 µl of 
protein solution (~12 mg/ml) with 2 µl of 50mM Tris pH 8.2, 10 % PEG-5K MME, 
1 % (v/v) MPD and 0.2 M sodium chloride. Crystals with a size of 400 x 250 x 
400 µm grew in 4 weeks. 
2.2.6.6 Crystal Freezing and Data Collection 
For myosin 2:effector soaked/co-crystallized crystals the cryo-solution, i.e. a 
solution that protects from the formation of ice upon freezing, was the same as 
the crystallization conditions with an additional 150mM NaCl and 20-25 % (w/v) 
ethylene glycol (Garman, 2003; Garman & Doublie, 2003). For non-muscle 
myosin-2C crystals, the cryo-solution was the same as the crystallization 
condition with an additional 20 % (w/v) ethylene glycol. Protein crystals were 
transferred in serial steps of increasing concentrations of the cryo-solution. Once 
the final concentration of the cryo-solution step reached, the crystals were then 
transferred into liquid nitrogen using a nylon loop or MiTeGen loops and stored at 
100 °K until data collection. At 100 °K crystals we re exposed to X-rays, because 
at this temperature radiation damage is lower than at room temperature. Also, 
conformational disorder and thermal vibrations are reduced at this temperature 
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(Nave & Garman, 2005). In general, for diffraction of macromolecule crystals, 
either home sources or synchrotron sources were used. Dd myosin-
2ammosamide complexes were collected at home source (Bruker proteum X8 
rotating anode, CuKα: 1. 5418Å). Nonmuscle myosin-2C crystals and Dd myosin 
2PClP complex data were collected at synchrotron source BESSY, BL14.1, 
Berlin. 
2.2.6.7 X-ray Diffraction 
X-ray diffraction from crystalline solids occurs as a result of the interaction of X-
rays with the electron charge distribution in the crystal lattice. The ordered nature 
of the electron charge distribution, whereby most of the electrons are distributed 
around atomic nuclei which are regularly arranged with translational periodicity, 
means that superposition of the scattered X-ray amplitudes will give rise to 
regions of constructive and destructive interference producing a diffraction 
pattern (Hiltner & Krieger, 1969; Marchesini et al, 2003).  
The diffraction maxima are some times individually considered to be the result of 
diffraction of the incident X-ray beam of Wavelength (λ) from crystal lattice planes, 
having miller indices h k l and spacing dhkl. Diffraction occurs at an angle of 
incidence equal to the Bragg angle θB, i.e. Bragg’s law is obeyed: 
λ = 2dhkl sinθB  
The way in which the separate scattered or diffracted rays combine to form an 
image depends on three factors associated with each ray: (a) the direction, (b) 
the amplitude and (c) the phase. In X-ray crystallography, the diffracted beams 
are separately observed and their intensities measured as the blackness of spots 
on an X-ray film or by direct quantum counting in a diffractometer. By identifying 
the Miller indices (hkl) of the crystal plane-giving rise to each diffracted beam, the 
direction of the beam is specified. From the measured intensity of the beam its 
amplitude can be deduced. The amplitude of the wave |Fhkl| is proportional to the 
square root of the intensity measured on the detector. So two of the three 
necessary pieces of information about each beam are known, but unfortunately 
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there is no direct method available yet for observing the phase of each diffracted 
beam, which is the third piece of information needed before mathematical 
recombination is possible to produce an image of the structure. This constitutes 
what is known as the phase problem in crystallography (Taylor, 2003). 
The solution of a crystal structure therefore consists of applying some technique 
for obtaining the approximate phases of at least some of the X-ray reflections, 
and the process of structure refinement is one in which the knowledge of phases 
is extended to all reflections and is made as accurate as possible for all 
reflections. Apart from the direct methods of obtaining some initial phases, both 
the solution and refinement processes depend on the ability to calculate structure 
factors for a proposed approximate arrangement of some or all of the atoms in 
the crystal structure. 
It is possible to calculate simultaneously both the amplitude |Fhkl| and phase αhkl 
of each beam that would be diffracted by the proposed structure. Since the 
phases cannot be compared with any observable quantities, the validity of the 
proposed structure must be tested by comparison of the calculated values of the 
amplitudes of the structure factor Fc with the observed amplitudes |F0|. This is 
represented by a reliability index or R factor: 
Rfactor =
Fo − Fc∑
Fo∑
 
Electron density at a position (xyz) in the unit cell of a crystal is the summation of 
all the hkl planes, which in words one can express as: electron density at (xyz) = 
the sum of contributions to the point (xyz) of waves scattered from plane (hkl) 
whose amplitude depends on the number of electrons in the plane, added with 
the correct relative phase relationship or, mathematically, 
ρ x, y, z( ) = 1V Fhklhkl∑ exp iαhkl( )exp −2pi i hx+ ky+ lz( )( )  
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Where, V is the volume of the unit cell and αhkl is the phase associated with the 
structure-factor amplitude |Fhkl|.  
In this thesis, Dd myosin 2ammosamide complexes diffracted from 2.4 Å to 2.9 
Å on Bruker proteum X8 rotating anode. Nonmuscle myosin-2C data diffracted to 
2.0 Å and Dd myosin 2PClP complex diffracted to 2.5 Å at the synchrotron 
source BESSY, BL14.1 in Berlin. 
2.2.6.8 Data Processing 
Dd myosin 2PClP complex data was indexed, integrated and scaled with XDS 
(Kabsch, 2010). Nonmuscle myosin-2C data processing was performed using 
XDS and SADABS (Blessing, 1995). Dd myoson-2ammosamide complexes 
data were collected at home source rotating anode generator and processed with 
proteum suite (Proteum X8, Bruker Inc).  
2.2.6.9 Structure Solution 
Phase problem can be partially solved by having an atomic model, from which 
estimates of the phases can be computed. Such a model can be obtained when 
the structure of a related protein is already known, or even the same protein from 
a different crystal form. But to build up an atomic model of the new crystal form, it 
is necessary to work out how the model should be oriented and position in the 
new cell. Rossmann et al. introduced the powerful molecular replacement 
technique to solve that problem (Rossmann & Blow, 1962).  
2.2.6.9.1 Molecular Replacement 
In this thesis, molecular replacement (Rossmann & Blow, 1962) was used as a 
method for solving the initial structure solution. Molecular replacement can be 
used to solve a structure with a good starting model covering reasonably large 
fraction of the structure in the crystal. As a rule of thumb, molecular replacement 
with modern programs will probably be fairly straightforward if the model is fairly 
complete and shares at least 30% sequence identity with the unknown structure. 
It becomes progressively more difficult as the model becomes less complete or 
shares less sequence identity (Taylor, 2003).  
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The molecular replacement (MR) solution of human nonmuscle myosin-2C motor 
domain construct in pre-power stroke state was obtained by using the template 
smooth muscle myosin motor domain (1BR4). Phaser (McCoy, 2007) module in 
Phenix (Adams et al, 2010) suite was used for this purpose. The MR solution for 
Dd myosin-2 motor domains was achieved by using the template Dd myosin-2 
motor domain crystal structures (1YV3 in case of PClP bound structure and 
2XEL in case of ammosamide bound structures). For Dd myosin-2 motor domain 
molecular replacement solution MolRep module (Vagin & Teplyakov, 1997) of 
CCP4 suite  was used. 
 
2.2.6.9.2 Structure Refinement 
Refinement of human nonmuscle myosin-2C motor domain in pre-power stroke 
state was carried out with Phenix.refine module (Afonine et al, 2010). Refinement 
of Dd myosin-2 motor domain complexed to the PClP was carried out using CNS 
(Brunger et al, 1998). Refinement of Dd myosin-2 motor domain complexed to 
the Ammosamide effectors was carried out using Phenix.refine. Further manual 
building and refinement of model were carried out using COOT in all cases of 
structural solution (Emsley et al, 2010). 
2.2.6.9.3 Structure Validation 
Validation of the refined models is very important in order to remove model 
geometric errors, clashes and artifacts. After refinement of the crystal structures, 
all models were initially validated in COOT and then further validated using 
Molprobity (Davis et al, 2007a) and Procheck (Laskowski et al, 1993).  
2.2.7 Homology Modeling 
Homology modeling of protein refers to constructing an atomic-resolution model 
of the "target" protein from its amino acid sequence and an experimental three-
dimensional structure of a related homologous protein known as the "template". 
Homology modeling is also known as “comparative modeling”. 
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Homology models of class-1 myosins (Dd myosin-1B, Rn myosin-1b, Rn myosin-
1c), class-2 (Oc myosin-2) and class-5 myosins (Dd myosin-5B) were built using 
MODELLER 9v6 (Sali & Blundell, 1993). The motor domain structure of Dd 
myosin-1E (1LKX) was used as template to built Dd myosin-1B, Rn myosin-1b, 
and Rn myosin-1c myosin motor domains. The motor domain structures of Dd 
myosin-2 (2JJ9) and Gg myosin-5a (1OE9) were used as templates to built Oc 
myosin-2 and Dd myosin-5B motor domains respectively. All motor domain 
models of myosins were built using closely related pre-power stroke state motor 
domain template structures with sequence similarity greater than 60%. Missing 
loop regions in the homology models were built by Modeller, followed by energy 
minimization using GROMACS 4.0 (Van Der Spoel et al, 2005).  
All homology models were validated by Procheck (Laskowski et al, 1993). For 
building homology models, the following strategy has been implemented (Figure 
2.5). PfMyoA–MTIP and PkMyoA–MTIP complex structures (2QAC and 2AUC) 
were used as templates to model the structures of TgMyoA, TgMLC1, TgMyoD 
and TgMLC2 (Polonais et al, 2011). Only the 14 most C-terminal residues were 
used for modeling of TgMyoA (residues 806 to 819) and TgMyoD (residues 803 
to 816). Residues 69 to 213 of TgMLC1 and residues 228 to 364 of TgMLC2 
were used for homology models. All models were built using MODELLER (Sali & 
Blundell, 1993). 
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Figure 2.5. Flowchart of homology modeling 
2.2.8 Docking 
The number of proteins with a known three-dimensional structure is increasing 
rapidly, and structures produced by structural genomics initiatives are beginning 
to become publicly available. The increase in the number of structural targets is 
in part due to improvements in techniques for structure determination, such as 
high-throughput X-ray crystallography. With large-scale structure-determination, 
many current target proteins have been selected for their therapeutic potential. 
Computational methodologies have become a crucial component of many drug 
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discovery programs, from hit identification to lead optimization and beyond, and 
approaches such as ligand- or structure-based virtual screening techniques are 
widely used in many discovery efforts. One key methodology — docking of small 
molecules to protein binding sites — was pioneered during the early 1980s and 
remains a highly active area of research (Jackson & Sternberg, 1995; Jones et al, 
1997). When only the structure of a target and its active or binding site is 
available, high-throughput docking is primarily used as a hit-identification tool. 
However, similar calculations are often also used later on during lead 
optimization, when modifications to known active structures can quickly be tested 
in computer models before compound synthesis.  
2.2.8.1 Protein-Ligand or Myosin Effector Docking  
The ligand (PClP) was generated and energy minimized with ChemDraw 
(CambridgeSoft). Protein input files for docking were prepared by GOLD 
(Verdonk et al, 2003). Initially, blind docking of PClP for all the myosins was 
performed. It was observed that PClP has shown preference to the PBP binding 
pocket (with highest Goldscore of 30 to 40 depending on myosin isoform).  PClP 
binding site was focused based on blind docking results and also from the 
experimental binding mode of PClP. Local docking was performed using partial 
flexible docking feature of GOLD, 8-10 residues in each case, for protein side 
chains in the binding pocket and limited the search to a radius of 10 Å from the 
active site.  
The binding pocket was defined as all residues within 10 Å of atom 2746 (-Nz 
atom of Lys186 in Dd myosin-1B), atom 1523 (-Nz atom of Lys189 in Rn myosin-
1c), atom 1515 (-Nz atom of Lys192 in Rn myosin-1b), atom 2789 (-Nz atom of 
Lys186 in Dd myosin-1E) and atom 4234 (-Nz atom of Lys289 in Dd myosin-5B). 
Docking was performed using the ‘Genetic algorithm’ implemented in GOLD. 
“Goldscore-Chemscore” has been used as a customized protocol for consensus 
docking. In this protocol, the dockings produced with the Goldscore function are 
used for initial scoring and then the Chemscore function is used for final ranking. 
Twenty solutions were generated for each myosin. In all instances, at least one 
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of the top five solutions (Goldscore 35 to 40) converged to a similar pose for the 
myosins tested. The best poses deviated by ~1 Å, when compared to the 
experimental ligand bound structure (2XEL).  
2.2.8.2 Protein-Protein or Peptide Docking  
Initially, the modelled TgMyoA tail and TgMyoD tail was manually docked and 
guided by the pose of the PfMyoA tail in the Plasmodium MTIP-MyoA crystal 
structure (Bosch et al, 2006; Bosch et al, 2007). Finally, the side chains of the 
MLC1: MyoA complex and MLC2: MyoD complex of T. gondii were energy 
minimized until convergence was achieved using the default parameterization in 
GROMOS force field (Van Der Spoel et al, 2005). Also, Particle swarm 
optimization (PSO) technique was employed in combination with genetic 
algorithm of autodock (Goodsell et al, 1996; Namasivayam & Gunther, 2007) and 
GOLD (Verdonk et al, 2003) to find the optimal protein–peptide complex. Similar 
results were obtained independently using ROSETTADOCK (Lyskov & Gray, 
2008).  
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3. RESULTS 
3.1 Small Molecule Effectors 
3.1.1 Pentachloropseudilin 
Recently, the total synthesis of halogenated pseudilins, natural products 
containing a 2-arylpyrrole moiety and their synthetic analogues have been 
described (Martin et al, 2009a). Pentabromopseudilin (PBP) was subsequently 
identified as a potent inhibitor of vertebrate myosin-5 motor activity. An IC50 of 
400 nM was determined for the inhibition of vertebrate myosin-5 ATPase activity 
by PBP (Fedorov et al, 2009). Based on this finding, related compounds to 
identify myosin effectors with altered selectivity for the members of different 
myosin classes were screened. Pentachloropseudilin (PClP), a chemical and 
structural analogue of PBP, was identified in this screening as a potent inhibitor 
of class-1 myosins. 
In the current project, the effects of PClP on myosin kinetics, actomyosin kinetics 
and myosin motor functions were described. Co-crystallization trials with class-1 
myosins in the presence of PClP were unsuccessful. Since most of the class-1 
myosin motor domains have 50% to 60% sequence similarity with class 2 myosin 
motor domains, Dictyostelium discoideum myosin-2 (Dd myosin-2) was used as 
a model system to interpret the binding site of PClP in other myosin isoforms. 
The resulting structure shows that the inhibitor binds in the same allosteric 
pocket as PBP, but the conformation of the inhibitor and details of its interaction 
with myosin are different. Molecular modeling and docking studies predicted 
preferential binding of PClP to class-1 myosins, a result that was confirmed by 
direct binding studies, cell-based assays, and in vitro enzyme assays.  
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3.1.1.1 Mechanism of PClP-Mediated Inhibition of Myosin Motor Activity 
In the present work, PClP was shown as potent inhibitor of myosin motor activity. 
PClP, a structural analogue of pentabromopseudilin (PBP) (Fedorov et al, 2009) 
(Figure 3.1.1.1).  
 
Figure 3.1.1.1: Schematic representation of PBP and PClP. 
To elucidate the inhibitory potency and selectivity of PClP, the action of PClP on 
the actomyosin ATPase activity of myosins from different classes was tested. For 
the steady-state ATPase assay, different myosin isoforms were preincubated 
with varying concentrations of PClP at 25 0C. For the purpose of reproducibility 
and accuracy, all independent measurements were performed in triplicates. The 
results of the PClP mediated inhibition of the actomyosin steady-state ATPase 
activity of a wide range of different myosins from various classes are summarized 
in Figure 3.1.1.2. 
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Figure 3.1.1.2: F-actin activated ATPase of different myosins in the presence of PClP. The semi-
logarithmic normalized plot shows the concentration dependence of PClP inhibition for (A) Dd 
myosin-2, (B) Dd myosin-1B, (C) Rn myosin-1b, (D) Rn myosin-1c, (E) Oc myosin-2 (HMM) and 
(F) Dd myosin-5b. The concentrations of PClP required for half-maximal inhibition (IC50) of the 
different myosin motors were determined from sigmoidal fits of the data. 
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Addition of PClP greatly decreased the rate of actin-activated ATP turnover for 
members of myosin classes-1, -2, and -5, whereas human myosin-6 and myosin-
7a motor domain constructs showed no sign of inhibition in the presence of 100 
µM PClP. The most potent inhibition was observed for class-1 myosins. Plots of 
the observed rates against the logarithm of inhibitor concentration were fitted with 
sigmoidal functions. The IC50 values for Dd myosin-1B, Rn myosin-1b and Rn 
myosin-1c correspond to 1.0 µM, 5.0 µM and 5.6 µM, respectively (Figure 
3.1.1.2). The potency of PClP for the inhibition of class-2 and class-5 myosins 
was considerably lower. IC50 values corresponding to 126 µM, 91 µM, and 99 µM 
were observed with Dd myosin-2, Oc myosin-2, and Dd myosin-5B, respectively 
(Figure 3.1.1.2).  
To investigate the interaction of PClP with class-1 myosins in detail, we took 
advantage of the 30% increase in fluorescence intensity that is observed upon 
binding to myosin. Stopped-flow transients were observed after the rapid mixing 
of PClP with myosin motor domain constructs. The fluorescence transients were 
well described by single exponential functions. A typical transient obtained for 
PClP binding upon Dd myosin-1B is shown in the inset of figure 3.1.1.3. The 
observed rate constants were linearly dependent on the PClP concentration in 
the range from 1-10 µM (Figure 3.1.1.3A). 
An apparent second-order rate constant for PClP binding to Dd myosin-1B (k+I = 
0.48 ± 0.04 × 10-9 µM-1s-1) was given by the gradient of the plot, while the y-
intercept defines an apparent dissociation rate constant of k
-I = 0.0024 ± 0.0002 
s-1. The ratio k
-I/ k+I defines an apparent dissociation equilibrium constant (KI) of 
5.0 ± 0.9 µM. Alternatively, KI was determined by plotting the observed changes 
in fluorescence amplitude against the PClP concentration (Figure 3.1.1.3B). The 
resulting data were well described by a hyperbola and gave a value of 4.2 ± 0.8 
µM for KI.  
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Figure 3.1.1.3: (A) Binding and dissociation kinetics for the interaction of PClP with Dd myosin-
1B. Rates were determined by the concomitant change in fluorescence intensity. (B) A hyperbolic 
fit to the data gives a Kd of 4.2 ± 0.8 µM for PClP binding to Dd myosin-1B. (The assays and the 
figure were produced in collaboration with Dr. Manuel H. Taft, Institute for Biophysical Chemistry, 
Hannover Medical School.) 
3.1.1.2 PClP is a Reversible Inhibitor of Myosin Motor Activity 
PClP binding reduced the affinity of myosin for filamentous actin (F-actin) in the 
presence of ATP. Further, the coupling between actin and nucleotide binding 
sites was affected thereby interfering with the activation of the ATPase activity of 
myosin by F-actin. To estimate the extent to which PClP binding affects coupling, 
the ATPase activity for Dd myosin-1B over the range from 1 to 70 µM F-actin 
were determined (Figure 3.1.1.4). Values for kcat and KM (actin) were estimated 
from fits of hyperbolic functions to the data. The apparent second order rate 
constant for actin binding in the presence of ATP (kcat/KM(actin)) is a direct measure 
of the coupling efficiency. Addition of 5 µM PClP lead to a more than 30-fold 
reduction in coupling efficiency from 0.028 µM-1s-1 to 0.00088 µM-1s-1.  
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Figure 3.1.1.4:PClP-mediated inhibition of the actin-activated ATPase activity of Dd myosin-1B.  
Hyperbolic fits to the data at 0 µM (■), 1 µM (●), and 5 µM PClP (▲) are shown. Increasing the 
PClP concentration leads to a gradual inhibition of the actin-activated ATPase activity and leads 
to a more than 30-fold reduction n coupling efficiency. 
3.1.1.3 In vitro Motility Assay of Dd myosin-1B in the Presence of PClP 
A direct weakening of the actin-myosin interaction was observed following the 
addition of PClP to actomyosin decorated glass surfaces in the in vitro motility 
assay. A Dd myosin-1B motor domain construct, fused to an artificial lever arm of 
12 nm in length, moved F-actin with an average velocity of 1.01 ± 0.13 µm·s-1 in 
the in vitro motility assay (Durrwang et al, 2006). The addition of 2 µM PClP 
resulted in a more than 2-fold reduction of the average sliding velocity to 0.51 ± 
0.08 µm·s-1 (Figure 3.1.1.5A). Furthermore, this direct functional assay revealed 
that the inhibition of myosin motor activity by PClP is reversible. Washout of the 
inhibitor resulted in complete recovery of motile activity (Figure 3.1.1.5B).  
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Figure 3.1.1.5: (A) Dd myosin-1B moves actin filaments in the in vitro motility assay with an 
average velocity of 1.01 ± 0.13 µm·s–1 (dark grey bars). In the presence of 2 µM PClP (light grey 
bars), filament velocity is reduced to 0.51 ± 0.1 µ·ms–1. (B) Washout of the inhibitor increased the 
average velocity to 1.01 ± 0.3 µm·s–1, which was similar to the motile activity of uninhibited Dd 
myosin-1B. (This assay and the figure were produced in collaboration with Dr. Falk K. Hartmann, 
Institute for Biophysical Chemistry, Hannover Medical School). 
3.1.1.4 PClP Inhibits Cellular Functions of Human Myosin-1c  
In mammals, myosin-1c is involved in a number of highly specialized and tissue 
specific functions, such as the adaptation of mechano-electrical transduction in 
the hair cells of the inner ear and the translocation of GLUT4 transporters to the 
plasma membrane in adipocytes (Bose et al, 2002; Gillespie & Cyr, 2004). In 
addition, myosin-1c was described to play a role in the late endocytic pathway 
delivering endocytosed macromolecules to the lysosome for degradation 
(Poupon et al, 2003). This observation was well supported by the finding that the 
inhibition of myosin-1c function by either PClP or RNA interference causes 
identical defects in lysosome morphology and intracellular localization of this 
organelle (Figure 3.1.1.6). HeLa cells were treated for 16 hours with PClP 
concentrations in the range from 1-5 µM display large, ring-like Lamp1 positive 
lysosomes clustered in the perinuclear region. These morphological changes 
were clearly visible at the lowest PClP concentration used (Figure 3.1.1.6). Loss 
of myosin-1c production after transfection of siRNA specific for myosin-1c 
induces identical morphological changes in the endo-lysosomal system of HeLa 
cells (Figure 3.1.1.6). Other changes and more general cytotoxic effects were 
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only observed at PClP concentrations higher than 25 µM. These results indicate 
that in mammalian cells, PClP can be used at concentrations smaller than 5 µM 
for selective inhibition of myosin-1c function and that the drug does not interfere 
with other enzymes in this concentration range. 
Figure 3.1.1.6: Inhibition of Hs myosin-
1c by PClP causes clustering and 
swelling of mammalian lysosomes.  (A) 
In control HeLa cells without PClP 
treatment (a, b and c) or siRNA 
transfection (g, h and i) the lysosomes 
are small vesicular organelles that are 
distributed throughout the cells with a 
slight enrichment in the perinuclear 
region and the vicinity of the Golgi 
complex. In PClP -treated (d, e and f) 
and myosin-1c siRNA transfected cells 
(j, k and l) the lysosomes are densely 
clustered in the perinuclear region. They 
are frequently tethered to form larger 
aggregates and are swollen to a larger 
size. The left panels (a, d, g and j) show 
confocal images of a group of cells 
stained for lysosomes with an antibody 
to Lamp1, the middle panels (b, e, h and 
k) show merged color images labeled 
for lysosomes in green, actin filaments 
in red and the nucleus in blue. The right 
hand panels (c, f, i, and l) show 
enlarged confocal images of single cells 
further highlighting the aggregated 
swollen lysosomes in PClP-treated and 
myosin-1c siRNA-depleted cells. The 
small inserts in the right hand panels are 
higher magnifications of the boxed 
regions. Bar: 10 µm. (B) Mock and 
myosin-1c siRNA treated HeLa cells 
were blotted and probed with antibodies 
to myosin-1c and α-tubulin as a loading 
control to confirm the successful 
myosin-1c knockdown. The assay was 
performed & the figure is contributed by 
Hemma Brandstadt and Folma Buss, 
Cambridge University, UK. 
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3.1.1.5 The Structural Basis of PClP-Mediated Inhibition 
Co-crystallization studies were performed with motor domain constructs derived 
from three class-1 isoforms. However, these constructs were proved refractory to 
crystallization. Therefore, PClP was co-crystallized with the Dd myosin-2 motor 
domain, which was complexed to Mg2+-ADP-meta-vanadate (Figure 3.1.1.7).  
These crystals were diffracted to 2.5 Å resolution and further data analysis 
indicated a space group C2221.  The nucleotide binding pocket of Dd myosin-2 is 
highly conserved among different myosin isoforms (Hiratsuka, 1994). Few of the 
conserved residues surrounding ADP.VO3 are depicted in the following Figure 
3.1.1.7.  
Figure 3.1.1.7: Section (A) was shown as the overview of ADP.VO3 and PClP binding sites in Dd 
myosin-2 motor domain. Section (B) ADP.VO3 was shown in the nucleotide-binding pocket of Dd 
myosin-2: PClP complex. Electron density, 2fofc, shown here was contoured at 1.5 σ. 
The crystallographic results were in good agreement with the allosteric 
mechanisms inferred from the kinetic data. The tip of the 50-kDa domain and 
near actin binding residues are involved in PClP binding. PClP binds at a 
distance of approximately 16 Å from the nucleotide-binding site (Figure 3.1.1.7A). 
This is the same allosteric binding pocket previously described for PBP (Fedorov 
et al, 2009). However, both the conformation of PClP and details of the 
interaction with myosin residues in the binding pocket differ from those observed 
with PBP. The average r.m.s. deviation for PClP and PBP was 2.3 Å. The planar 
anti-conformer of PClP binds to myosin. This differs from the binding mode of 
PBP, where the syn-conformer is observed to bind with the phenyl and pyrrole 
ring systems bent 12º out of plane and twisted 20º against each other (Fedorov 
et al, 2009). Towards the actin-binding interface, PClP is enclosed by the strut 
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loop (Asn588–Gln593) and loop 2 (Asp614–Thr629). Towards the core of the 
motor domain the binding pocket is lined by helix 10 (Lys265–Val268) and helix 
18 (Val411–Leu441) from the upper 50-kDa domain. Additionally, helix 26 
(Val630–Glu646) and the loop connecting β7 (Ile253–Leu261) with helix 10 
contribute to the binding pocket (Figure 3.1.1.8B and 3.1.1.8C). The total protein 
surface area in contact with PClP comprises 240 Å2.  
A network of interactions stabilizes PClP binding. Important binding site 
rearrangements include a change in the orientation of the side chain of Lys265, 
which moves 3.1 Å from its position in the uninhibited form to facilitate formation 
of a hydrogen bond between the ε-amino group and the hydroxyl group of PClP. 
The amino group of the pyrrole ring interacts with the main chain carbonyl groups 
of Ile617 and Ser619. Two water molecules form part of a network of interactions 
that involves the main chain carbonyl groups of Ala420 and Pro591, the side 
chains of Lys265 and Asp590, and the hydroxyl and 2-chloro groups of the 
phenyl ring. Additional interactions are formed between the side chains of Arg428 
and Leu431 and chloro groups of the inhibitor (Figure 3.1.1.8D).  
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Figure 3.1.1.8: Structure of Dd myosin-2 motor domain in complex with PClP and Mg2+-ADP-
meta-vanadate. (A) Section of the 2Fo-Fc electron density omit map, contoured at 1.0 σ, 
depicting the PClP binding site. (B) Overall view of the myosin motor domain in ribbon 
representation. PClP and ADP•VO3 are shown in spheres mode; N-terminal residues are shown 
in green and the C-terminal converter region in cyan. (C) Close-up view of allosteric binding 
pocket with protein residues in cartoon representation and PClP in stick representation. Important 
structural features around the binding pocket are colored and labeled accordingly. (D) Schematic 
view of the anti-conformer of PClP and its contact residues. Contacts with residues closer than 4 
Å are shown. 
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Table 22: Summary of data collection and refinement statistics 
 Dd Myosin-2 – ADP•VO3 – 
pentachloropseudilin 
Data collection  
Space group C2221 
Wavelength (Å) 0.9871  
Cell dimensions    
    a, b, c (Å) 89.53, 147.49, 153.78 
    α, β, γ  (°)  90, 90, 90 
Rsym (%) 6.2 (48.3)* 
I / σI  15.97 (5.01) 
Completeness (%) 99.8 (100) 
Redundancy 8.2 (8.4) 
  
Refinement  
Resolution (Å) 24.6-2.5 
Rwork / Rfree (%) 22.9 / 25.3 
No. reflections 
working / test set 
 
33755/ 1777 
No. atoms  
    Protein 6240 
    Ligands/ions 48/ 1 
    Water 458 
R.m.s. deviations  
Bond lengths (Å) 0.008 
Bond angles (°) 1.6 
Ramachandran plot  
(% Favored/allowed/outliers)§ 
 92.3/7.7/0 
 
*Values in the parenthesis are for highest resolution (2.60-2.50). 
§Residues in favored, allowed, and outlier regions of the Ramachandran plot as reported by 
MolProbity (Davis et al, 2007a). 
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3.1.1.6 Myosin Isoform-Dependent Interactions with PClP 
To rationalize the structural basis for the experimentally observed preferred 
inhibition of class-1 myosins, we performed docking studies using the crystal-  
 
Figure 3.1.1.9: Surface representation of the PClP binding site in different myosin isoforms. 
Highly conserved residues interacting with PClP are shown in pink. Non-conserved residues 
interacting with PClP are colored green. Amino acid residues are indicated using the single letter 
code. PClP binding pocket of (A) Dd myosin-2 crystal structure [*reference structure],  (B) Dd 
myosin-1B, (C) Rn myosin-1b, (D) Rn myosin-1c, (E) Dd myosin-1E, and (F) Dd myosin-5b. 
structure of the motor domain of Dd myosin-1E (1LKX) and homology models of 
Dd myosin-1B, Dd myosin-5B, Rn myosin-1b and Rn myosin-1c in the pre-power 
stroke state. For all myosin isoforms tested, initial blind docking studies predict 
that PClP binds to the same site described above for the complex with the Dd 
myosin-2 motor domain. To achieve better sampling of the translational, 
rotational, and torsional degrees of freedom of the ligand, local docking using a 
10 Å grid around this site was performed (Ghersi & Sanchez, 2009). The highest 
ranked binding poses are shown in Figure 3.1.1.9 and the predicted contact 
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residues for PClP in complex with the individual myosin isoforms are shown in 
Table 28.  
The results of the docking studies indicated that the contact between the 
hydroxyl group of PClP and Lys265 is a common and important feature of the 
interaction between myosin and effector molecule. Additionally, the polarity of the 
allosteric binding pocket appears to make an important contribution to the 
preferred binding of PClP to class-1 myosins (Figure 3.1.1.9). 
 3.1.1.7 Energetic Coupling between Active and Allosteric Binding Sites  
Since X-ray crystallography favors particular stable intermediates, observable 
changes resulting from the binding of an allosteric effector tend to be subtle in 
terms of impact on an experimentally determined 3D structure (Goodey & 
Benkovic, 2008). Experimental manifestations of an allosteric effect are thus 
frequently limited to the rates of interchange between different conformer 
populations at any given point along the enzymatic reaction coordinate (Swain & 
Gierasch, 2006). Typical for this type of energetic coupling between the active 
and allosteric sites, the available X-ray structures in the presence (2XEL) and 
absence (2JJ9) of bound PClP do not indicate a major conformational change. 
The myosin backbone Cα atoms in both structures superimpose with an RMSD of 
0.41Å. 
Analysis of pre-power stroke state myosin structures in the absence  (2JJ9) 
and presence of PClP (2XEL) indicate the existence of two communication 
pathways that transmit information between the allosteric and nucleotide binding 
sites: a direct communication pathway (Figure 3.1.1.10) and a pathway that 
operates via global changes (Figure 3.1.1.12).  
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Figure 3.1.1.10: Schematic illustration of the relay pathway connecting the allosteric pocket and 
the nucleotide-binding site in the absence and presence of PClP. (A) Residues involved in the 
relay pathway and selected side chains are shown for the myosin motor domain in the absence of 
PClP (2JJ9). (B) PClP induced changes in the orientation of selected side chains along the relay 
pathway. Distances between residues are shown as dashed lines indicated in Å. Main chain 
interactions are not explicitly shown. Magnesium ion (green) and waters (red) are shown as 
spheres; W lyt denotes the lytic water molecule and Whelp denotes the helper water. 
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A network of hydrogen bonds is extended over a distance of 19 Å forming a 
direct link between PClP and the γ-phosphate position of ATP.  Side chains as 
well as main chain interactions are part of this network. Lys265 is the starting 
point for this allosteric relay mechanism.  The ε-amino group of Lys265 moves 
3.1 Å from its position in the uninhibited form to facilitate an interaction with the 
hydroxyl group of PClP.  The salt-bridge connecting Arg238 in Switch I with 
Glu459 in Switch II forms part of the relay path. The distance between Arg238 
and Glu459 increases by 0.3 Å upon PClP binding. Other key residues involved 
in the relay mechanism are S236 and S237 in Switch I, Gln468 in the relay helix, 
and residues K265, S266 and R267 in helix 10 (Figure 3.1.1.10A). The major 
consequence of the rearrangements induced by PClP-binding is 
the displacement of the “catalytic water” molecule at the active site (Figure 
3.1.1.10B). In contrast, the catalytic water positioned appropriately for in-line 
attack to the γ-phosphate analogue of nucleotide, is present in the active site of 
the pre-power stroke state structures with bound ADP-VO3 (2JJ9), ATP-γ-S, 
(1MMG), ADP-AlF4 (1W9L), and mantADP-BeFx (1D1C) (Gulick et al, 2000; 
Gulick et al, 1997).  
In the absence of PClP the 2Fo-Fc electron density for Mg.ADP.VO3 in structure 
2JJ9 allows the unambiguous placement of an extra water molecule (Figure 
3.1.1.11A). This water molecule is ideally positioned for inline attack relative to Vγ 
and can thus act as catalytic water. PClP-binding induces the displacement of 
the catalytic water (Figure 3.1.1.11B).   
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Figure 3.1.1.11: (A) Mg.ADP.VO3 fit into the 2Fo-Fc electron density map from structure 2JJ9 
obtained in the absence of PClP. (B) Mg.ADP.VO3 fit into the 2Fo-Fc electron density map from 
structure 2XEL obtained in the absence of PClP. The 2Fo-Fc electron density maps are contoured 
at 1.5σ. Side chains and ADP-meta-vanadate are shown in stick mode. Magnesium ion (green) 
and waters (red) are shown as spheres; W lyt denotes the lytic water molecule and Whelp denotes 
the helper water. 
Global changes induced by effector binding, which contribute to the allosteric 
communication, are indicated by B-factor analysis. Plots showing the difference 
in B-factor (∆B) between the free and inhibitor-bound structures per residue 
indicate changes in protein dynamics throughout the motor domain (Figure 
3.1.1.12).  
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Figure 3.1.1.12: Flexibility of the myosin-2 motor domain in the presence and absence of bound 
PClP. B-factors describe the size of displacements available to the individual atoms in an X-ray 
structure. They provide thus information about the relative flexibility of different parts of a 
structure. We used normalized B-factors to compare the relative flexibility of the myosin-2 motor 
domain in the presence and absence of bound PClP and PBP. Normalized B-factors were 
calculated as B = (Batom/Baverage) x 100, where Batom is the B-factor of an individual protein atom 
and Baverage is the average B-factor of the whole protein molecule.  Histogram showing ∆B, the 
difference in the normalized B-factors (B2JJ9 – B2XEL) plotted against residues 1 to 693 of the 
Dd myosin-2 motor domain. Positive ∆B values indicate higher B-factors of ligand free structure 
over ligand bound structure, whereas negative ∆B values represent higher B-factors of ligand 
bound structure. 
Differences in the flexibility of surface loops and secondary structure elements in 
the nucleotide-binding region can be related to PClP binding (Figure 
3.1.1.12A).  Changes in B-factor induced by the binding of PBP to myosin-2, 
shown in Figure 3.1.1.12B, are even more pronounced. This observation is in 
good agreement with the more potent effect of PBP on myosin-2 activity 
(Fedorov et al, 2009). 
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3.1.2 Ammosamides 
Deep-sea microbes are rich in valuable metabolites that can target the structural 
components of the cytoskeleton (Fenical & Jensen, 2006). Natural compounds 
like ammosamides were isolated from the Streptomyces strain CNR-698 
(Macmillan et al, 2008), which was isolated from bottom sediments of the deep-
sea in the Bahamas Islands (Hughes et al, 2009b). The same group of 
researchers performed the total synthesis of ammosamides (Hughes & Fenical, 
2010).  
3.1.2.1 Ammosamides Target Myosin-2 
This work was carried out with the basic idea that ammosamides target myosins 
as described by Hughes et al. (Hughes et al, 2009a). Hence, a meaningful 
collaboration with the group of Prof. William Fenical, Scripps Institution of 
Oceanography, UCSD, USA has been established in order to investigate the 
kinetic and structural basis of the ammosamide mediated effects on myosins. As 
small molecule effectors, ammosamide A, ammosamide B and other 
ammosamide derivatives (Figure 3.1.2.1) were selected and tested in the actin-
activated steady-state ATPase assay, in single-turnover stopped-flow 
experiments and in crystallographic approaches to obtain a better understanding 
of the molecular mechanisms underlying their efficacy on myosin motor domains.  
Prior to the experimental procedures, all compounds were solubilized in 80 % 
(w/v) DMSO. To minimize the side effects, the working concentration of DMSO in 
the kinetic and crystallographic studies was maintained below 2 % (w/v). Initially, 
in a rapid screen, the actin-activated steady-state ATPase activity of Dd myosin-2 
in the presence of 10 µM and 100 µM ammosamides was determined. 
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Figure 3.1.2.1: Schematic representation of the ammosamides studied in the present work. 
 
Out of eight compounds tested, ammosamide A (CNR-698.307), ammosamide B 
(CNR-698.291), deschloroammosamide B (CNR-698.257) and ammosamide 272 
(CNR-698.272) display a clear inhibition pattern of the Dd myosin-2 ATPase 
activity. Although, it was known that ammosamide A and B inhibits skeletal 
myosin-2 (Hughes et al, 2009a), this study showed that two other ammosamide 
derivatives, deschloroammosamide B (Des B) and ammosamide 272, exhibit 
inhibitory effects on Dd myosin-2. The remaining ammosamides did not show 
any effect at concentrations as high as 500 µM. Hence, the remainder of the 
present work focuses on the detailed kinetic and structural analysis of the 
compounds displaying inhibitory activity.  
3.1.2.2 Ammosamides Inhibit Myosin-2 ATPase Activity 
To explain the inhibitory potency of ammosamides, the action of these natural 
compounds on the actomyosin ATPase activity of Dd myosin-2, Hs nonmuscle 
myosin-2C and Hs myosin-7a was tested under steady-state conditions. In the 
experimental set up, myosin motor domain constructs were preincubated with 
varying concentrations of ammosamides at 25°C for 3 0 minutes prior to the 
measurements. The results of the ammosamide mediated inhibition of the 
actomyosin steady-state ATPase activity of Dd myosin-2 is shown in Figure 
3.1.2.2. 
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Figure 3.1.2.2: Inhibition of the actin-activated ATPase activity of Dd myosin-2 in the presence of 
ammosamides. The semi-logarithmic normalized plots show the concentration dependence of the 
ammosamide mediated inhibition of Dd myosin-2 ATPase activity as a function of (A) 
ammosamide 272, (B) Des B, (C) ammosamide A and (D) ammosamide B concentration. Fitting 
results give IC50 values of 17.16 ± 0.74 µM, 25.21 ± 2.39 µM, 45.71 ± 5.12 µM and 72.38 ± 5.96 
µM for ammosamide 272, deschloro ammosamide B, ammosamide A and ammosamide B, 
respectively.  
As depicted in Figure 3.1.2.2, addition of ammosamides greatly decreased the 
rate of actin-activated ATP turnover for Dd myosin-2. The plots of the observed 
rates against the logarithm of inhibitor concentrations were fitted with sigmoidal 
functions. The IC50 values for ammosamide 272, Des B, ammosamide A and 
ammosamide B correspond to 17.16 ± 0.74 µM, 25.21 ± 2.39 µM, 45.71 ± 5.12 
µM, and 72.38 ± 5.96 µM, respectively. In contrast, human nonmuscle myosin-
2C and myosin-7a motor domain constructs showed no sign of inhibition in the 
presence of 100 µM ammosamides (data not shown). Interestingly, the most 
potent inhibition of the Dd myosin-2 actin-activated ATPase activity was 
observed for ammosamide 272 and the less potent inhibition was observed in the 
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case of ammosamide B.  
3.1.2.3 Single-Turnover Experiments with Ammosamides 
To gain details about the kinetic steps affected by ammosamide binding, single-
turnover stopped-flow experiments were performed with Dd myosin-2 using 
mantATP as a substrate (Figure 3.1.2.3).  
Figure 3.1.2.3: Single turnover experiments showing the changes in fluorescence signal upon 
mixing 0.5 µM Dd myosin-2 with 0.4 µM mantATP in the presence of increasing concentrations of 
(A) ammosamide 272, (B) Des B, (C) ammosamide A and (D) ammosamide B over a time range 
of 600 seconds.  
In the absence of ammosamides, the time evolution of the reaction can be 
separated in three phases: an initial rise in mant-fluorescence corresponding to 
mantATP binding to myosin, a short plateau phase determined by the rate of the 
conformational change that follows mantATP binding, and a drop in mant-
fluorescence corresponding to release and rebinding of mantADP (Fedorov et al, 
2009). All three phases are extended in the presence of ammosamides in a 
concentration dependent manner. However, the extension of different phases in 
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single-turnover experiments was larger in the case of ammosamide 272 and was 
smaller for ammosamide B at same concentrations.  
3.1.2.4 Structural Basis of Ammosamides Inhibition 
Ammosamides inhibit rabbit skeletal muscle myosin-2, but the structural basis for 
the mode of inhibition is not yet evident (Hughes et al, 2009a). In order to explain 
the structural basis of inhibition, the crystal structures of ammosamide 272 and 
ammosamide B in complex with the Dd myosin-2 motor domain were solved at a 
resolution of 2.5 Å and 2.3 Å, respectively. The structures of ammosamides were 
determined in a C-centered orthorhombic form. Both ammosamide bound 
structures revealed the presence of two molecules and similar binding sites 
(Figure 3.1.2.4). One of the molecules binds in the allosteric pseudilin-binding 
pocket (Fedorov et al, 2009) (Figure 3.1.2.4).  The second molecule binds in a 
novel-binding site adjacent to the helix-loop-helix and the helix connecting to the 
relay loop. The structures of ammosamide A and Des B bound to myosin motor 
domain remain to be solved.   
 
 
Figure 3.1.2.4: Overview of the crystal structures of the Dd myosin-2 motor domain complexed 
with ADPVO4 and (A) ammosamide 272 and (B) ammosamide B. For clarity, ammosamide 272 
was labeled as 272 and myosin motor domain was colored according to the secondary structure 
pattern. The ammosamide 272 is colored in green and ammosamide B colored in violet and 
ADPVO4 was colored in cyan. Functional groups (-OH, -NH2) of ammosamides were colored 
according to the element color. All the heterogens were shown in sphere representation. 
Ammosamide 272 and ammosamide B molecules bound in the characterized 
pseudilin-binding pocket (Chinthalapudi et al, 2011; Fedorov et al, 2009) 
comprise 100% occupancy and 68% occupancy, respectively (Figure 3.1.2.5). 
Both ammosamides show better fitting to the pseudilin-binding pocket because of 
their bulky rings and substituents, which geometrically fits to the much available 
space of the allosteric binding site.  
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Figure 3.1.2.5: Section (A, left panel) shows the electrostatic potential surface with 2Fo-Fc 
electron density map of ammosamide 272, which was contoured at 1σ.  Section (A, right panel) 
shows the schematic interaction of ammosamide 272 with Dd myosin 2 at the PClP site. Section 
(B, left panel) shows the electrostatic potential surface of ammosamide B and the 2Fo-Fc electron 
density of the molecule, which was contoured at 0.7σ.  Section (B, right panel) shows the 
schematic interaction of ammosamide B with Dd myosin 2 at the PClP site. 
As a common feature, both ammosamides align their carbonyl groups, which are 
substituted on the pyrrolidine ring, to Lys265 of Dd myosin-2 to form an ideal 
hydrogen bond, both in the direction and also in the distance (2.5 Å). Thus, the 
presence of interactions with Lys265 indicates the importance of this residue in 
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mediating the allosteric inhibition. Residues Asp590, Ser619 and Ile617 form 
hydrogen bonds with the compound. In the case of ammosamide B, Ser619 only 
forms van der Waals interaction with the compound. Arg428 was identified as the 
cation-π interaction contributor in both cases.  
 
Figure 3.1.2.6: Section (A, left panel) shows the electrostatic potential surface of the myosin-2 
motor domain at the novel-binding site of the ammosamide 272. The 2Fo-Fc electron density map 
of ammosamide 272 was contoured at 0.8σ. Section (A, right panel) shows the schematic 
interaction of ammosamide 272 with Dd myosin 2 at the Proline bulge (Pro522 and Pro523). 
Section (B, left panel) shows the electrostatic potential surface of the myosin-2 motor domain at 
the 2nd binding site of the ammosamide B. The 2Fo-Fc electron density map of ammosamide B 
was contoured at 0.8σ. Section (B, right panel) shows the schematic interaction of ammosamide 
B with Dd myosin-2. 
Furthermore, residues Ile617, Leu592, Ala424, Ala618, and Leu431 are involved 
in hydrophobic contributions. Figure 3.1.2.5, schematically summarizes the 
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interactions between ammosamides and residues of the pseudilin binding site. 
The second binding site of ammosamides within the Dd myosin-2 motor domain 
was identified as a novel-binding site for myosin inhibitors. As depicted in Figure 
3.1.2.4, the novel allosteric binding pocket is located adjacent to the 2nd helix 
(residues 524-534) of the helix-loop-helix motif and near the relay loop. This 
allosteric site is one of the easily accessible solvent channels of the myosin 
motor domain. Molecules of ammosamide 272 and ammosamide B comprise 
80% and 71% occupancy in this binding pocket, respectively. Close-up views of 
the inhibitors bound in the identified binding pocket and the interaction profile 
with neighboring amino acids are depicted in Figure 3.1.2.6.  
Detailed structural analysis of the second allosteric binding site revealed that the 
aromatic/hydrophobic rings of the ammosamides face towards the hydrophobic 
core, which consists of amino acids Leu516, Pro522, Pro523 and Phe551. One 
of the amino groups at the C6 atom of the ‘4,6-diamine benzene’ of the 
ammosamide forms a hydrogen bond network with the backbone carbonyl 
oxygen atoms of Asp515, Pro522 and Pro523. Furthermore, the amino group on 
the C4 atom of the ‘4,6-diamine benzene’ of ammosamide 272 present towards 
the helix–loop-helix forms a direct interaction with Asn555 (Figure 3.1.2.6). In the 
case of ammosamide B, a water molecule mediates this interaction.  
The carbonyl moiety in the ‘methoxy carbonyl’ of ammosamide 272 or ‘amide’ of 
ammosamide B forms hydrogen bonds with the backbone carbonyl moiety of 
Gln521 and Arg520. Furthermore, the Carbonyl bond in the ‘N-Methyl-2-
pyrrolidone’ or the ‘N-methyl γ-lactam’ group forms a solvent interaction in the 
case of ammosamide 272. This interaction is absent in the ammosamide B 
bound structure. However, most of the interactions, in ammosamide 272 and 
ammosamide B, are conserved. Even the orientation of the inhibitors is 
preserved. Although structures of ammosamide A and Des B are not yet solved, 
above results indicate that most of the ammosamides follow similar structural 
basis of allosteric inhibition. 
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3.2 Human Nonmuscle Myosin-2C (NMH-2C) 
Myosins have been implicated in various motile processes, including organelle 
translocation, ion-channel gating, and cytoskeleton reorganization. Class-2 
myosins involve the largest group with several subfamilies including skeletal, 
cardiac, smooth muscle and nonmuscle myosins (Berg et al, 2001). Cytoplasmic, 
nonmuscle myosins are among the most prevalent myosins and are expressed in 
a spatial and developmentally dependent manner (Golomb et al, 2004; Maupin et 
al, 1994; Simerly et al, 1998). Nonmuscle myosins are major cytoskeletal 
proteins that interact with actin and are involved in wide range of cellular 
functions like cell adhesion (Betapudi et al, 2006), cell migration (Even-Ram et al, 
2007) and cytokinesis (Pollard, 2010). Three separate genes (MYH9, MYH10, 
MYH14) encode the nonmuscle myosin heavy chain (NMHC-2) proteins (NMHC-
2A, -2B, and -2C, respectively), which together with the light chains are referred 
to as NM2A, NM2B, and NM2C (Vicente-Manzanares et al, 2009a). At the 
protein level, all nonmuscle myosin heavy chains have a basic domain 
architecture consisting of three structural units: a catalytic motor domain, a neck 
domain comprising 2 IQ motives that bind the regulatory as well as the essential 
light chain, and a rod-like tail domain that forms an alpha-helical coiled-coil 
(Kengyel et al; Sellers, 2000a). The presence of the extended coiled-coil region 
promotes self-association into short bipolar filaments (Niederman & Pollard, 
1975; Verkhovsky et al, 1995). These filaments power interactions with actin 
filaments producing force, driving directed movement and maintain tension 
forces.  
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3.2.1 Crystal Structure of Human Nonmuscle Myosin-2C (NMH-2C) Motor 
Domain in the Pre-Power Stroke State 
 
The splice variants of nonmuscle myosin-2C have been kinetically well described 
(Heissler & Manstein, 2011). The putative amino acid sequences between the 
nonmuscle myosin-2C motor domains of the transcript variants are well 
conserved with an identity of 96-99% (Heissler & Manstein, 2011). In this study, 
Hs NM2C0, one of the three splice variants of nonmuscle myosin 2C comprising 
the shortest loop-1 and loop-2, was used for the structural analysis (Heissler & 
Manstein, 2011). For clarity, Hs NM2C0 will be addressed as NM2C for the rest 
of the document. It was observed that the native NM2C motor domain with a non-
conserved, unique N-terminal extension (residues 1 to 45) of NM2C were 
refractory for crystallization (Figure 3.2.1). This unique N-terminal extension of 
NM2C was identified as highly disordered and hence, it was truncated in order to 
improve the chances of obtaining crystals. It was also observed that the 
truncated motor domain has similar ATPase activity compared to native motor 
domain of NM2C0. Further, the NM2C motor domain was fused to two 
Dictyostelium discoideum α-actinin repeats that can functionally replace the lever 
arm (Kliche et al, 2001).  
The recombinant protein was produced in the baculovirus/sf9 system and purified 
to homogeneity by Ni-NTA affinity chromatography and gel filtration. The 
crystallization trials were performed with ~12 mg/ml of protein and multiple 
rectangular-plate like stacked crystals were grown in 3 weeks (Figure 3.2.2). 
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Figure 3.2.1: Sequence of NM2C0 with predicted secondary structure representation. Residues 
labeled in red are (a) Unique N-terminal extension (1st 45 residues in yellow), (b) loop-1 (175-189), 
(c) Upper 50 kDa loop (282-296) and (d) extended loop-2 (597-624). The predicted secondary 
structures (DSSP prediction) like α-helices are shown in zigzag representation, β-sheets as 
arrows and loops & turns are represented in cylinders. The N-terminal 45 residues highlighted in 
yellow are truncated in the crystallized motor domain. Therefore, the construct numbering starts 
from a starting methionine (residue 1), followed by the second residue Glutamine. 
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Figure 3.2.2: (A) Gel filtration elution profile of the N-terminal truncated NM2C motor domain 
construct. For crystallization purpose, only the central peak fractions were collected. (B) Stacked 
rectangular plates of NM2C crystals.  
The crystal structure of NM2C complexed with the transition state analogue 
Mg2+-ADP•VO4 was solved at 2.25 Å resolution in the pre-power stroke state 
conformation (Figure 3.2.3).  
 
Figure 3.2.3: (A) Overview of the structure of NM2C motor domain fused to two α-actinin repeats, 
which mimic the natural lever arm. (B) Close up view of the motor domain. Coloring was done 
according to the secondary structure. Helices are shown in green, sheets are shown in violet and 
the loops/turns are shown in white. (C) The 2Fo-Fc electron density map of Mg2+·ADP·VO4 and 
key residues shown in the active site are contoured at 1.5 σ. 
Results 
 
101 
 
Crystallographic refinement statistics are given in Table 23. The detailed 
structural analysis of the human NM2C MD provides the identification of novel 
structural features as well as similarities and variations of its structure in 
comparison to other class-2 myosins. 
Table 23: Data Collection and Crystallographic Refinement Statistics 
Data collection &  
Refinement Statistics 
Hs NM2C – ADP•VO4 
Data collection 
 
Space group P22121 
Wavelength (Å) 0.91841 (BL 14.1, BESSY) 
Cell dimensions   
 
a, b, c (Å) 81.12, 125.61,153.96 
α, β, γ (0) 90, 90, 90 
Rsym (%) 12 (23)* 
I / σ[I] 13.60 (2.70) 
Completeness (%) 99.9 (100) 
Redundancy 14.95 (14.9) 
 
Refinement 
 
Resolution (Å) 34.77-2.25 
Rwork / Rfree (%) 20.5 / 25.7 
No.reflections 
working / test set 
75206/ 3785 
No. atoms 
 
          Protein 7727 
          Ligands/ions 45/ 1 
          Water 522 
R.m.s. deviations 
 
         Bond lengths (Å) 0.015 
         Bond angles (°) 1.83  
Ramachandran plot  
(% Favored/allowed/outliers)§ 
92.3/7.7/0 
 
*Values in parentheses are for highest-resolution shell (2.35–2.25).  
§ Residues in favored, allowed, and outlier regions of the Ramachandran plot as reported by 
MolProbity module in Phenix crystallographic software (Davis et al, 2007b). 
3.2.2 Comparison of Pre-power Stroke State Structures of Class-2 Myosins 
The motor domain (MD) of NM2C displays an overall topology that is very similar 
to that of other class-2 myosin isoforms in the pre-power stroke state (Figure 
3.2.4), such as the MD of the scallop striated muscle myosin complexed with 
ADP•VO4 [1QVI], (Gourinath et al, 2003) and the MD of the chicken smooth 
muscle myosin complexed with ADP•BeFx [1BR4] (Dominguez et al, 1998).  
Results 
 
102 
 
 
Figure 3.2.4: Pre-power stroke state structures of Hs NM2C motor domain fused to an artificial 
lever arm [2YCU] colored in blue, scallop striated Myosin S1 [1QVI] in light orange and chicken 
smooth Myosin S1 [1BR4] in green. For clarity, myosin light chains from 1QVI and 1BR4 are not 
shown in the figure. 
NM2C motor domain shows that the nucleotide-binding pocket comprises the 
purine-binding loop or adenine binding loop [A-loop] (NPxxxxxxY) on one side 
and the switch-1 (NxxSSR), P-loop (GESGAGKT) and switch-2 (DIxGFE) 
elements that sandwich the polyphosphate moiety of the nucleotide on the other 
side (Figure 3.2.5). As in other structural studies of class-2 myosins, the present 
work shows that the ATP analogue ADP•VO4 forms strong interactions with 
switch-1 residues in the active site, inducing switch-1 to close. Closing of switch-
1 results in a movement of the loop towards the β- and γ-phosphates of the 
bound nucleotide. Additionally, switch-2 closes by moving the lower part of β-
strand 5 back into the plane of the seven-stranded β-sheet (Gourinath et al, 
2003; Kliche et al, 2001). Switch-2 closing induces formation of the kink in the 
relay helix, causing a 60° rotation of the converter domain and the neck helix into 
the up position (Kliche et al, 2001).  
The structural analysis revealed a root mean square deviation (rmsd) between 
the Cα atoms of human NM2C MD and chicken smooth Myosin MD of 0.74 Å as 
well as Cα atoms of human NM2C MD and scallop striated Myosin MD of 0.76 Å. 
As depicted in Figure 3.2.5, the catalytically active core region of the myosin 
motor domain is highly conserved indicating the preservation of the basic motor 
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function and ATPase activity. 
 
Figure 3.2.5: (A) Highly conserved active site elements are shown in ribbon representation. (B) 
Corresponding sequence alignments of these sites are shown for Hs NM2C (2YCU), Ai stMyosin 
[1QVI], and Gg smMyosin [1BR4]. 
It is of note that the surface loops-1 and -2 were excluded from the rmsd 
calculations, since the loop regions were truncated or missing in the reference X-
ray structures. Despite its high sequence homology with the motor domain 
structures of smooth muscle myosin [1BR4] (88%) and striated muscle myosin 
[1QVI] (68%), NM2C motor domain has shown significant differences in the 
important surface loops like loop-3, and a new loop introduced here as the 
“Upper 50 kDa loop (327-341)” (Figure 3.2.6).  
Atomic models of the actomyosin complex implicate loop-3 as major contributor 
of myosins secondary actin binding region (Geeves et al, 2005; Lorenz & Holmes, 
2010; Van Dijk et al, 1999). The length of the NM2C loop-3 is similar to smooth 
muscle myosins (15 residues) but substantially shorter when compared to other 
class-2 myosins (≥ 19 residues). Furthermore, the orientation of loop-3 in the 
NM2C structure is different from other related myosin isoforms (Figure 3.2.6). 
These structural features cause an increase in the accessible surface area 
between actin and loop-3, which is in striking contrast to other class-2 myosins.  
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Figure 3.2.6: (A) Variations in the surface loops like Upper 50 kDa loop and loop-3 of nonmuscle 
myosin-2C (blue), smooth muscle myosin (green) and the muscle myosin were shown (light 
orange). (B) Sequence alignment of the Upper 50 kDa loop and loop-3. Identical residues are 
marked in cyan; similar residues in green, non-conserved residues are not highlighted.  
The Upper 50 kDa loop forms an integral part of a small helix-loop-helix motif, 
and is one of the connecting links between the active site and the Upper 50 kDa 
subdomain (Risal et al, 2004). The present NM2C structure reveals prominent 
changes within the Upper 50 kDa subdomain. The major contribution in 
conformational changes is from the Upper 50 kDa loop followed by the 
rearrangements of the helices in the Upper 50 kDa subdomain (Figure 3.2.7). In 
addition, other surface loops like loop-4 and cardiomyopathy loop (CM-loop), 
which are playing an important role in the actin-binding interface, show significant 
conformational changes. In the pre-power stroke state structure of scallop 
striated muscle myosin (1QVI), key residues D320 and N321 from this Upper 50 
kDa loop interact with switch-1 residues N239 and K233. 
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Figure 3.2.7: (A) Close-up view of the superimposition of the Upper 50 kDa loop of nonmuscle 
myosin-2C (blue), smooth muscle myosin (green) and the muscle myosin (light orange). (B) 
Interactions between Upper 50 kDa loop and the switch-1 region are compared between the 
nonmuscle myosin-2C (blue), and the muscle myosin (light orange). To avoid complexity, 
interactions of these regions in chicken smooth muscle myosin [1BR4] were not shown. Q105 of 
NM2C is 4.4 Å away from N3 atom of adenine ring and 5.8 Å away from the O2’ of ribose in the 
active site. Residue N321 is only ~4.6 Å away from the hydroxyl group of C2’ of the ribose ring in 
the ADP. This hydroxyl group of ribose (~4.0 Å) and one of the nitrogen [N3] of adenine (3.2 Å) 
also forms an interaction with the residue R128 in the case of muscle myosin. 
Interestingly, N231 of muscle myosin is replaced by G294 in the NM2C 
sequence. Further, the Upper 50 kDa loop is substantially shortened in length in 
comparison to both, smooth muscle (1BR4) and striated myosin (1QVI).  In 
addition to the shortened length, this region coupled to further conformational 
changes in the Upper 50 kDa domain. These rearrangements resulted in a large 
gap (9.5 Å) in between Upper 50 kDa loop and switch-1. Consequently, the gap 
between C2’ of ADP and the Upper 50 kDa loop increases to ~12 Å.  
Sequential studies show that R128 of striated muscle myosin is replaced by 
Q105 in the purine-binding loop of NM2C. Significance of this modification 
involves the lack of interactions between ADP and Q105 in the NM2C active site 
(Figure 3.2.7). These intra domain rearrangements suggest a mechanism of 
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coupling between the Upper 50 kDa loop and active site region. The position of 
the loop might play a very important role in actin binding dynamics as this loop 
might act like a lid on the distal part of the actin-binding cleft.  
3.2.4 Unique Features of Lever Arm 
The structural analysis of the NM2C motor domain further revealed striking 
differences between the pre-power stroke state structures of the chicken smooth 
muscle myosin, scallop striated muscle myosin and nonmuscle myosins in the 
orientation of the lever arm (Figure 3.2.8).  
The reactive thiol helices preceding the converter domain are varied in their 
conformation when compared to chicken smooth muscle myosin (1BR4) and 
resemble those described for scallop-striated myosin (1QVI). This finding was 
unexpected because of the high sequence similarity between smooth- and 
nonmuscle myosins. The reactive thiols in NM2C and scallop striated muscle 
myosin are slightly bent when compared to the kink in the chicken smooth 
muscle myosin. Gourinath et al have shown that the difference between pre-
power stroke state structures of Ai stMyosin (1QVI) and Gg smMyosin (1BR4) is 
associated with a “pliant region”, which is part of the heavy chain at the MD/lever 
arm junction (Gourinath et al, 2003). 
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Figure 3.2.8: Orientation of lever arm and reactive thiol helices (SH1 and SH2) in three pre-power 
stroke state structures. The reactive thiol regions shown in smooth muscle myosin (1BR4), 
scallop-striated myosin (1QVI) and nonmuscle myosin-2C (2YCU) are two small helices. A small 
kink is present in the SH1 and SH2 helices of scallop-striated myosin (1QVI) and Hs NM2C 
(2YCU). The extent of kink in the reactive thiol helices in smooth muscle myosin (1BR4) is larger 
than the above-mentioned myosins. 
 
In contrast, in NM2C, an artificial lever arm [α-alpha actinin repeats] (Kliche et al, 
2001) is attached at the end of the converter domain (R754), which is exactly at 
the position of the plaint region. Even though the NM2C structure lacks light 
chains, the α-actinin repeats align in the same orientation as the lever arm of 
scallop striated muscle myosin with a slight change in the orientation of about 
~10° to 15°. The difference between the lever arms of chicken smooth muscle 
myosin (1BR4) and NM2C can be explained in the same terms as the lever arms 
of striated muscle myosin (1QVI) and smooth muscle myosin (1BR4). This 
finding supports the results from Anson et al. highlighting that the artificial lever 
arm is not only a useful tool for the recombinant protein production and functional 
studies of the myosin motor domain but indeed mimics the structure of the 
natural lever arm without bound light chains (Anson et al, 1996b). 
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Figure 3.2.9:  Crucial interactions in the junction of converter and the beginning of the lever arm. 
It is also observed that a crucial interaction between the converter domain and the start of the 
lever arm is mediated by strong hydrogen bonding interactions in the above-mentioned myosins. 
Further, it is important to note that a positive Arginine (R743) in the NM2C motor domain replaces 
the conserved Glutamate at the beginning of the lever arm. 
In the interface between converter and the start of the lever arm, residues 
Arginine and Tyrosine from converter domain are involved in a strong hydrogen 
bonding with a Glutamate in the lever arm of chicken smooth muscle myosin 
(1BR4) and scallop striated muscle myosin (1QVI) pre-power stroke state 
structures. However, in the case of Hs NM2C, an Arginine is replaced the 
conserved Glutamate at the start of the lever arm (Figure 3.2.9). Furthermore, 
the guanidine group of R743 from the lever arm is not forming an ideal hydrogen 
bond with the converter domain residue R699.  
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3.3 Structural Models of Toxoplasma gondii Myosin Heavy Chain 
(MHC) and Myosin Light Chain (MLC) Complexes 
TgMyoA is the best-understood Apicomplexan myosin motor. TgMyoA is a very 
short myosin heavy chain with a short neck and no true tail domain (Foth et al, 
2006). It is a fast, single-headed and plus-end directed molecular motor with 
kinetic and mechanical characteristics that are similar to fast skeletal muscle 
myosin-2 (Herm-Gotz et al, 2002). MyoA co-localizes with a myosin light chain 
that is referred as “myosin light chain 1 (TgMLC1) in T.gondii (Herm-Gotz et al, 
2002) and myosin-tail-interacting protein (MTIP) in Plasmodium spp (Baum et al, 
2006). The interaction of the MTIP/MLC1 is dependent on a dibasic motif in the 
C-terminal part of MyoA, i.e., the “degenerate” IQ motif (Hettmann et al, 2000; 
Opitz & Soldati, 2002).  
3.3.1 Structural model of TgMLC1 in Complex with TgMyoA-tail 
To gain further insight into the interaction of TgMyoA-MLC1 complex, homology 
models of the C-terminal TgMyoA tail (residues 806 to 819) and TgMLC1 
(residues 69 to 213) were built using the PfMTIP:MyoA crystal structure as 
template (Bosch et al, 2006). Protein-peptide docking was performed later using 
these models. TgMyoD and TgMyoA are highly conserved (51% of identity, 
69.6% of similarity). Also, the C-terminal part of PfMyoA, TgMyoA and TgMyoD 
are highly conserved (Figure 3.3.1). TgMLC2 sequence is less conserved (15% 
of identity, 25% of similarity) because of the presence of a long N-terminal 
extension in TgMLC2 when compared to PfMTIP (Polonais et al, 2011).  
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Figure 3.3.1: Sequence alignment of the C-terminal part of PyMyoA, TgMyoA and TgMyoD and of 
the CaM-like domain of PfMTIP, TgMLC1 and TgMLC2. The positions of the secondary structure 
elements (helices represented as springs and strands represented as arrows) are based on the 
PyMyoA–PfMTIP crystal structure (2QAC) (Bosch et al, 2006). 
The resulting homology model of the TgMLC1-MyoA complex shows that the two 
MLC1 subdomains surround the MyoA-tail helix in a clamp-like manner (Figure 
3.3.2). For clarity, the two proteins will be referred as MLC1 and MyoA for the 
rest of the document. The MLC1 model is predicted to consist of two CaM-like 
subdomains. The N-Domain formed by residues 69 to 139 contains two EF-hand 
motifs; the C-Domain formed by residues 147 to 213 contains two more EF-hand 
motifs. The subdomains are predicted to be connected by a short unstructured 
“hinge” loop formed by residues 140 to 146. MyoA tail residues 806 to 819 form 
an IQ-like motif with the sequence ‘AQAHIRRHLVD’. 
 
Figure 3.3.2: TgMyoA-MLC1 
complex showing the compact 
binding with distinct N- and C-
Domain. The N-Domain is 
colored in light pink, the C-
Domain is colored in yellow and 
the middle hinge region is 
colored in blue. The MyoA-tail is 
presented in green. 
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The interface accessible surface area of MLC1-MyoA complex is 1108 Å2, 
whereas the corresponding surface area in PfMTIP-MyoA is 958 Å2. Thus, 
TgMLC1 forms the better compact contact area with the MyoA-tail than PfMTIP. 
The interface of MLC1:MyoA consists reasonable percentage of non-polar 
residues (46 %) than the charged (23 %) and polar amino acids (31 %). The 
MyoA-tail is buried by numerous interactions ranging from strong salt-bridges, 
hydrogen bonding to moderate hydrophobic interactions. Apolar residues F154, 
L174, L181 and F204 from the C-Domain of MLC1 form hydrophobic interactions 
with the N-terminal residues (I811, L815) of MyoA-tail (Figure 3.3.3A).  
Figure 3.3.3: Homology models depicting the hydrophobic interactions between C-Domain of 
MLC1 and MyoA-tail (A) and the hydrophilic network of MyoA-MLC1 complex (B). Residues are 
colored according to the location. 
In the TgMyoA model, R815 occupies the 7th position of the IQ motif forming a 
tight network of hydrogen bonds with residues in the C-Domain (Figure 3.3.3B). 
In addition, H816 replaces a conserved positive residue (Arginine or Lysine) in 
this position in PfMyoA and TgMyoD. The tighter interactions with the C-Domain 
may contribute to the compactness of the interface. Conserved basic residues 
R808 and R815 in the MyoD-tail helix are involved in a tight network of polar 
Results 
 
112 
 
interactions with MLC1 residues D149, D116 and S113. H814 of MyoA-tail forms 
a hydrogen bond with D145 in the MLC1 hinge region (Figure 3.3.3B). Also, the 
interaction is further stabilized by the H142 residue of the hinge region, which 
forms a tight network with the N-Domain residue D116. All these interactions thus 
contribute to the stability of the MLC1-MyoA complex.  
3.3.2 The Compact Structure of TgMLC2 in Complex with TgMyoD-tail 
In order to build the structural models of TgMyoD and TgMLC2 lacking N-
terminal, the PfMTIP–MyoA crystal structure (Bosch et al, 2007) was used as a 
template for homology modeling. For simplicity, the two proteins will be referred 
as MLC2 and MyoD for the remainder of the text. The MLC2 model is predicted 
to consist of two subdomains. The N-Domain formed by residues 228 to 292 
contains EF-hand motifs 1 and 2, whereas the C-Domain formed by residues 299 
to 367 contains EF-hand motifs 3 and 4. In analogy to the PfMTIP structure 
(Bosch et al, 2006), the subdomains are predicted to be connected by a short 
unstructured ‘hinge’ loop formed by residues 293 to 298 (Figure 3.3.1). MyoD-tail 
residues 803 to 816 containing a degenerate IQ motif (ICANVRRKLVQ) are 
modeled as an α-helix. 
 
The resulting model of the MLC2–MyoD complex shows that the two MLC2 
subdomains surround the MyoD-tail helix in a clamp-like manner (Figure 3.3.4). 
Figure 3.3.4: Cartoon representation of 
the TgMyoD-tail bound to TgMLC2, view 
along the MyoD-tail helix, in white. The 
N-Domain is colored in green and the C-
Domain is colored in blue. 
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The MLC2–MyoD interface contains predominantly non-polar residues (55%). 
Charged and polar neutral amino acids contribute for 28 and 17%, respectively. 
Similar to the experimentally solved structures, the N-Domain is predicted to form 
crucial interactions with the tail region (Bosch et al, 2006; Bosch et al, 2007). In 
contrast, the interactions involving the C-Domain appear more dominant than in 
PfMTIP–MyoA crystal structure (Bosch et al, 2007). Previous studies have shown 
that a glycine or other small residue is not required at the seventh position of the 
IQ motif to accommodate MLC binding (Bosch et al, 2007). 
In fact, the same group (Bosch et al, 2007) showed through mutagenesis and 
structural studies that mutation of G812K in PfMyoA promotes a compact 
conformation of the complex. In the TgMyoD model, R812 occupies the seventh 
position of the IQ motif forming a tight network of hydrogen bonds with residues 
in the C-Domain (Figure 3.3.5A). The tighter interactions with the C-Domain may 
contribute to the compactness of the interface. The predicted accessible surface 
area in the interface of the MyoD–MLC2 complex corresponds to 884 Å2, 
compared to 1108 Å2 for the homology-modeled TgMLC1–MyoA complex and 
958 Å2 for the PfMTIP–MyoA complex (Bosch et al, 2007). 
Residues F305, F306, F309 and F342 from the C-Domain of MLC2 form a 
hydrophobic cluster that interacts with residues A803, I806, C807, A808 and 
V810 in the MyoD-tail helix (Figure 3.3.5B). The presence of C807, which 
replaces the conserved glutamine in the MyoD IQ motif, favors the interaction 
with the hydrophobic cluster in the C-Domain of MLC2. 
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Figure 3.3.5: Interaction network of TgMLC2-MyoD. (A) Hydrophilic network around the MyoD-tail 
shown as stick representation in white. The contacting residues of TgMLC2 are colored according 
to their location: C-Domain residues are colored in blue, hinge region residues in orange and N-
Domain residues in green. Distances are shown in Å. (B) Illustration of hydrophobic interactions 
between the N-terminal extremity of MyoD-tail and C-Domain of TgMLC2. Non-polar residues of 
the C-Domain of TgMLC2 are shown as stick representation in violet, and MyoD-tail buried non-
polar residues are shown as sticks in yellow. 
Glutamine, being a polar residue, cannot be accommodated in this position. 
N809 of MyoD-tail is one of the key residues in the interface with MLC2. Mostly, 
histidine residues are preferred in this position and H811 as well as H812 are the 
corresponding residues in TgMyoA and PfMyoA. The PfMyoA and TgMyoA tail 
regions differ in MyoD positions 804 and 807 that are involved in the interactions 
with MLC2 (Figure 3.3.6A). Conserved basic residues R811 and R812 in the 
MyoD-tail helix are involved in a tight network of polar interactions with MLC2 
residues E331, E332, M361 and L362, E364. R805 forms hydrogen bonds with 
H294 and D297 in the MLC2 hinge region (Figure 3.3.6). Thus, most residues in 
the MLC2 C-Domain are predicted to be involved in direct interaction with the 
MyoD-tail. 
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Figure 3.3.6: Stereo views of Apicomplexan MHC tails (A) Superimposition of TgMyoD-tail helix in 
the TgMLC2–MyoD complex, in white, with PfMyoA-tail helix of the PfMTIP–MyoA complex, in 
cyan. (B) Superimposition of TgMyoD-tail helix in white, with TgMyoA-tail helix, in green.  
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3.4 Structural and Kinetic Characterization of Human Nonmuscle 
Myosin-2A and its Switch-2 Mutant 
The most important structural elements that enable the allosteric coupling 
between the myosin motor domain and F-actin include the P-loop, switch-1 and 
switch-2 (Nagy et al, 2010). These switch motifs form part of the nucleotide 
binding site (Geeves et al, 2005). Structurally, switch-1 and switch-2 contact the 
nucleotide at the rear of the nucleotide binding-site and act as γ-phosphate 
sensors (Geeves et al, 2005; Reubold et al, 2003). In the ATP-bound state, the 
switch elements move towards each other. In the ADP-bound state, they move 
apart from each other (Geeves et al, 2005; Reubold et al, 2003). This mechanism 
is the base for the enzymatic mechanism of ATP hydrolysis and the production of 
mechanical work (Nagy et al, 2010). 
3.4.1 Switch-2 Motif in Different Myosin Isoforms 
Class-2 myosins have either Serine or Alanine in the 3rd position of the switch-2 
loop whereas most unconventional myosins (class-1, class-5 and class-7 
myosins) either have Phenylalanine or Tyrosine in this position (Figure 3.4.1). 
Figure 3.4.1: Sequence alignment of the switch-2 loop (DIXGFE) region of different myosin 
classes from different species.  
In the present work, the question why class-2 myosins do have different residue 
at the 3rd position of the switch-2 loop was addressed. To answer this question, 
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nonmuscle myosin 2A (NM2A) was chosen as a model system to analyze the 
effect of the mutation A454S in the consensus sequence DIXFGE of the switch-2 
loop. The aim was to study the influence of the point mutation on the 
chemomechanical coupling and the actomyosin ATPase cycle. To accomplish 
this, the complete kinetic characterization of human nonmuscle myosin-2A and 
nonmuscle myosin-2A-A454S was performed. Further, in silico modeling 
techniques were used to build a structural model of the myosin motor domains. 
Throughout the work, the native myosin will be referred to as wild type (Wt) and 
nonmuscle myosin-2A-A454S will be referred to as A454S. NM2A constructs 
comprising amino acids 1-775 of human NM2A motor domain and in the case of 
A454S additionally the switch-2 mutation A454S, each fused to an artificial lever 
arm were produced in the baculovirus/Sf9 system and purified to homogeneity as 
described in section 2.2.3.6. The artificial lever arm comprises two spectrin-like 
repeats from Dictyostelium discoideum and functionally replaces the native light 
chain binding region (Anson et al, 1996a; Kliche et al, 2001). The advantage of 
the fusion-constructs is the production of single headed, constitutively active 
myosin motor domain constructs. It was previously shown that the fusion of the 
artificial lever arm to the myosin motor domain does not alter the native kinetic 
and functional properties of myosin motor domains of different classes of various 
species (Durrwang et al, 2006; Heissler & Manstein, 2011; Liao et al, 2009; Taft 
et al, 2008). 
The steady-state and transient kinetic parameters of the ATPase cycle of both 
constructs were studied using stopped-flow and spectroscopic methods. The 
transient kinetic analysis of the individual rate and equilibrium constants of 
relevant steps of the ATPase cycle enables a detailed description of the 
enzymology and mechanic function of the myosin motor domain. The observation 
that the ADP interaction of NM2A is regulated by the concentration of free 
magnesium ions and that the mutation A454S in the switch-2 region is modulator 
of the ADP kinetics shows a new aspect of the chemomechanical coupling of the 
myosin motor domain.   
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3.4.2 In silico modeling of Hs NM2A and its switch mutant A454S 
To gain the structural details of the nucleotide-binding pocket, a homology model 
of NM2A motor domain the pre-power stroke state was built (Figure 3.4.2). As 
the nucleotide-binding pocket is highly conserved in myosins, the x-ray structure 
of Hs nonmuscle muscle myosin-2C (PDB-code 2YCU) was used as a template.  
ADP.VO4 was superimposed exactly onto the nucleotide analogue structure in 
the model for clarity and analysis purpose. To generate a model of A454S, in 
silico mutagenesis of Alanine 454 to Serine (A454S) was performed and the 
resulting structure was energy-minimized by using Gromacs (Van Der Spoel et al, 
2005). 
 
Figure 3.4.2: Overall view of the Hs NM2A motor domain structure. This model was built by using 
the crystal structure of Hs NM2C motor domain (PDB-code: 2YCU) as a template. 
The structural model of NM2A motor domain revealed that the bound nucleotide 
is surrounded by three loops whose sequences are highly conserved among the 
myosin family: the P-loop (residues 173-179), switch-1 loop (229-234) and 
switch-2 loop (452-458).  The consensus sequence (DIXGFE) of the switch-2 
loop exhibits an Alanine at the 3rd (central) position. Examination of the in silico 
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mutation A454S revealed that Ser454 in the switch-2 loop forms an ideal 
hydrogen bond with the back bone atoms of the residues S233 and F235 in the 
switch-1 loop.  Further, S233 coordinates to the magnesium ion.  The Wt 
structure revealed that A454 is not interacting with any switch-1 residue. Since 
alanine lacks a polar side chain capable to form a hydrogen bond, no direct 
interaction via A454 is possible (Figure 3.4.3).   
This observation can be hypothesized in the following way.  
(1) No hydrogen bonding interaction with switch-1 is possible when Ala454 is 
present in the central position of switch-2. This can lead to faster release 
of magnesium during the hydrolysis reaction in the wild type, as the S233 
is only coordinated to the magnesium ion but not to A454. 
 
(2) In the case of A454S, Ser454 interaction to switch-1 may lead to a slower 
release of the magnesium ion because of the additional bond energies on 
the Ser233.  
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Figure 3.4.3:  Close-up view of the nucleotide binding pocket of Hs NM2A Wt and A454S. Red 
spheres shown are the predicted waters from Hs NM2C structure (PDB: 2YCU). The predicted 
distances in the network between N231, water and Magnesium (Mg) as well as the predicted 
distance between oxygen from Pα, water and Mg are not shown. These water positions are at the 
equivalent positions of waters in Hs NM2C motor domain and also other myosin 2 isoform motor 
domain pre-power stroke state structures. The predicted distances are shown in Å.  
3.4.3 Expression and Purification 
The expression and purification of Wt and A454S were performed as described 
in section 2.2.3.6. Typically, recombinant protein was prepared to homogeneity 
from 5-10 L Sf9 insect cells by Ni2+-chelate affinity chromatography and 
subsequent gel filtration. A representative SDS-PAGE analysis and gel filtration 
elution profile are shown in Figure 3.4.4. 
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Figure 3.4.4: Purification of NM2A Wt and A454S. (A) SDS-PAGE analysis of fractions obtained 
through gel filtration step of NM2A Wt. The first lane shows the standard protein size marker. (B) 
Gel filtration elution profile of A454S. The protein elutes as a single peak with an elution volume 
between 155 and 180 ml. Fractions of the main peak were pooled and used for the kinetic 
characterization.  
3.4.4 Kinetic Measurements 
The kinetic measurements were interpreted in terms of the basic kinetic scheme 
depicted in Figure 3.4.5. The upper line of the scheme represents the pathway 
with the steps ATP binding, ATP hydrolysis and product release in the absence 
of F-actin. The lower line represents the same steps in the presence of F-actin. 
The asterisk (*) symbol represents changes in fluorescence intensity.  
 
Figure 3.4.5: Basic kinetic mechanism of the actomyosin ATPase. The abbreviations used are as 
follows: A=F-actin, M=myosin, Pi=inorganic phosphate. The predominant flux of the reaction 
pathway is highlighted in blue. Rate constants are referred to as k+n and k-n, respectively. 
Dissociation equilibrium constants are denoted as Kn. Bold notation (Kn, k+n) represents the 
kinetic constants in the presence of F-actin. Subscript A and D refer to actin and ADP, 
respectively. KA represents the affinity of myosin for F-actin, KD the affinity of ADP for myosin, KAD 
the affinity of ADP for the actomyosin complex, and KDA the affinity of actin for myosin in the 
presence of saturating concentrations of ADP according to Heissler and Manstein (Heissler & 
Manstein, 2011). 
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3.4.4.1 Active-site Titration 
The exact number of active sites of the produced myosin motor domain 
constructs was analyzed prior to the kinetic characterization. To assay the 
number of active myosin motor domains, 0.5 µM myosin was mixed with 
increasing amounts of mantATP (0.005-0.35 µM) in a stopped-flow 
spectrophotometer. The obtained transients follow a double-exponential behavior. 
As depicted in Figure 3.4.6, the dependence of relative amplitude increased with 
increasing nucleotide concentration and reached a plateau. Linear fit of both, the 
initial slope and the plateau phase results in a point of intersection that 
corresponds to the amount of active sites in the preparations. Under the 
experimental conditions, points of intersection at 0.091 µM mantATP and 0.113 
µM mantATP were determined for Wt and A454S, corresponding to 36.5% and 
45% active myosin motor domains, respectively.  
 
Figure 3.4.6: Active-site titration of Wt (A) and A454S (B). The dependence of the observed 
relative amplitude was plotted as function of [mantATP]. Linear fit to the initial slope and plateau-
phase defines a point of intersection that corresponds to the active myosin concentration of the 
protein preparation. Active concentrations of 36.5% and 45% were determined for Wt and A454S, 
respectively.  
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3.4.4.2 Steady-State ATPase Activity 
The steady-state ATPase activity of Wt and A454S was assayed with the NADH-
coupled assay in the presence of an ATP regeneration system. The active 
myosin concentration for both, mutant and Wt was kept at 0.73 µM and 0.9 µM.  
In the absence of F-actin, a basal ATPase activity of kbasal=0.013±0.001 s-1 and 
kbasal=0.004±0.002 s-1 was determined for Wt and A454S, respectively. As 
depicted in Figure 3.4.7, the ATPase activity of Wt and A454S was activated 10-
fold by F-actin. Especially for the mutant, it was very difficult to quantify the 
ATPase activity in precision, but estimated from fitting the data sets to a 
hyperbolic equation suggest a vmax of 0.11±0.01 s-1 and 0.04±0.004 s-1 for Wt 
and A454S at a F-actin concentration of 140 µM with Kapp values >140 µM for 
both proteins. Wt and A454S show comparable basal ATPase activities 
(kbasal=0.013 s-1 and 0.007 s-1) and maximal ATPase activities (vmax=0.17±0.005 
s-1 and 0.13±0.01 s-1) as human nonmuscle myosins-2A and -2B S1-like 
constructs characterized in previous studies (Kovacs et al, 2003; Wang et al, 
2003). It is of note that Kapp parameters determined in the present study are 2 
fold higher than those obtained by Kovacs and coworkers (Kovacs et al, 2003) 
for human NM2A S1-construct. This difference might be attributed to different 
buffer conditions and a different assay temperature. Low vmax and high Kapp 
parameters indicate a very weak coupling between the nucleotide binding site 
and the actin binding region of both, Wt and A454S, and was already described 
for human nonmuscle myosin-2C isoforms (Heissler & Manstein, 2011). The 
parameters of the steady-state ATPase measurements are listed together with 
published data from a previous study in Table 24. 
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Figure 3.4.7: Actin-activated steady-state ATPase activity of Wt and A454S. The plot shows the 
F-actin-dependence of the steady-state ATPase activity. Hyperbolic fit of the data sets gives the 
parameter vmax of 0.11±0.01 s-1 and 0.04±0.004 s-1 for Wt and A454S at a concentration of 140 
µM F-actin. It is of note that the parameter Kapp is >140 µM. Therefore, the given values need to 
be treated with some caution. The basal ATPase activity was subtracted from the data in the 
presence of F-actin.  
 
Table 24: Kinetic parameters of the basal and actin-activated steady-state ATPase activity.  
Parameter Signal or 
calculation 
NM2A-Wt NM2A-A454S NM2A 
(Kovacs et al, 
2003) 
kbasal [s-1] NADH Assay 0.013±0.001 0.004±0.002 0.013±0.0042 
vmax [s-1] NADH 
Assay1 
0.11±0.01 0.04±0.004 0.17±0.0052 
Kapp [µM] NADH Assay >140 >140 72.4±42 
vmax/ Kapp  
[µM-1s-1] 
vmax/ Kapp3 ~0.0008 ~0.0003 ~0.002 
1
 at 140 µM F-actin, the highest F-actin concentration experimentally accessible 
2 Experimental conditions: 25°C, 2 mM MgCl 2, 1 mM ATP (Kovacs et al, 2003)  
3
 At 140 µM F-actin 
 
In comparison with the steady-state ATPase activity of other class-2 nonmuscle 
myosins determined in previous studies, a common feature of all myosin motors 
is a very slow ATPase activity (0.13-0.23 s-1) (Heissler & Manstein, 2011; Kovacs 
et al, 2003; Wang et al, 2003). The behavior is in striking contrast to other class-2 
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myosins such as skeletal, smooth muscle, and cardiac myosin (0.7-29 s-1) 
(Marston & Taylor, 1980; Wagner, 1981). The point mutation A454S in human 
nonmuscle myosin-2A results in a 3-fold reduced steady-state turnover when 
compared to the kinetic parameter obtained for Wt at a F-actin concentration of 
140 µM.  This behavior indicates that the mutant comprises the intact capability 
to bind and hydrolyze ATP, even though either the rates of nucleotide binding, 
hydrolysis or product release are reduced (Nagy et al, 2010). Interestingly, a 
point mutation Y439A present at the equivalent position in switch-2 of murine 
myosin-5a had shown a ~8-fold reduction in vmax (Nagy et al, 2010). 
3.4.4.3 Interaction between Myosin and ATP 
ATP binding to Wt and A454S was monitored the fluorescence enhancement 
upon ATP binding to myosin according to the following scheme.  
 
The intrinsic tryptophan fluorescence was excited at a wavelength of 297 nm and 
the emission was detected through a WG320 cut-off filter. The fluorescence 
signals were biphasic with the observed rate constant depending hyperbolically 
on the nucleotide concentration (Figure 3.4.8B). A hyperbolic fit of the data sets 
defines the parameter 1/K1 to 78.09±10.08 µM for Wt and 167.04±17.72 µM for 
A454S. The plateau phase describes the rate of ATP hydrolysis (k+3+k-3) to 
44.85±1.36 s-1 and 174.88±5.27 s-1 for Wt and A454S. Up to a concentration of 
50 µM ATP, the observed rate constants depend linearly on [ATP] (data not 
shown) defining the second order rate constant for ATP binding, K1k+2 to 
0.39±0.01 µM-1s-1 and 0.77±0.03 µM-1s-1 for Wt and mutant, respectively.  
By using the fluorescent mant analogue mantATP as a substrate, a K1k+2 of 
0.86±0.02 µM-1s-1 and 1.00±0.02 µM-1s-1 for Wt and mutant was obtained when 
fitting the dependence of the observed rate constants against the mantATP 
concentration with a linear function (Figure 3.4.8A).  
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Figure 3.4.8: ATP binding to Wt and A454S. (A) Dependence of the observed rate constants 
upon mixing myosin with increasing concentrations of mantATP. Linear fit to the data set defines 
the apparent second-order rate constant K1k+2 of 0.86±0.02 µM-1s-1 and 1.00±0.02 µM-1s-1 for Wt 
and A454S, respectively. (B) ATP-dependence of the observed rate constants (kobs) of the 
transient fluorescence increase upon mixing myosin with ATP. Hyperbolic fits to the individual 
data sets define the rate of ATP hydrolysis (k+3+k-3) to 44.85±1.36 s-1 and 174.88±5.27 s-1 for Wt 
and A454S. The second-order binding rate constant K1k+2 was determined to 0.39±0.01 µM-1s-1 
and 0.77±0.03 µM-1s-1 for Wt and mutant from the initial slope. Half saturation (1/K1) was reached 
at 78.09±10.08 µM ATP for Wt and 167.04±17.72 µM ATP for A454S. 
 
The kinetic parameters describing the interaction between myosin and ATP are 
summarized in Table 25. 
3.4.4.4 Interaction between Actomyosin and ATP 
The interaction between the rigor complex and ATP was modeled as a two-step 
binding reaction according to the following scheme.  
 
Rapid mixing of pyrene-actomyosin with increasing ATP concentrations in a 
stopped-flow apparatus resulted in a time-dependent fluorescence increase. The 
obtained transients were fitted with an exponential function. As depicted in Figure 
3.4.9A, the secondary plot of the observed rate constants (kobs) versus the ATP 
concentration follows a hyperbolic behavior. Fitting of the data sets gives the 
maximum isomerization rate constants k+2 of 204.63±16.02 s-1 and 160.41±15.30 
s-1 for Wt and A454S at saturating ATP. Half saturation, corresponding to 1/K1, 
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was reached at ATP concentrations of 643.68±126.95 µM and 502.76±112.09 
µM for Wt and A454S, respectively. Linear fits of the initial slopes define the 
second order rate binding constants K1k+2 of 0.26±0.04  µM-1s-1 and 0.24±0.04 
µM-1s-1 for Wt and A454S (Figure 3.4.9A).  
Additionally, the increase in fluorescence upon mixing 0.3 µM actomyosin with 
increasing concentrations of mantATP results in an exponential fluorescence 
increase. As depicted in Figure 3.4.9B, the dependence of the observed rate 
constants (kobs) on the mantATP concentration is linear in the assayed 
concentration range up to 15 µM mantATP. Linear fits to the data sets give the 
second order rate constants for ATP binding to the actomyosin complex K1k+2 of 
0.11±0.01 µM-1s-1 and 0.27±0.02 µM-1s-1 for Wt and A454S, respectively. 
The kinetic parameters describing the interaction between the actomyosin and 
ATP are summarized in Table 25. 
 
Figure 3.4.9: Interaction of actomyosin with ATP. ATP-concentration dependence of the observed 
rate constants upon mixing pyrene-labeled actomyosin with increasing concentrations of ATP. 
Hyperbolic fits to the data sets define the parameters k+2 at the plateau phase as well as K1k+2 
from the initial slope (inset). The values 1/K1 indicate half-saturating ATP concentrations, are 
listed in Table 25. (B) Dependence of the observed rate constants upon mantATP binding to 
actomyosin on the nucleotide concentration. Linear fit of the data sets define the second-order 
binding rate constant K1k+2 to 0.11±0.01 µM-1s-1 and 0.27±0.02 µM-1s-1 for Wt and A454S, 
respectively. 
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Table 25: Kinetic parameters of the interaction of myosin and actomyosin with ATP. 
Parameter Signal NM2A-Wt NM2A-A454S NM2A 
(Kovacs et al, 
2003) 
K1k+2 [µM-1s-1] Tryptophan 0.39±0.01 0.77±0.03 0.56±0.01 
K1k+2 [µM-1s-1] mantATP 0.86±0.02 1.00±0.02 1.03±0.14 
1/K1 [µM] Tryptophan 78.09±10.08 167.04±17.72 n.d. 
k+3+k-3 [s-1] Tryptophan 44.85±1.36 174.88±5.27 14.1±0.5 
K1k+2 [µM-1s-1] Pyrene-actin 0.26±0.04 0.24±0.04 0.21±0.04 
K1k+2 [µM-1s-1] mantATP 0.11±0.01 0.27±0.02 0.14±0.003 
1/K1 [µM] Pyrene-actin 643.68±126.9
5 
502.76±112.09 ≈900 
k+2 [s-1] Pyrene-actin 204.63±16.02 160.41±15.30 ≈190 
 
The interactions between myosin and actomyosin with ATP do not reveal major 
impact of the A454S mutation on NM2A ATP-binding kinetics. The A454S mutant 
exhibits slightly accelerated ATP binding properties as the Wt. In the absence of 
F-actin, the rate constant of the ATP hydrolysis step (k+3+k-3) is 4-fold faster in 
A454S when compared to the Wt. Additionally, the association rate constant 1/K1 
is 2 fold reduced in A454S in comparison to Wt.  
The comparison of the determined rate and dissociation equilibrium constants of 
the interaction between actomyosin and ATP indicate, that the point mutation 
A454S does not markedly change the actomyosin-substrate interaction. 
3.4.4.5 Interaction of Myosin and ADP 
The fluorescence enhancement of mantATP upon binding to myosin and 
actomyosin is analyzed in terms of the following scheme, in which the asterisk (*) 
represents the high fluorescent state of mantADP. 
 
The fluorescent ADP analogue mantADP was used to characterize the 
interaction of ADP and myosin. MantADP binding to myosin was performed 
under pseudo-first order conditions. The time courses of the fluorescence 
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enhancement upon mantADP binding to Wt and A454S were fitted double-
exponentially. As depicted in the kobs versus mantADP plot (Figure 3.4.10A), the 
rate of the fast phase of Wt depends linearly on the nucleotide concentration up 
to 7.5 µM (Figure 3.4.10A). Linear approximation of the data set defines the 
second-order rate constant k+D to 4.39±0.28 µM1s-1 and the rate constant of ADP 
release k
-D to 0.68±1.06 s-1 from the slope and intercept of the linear fit. As shown 
in Figure 3.4.10A for A454S, the observed rate constants show a hyperbolic 
dependence on [mantADP]. Extrapolating the fit to zero [mantADP] suggests a 
rate constant for ADP release k
-D of 0.77±0.05 s-1. Linear fit of the initial slope 
(with a fixed k
-D of 0.77±0.05 s-1) of the data set indicates a second order binding 
rate constant k+D of 2.71±0.04 µM1s-1. 
The ADP dissociation from myosin was assayed by chasing the 
myosin•mantADP complex with excess ATP. The fluorescence of the mant-
moiety was excited at a wavelength of 365 nm and the time courses of the 
fluorescence decay were monitored after passage through a KV389 cut-off filter. 
As shown in Figure 3.4.10B, the transients follow a single-exponential function 
plus lag-phase for Wt and A454S. Dissociation rate constants k
-D of 0.38±0.01 s-1 
and 0.54±0.02 s-1 were determined for Wt and A454S, respectively.  
Furthermore, the ADP release kinetic from Wt and A454S was determined in an 
independent experiment, in which the myosin•ADP complex was chased with 
excess ATP. The change in intrinsic protein fluorescence was excited at 297 nm 
and the time dependent fluorescence increase was monitored through a WG320 
filter. Exponential fits to the fluorescence transients define the rate constant of 
ADP release k
-D to 0.34±0.01 s-1 and 0.47±0.03 s-1 for Wt and A454S, 
respectively. 
The results of the independent measurements of the ADP release kinetics from 
myosin are in good agreement with the parameters obtained from the binding 
titrations and listed in Table 26.  
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Figure 3.4.10: ADP binding and dissociation from myosin. (A) MantADP dependence of the 
observed rate constants upon myosin binding to Wt and A454S. In the concentration range 
examined, Wt shows a linear behavior, defining the second-order rate constant k+D to 4.39±0.28 
µM1s-1. For A454S, the observed rate constants depend hyperbolically on the mantADP 
concentration. Linear fit of the initial slope defines k+D  to 2.71±0.04 µM1s-1. From the ordinates of 
the fits, k
-D values of 0.68±1.06 s-1 and k-D of 0.77±0.05 s-1 were determined for Wt and A454S, 
respectively. (B) ADP dissociation from myosin Wt and A454S (inset). The shown transients were 
obtained by casing 0.15 µM myosin and 1.5 µM mantADP with 500 µM ATP. The shown transient 
for Wt has an amplitude of -5.275 and a kobs of 0.38 s-1. The shown transient for the A454S 
mutant has an amplitude of -6.71% and a kobs of 0.54 s-1. 
Calculation of the dissociation equilibrium constants of ADP binding to myosin KD 
from the ratio k
-D/k+D gives constants of 0.16±0.03 µM for Wt and 0.28±0.02 µM 
for A454S.  
3.4.4.6 Interaction between Actomyosin and ADP 
In the presence of F-actin, mantADP binding to the rigor complex was assayed 
by mixing actomyosin under pseudo-first order conditions with increasing 
amounts of mantADP in a stopped-flow spectrophotometer. The transients were 
fitted to double-exponentials. As depicted in Figure 3.4.11A, the observed rate 
constants depend linearly on the mantADP concentration in the concentration 
range examined. Fitting a straight line to the data set of Wt defines the second 
order rate constant for mantADP binding to the rigor complex k+AD of 4.92±0.09 
µM-1s-1 and k
-AD of 1.69±0.25 s-1 from the slope and the intercept, respectively. 
For A454S, the fit parameters k+AD =5.52±0.11 µM-1s-1 and k-AD of 0.41±0.31 s-1 
were obtained.  
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The actin-activated ADP release from actomyosin was assayed by chasing the 
ternary actomyosin.mantADP complex with excess ATP. The obtained 
fluorescence transients were fitted to single exponentials defining the constants 
k
-AD = 2.39±0.21 s-1 and k-AD = 0.52±0.05 s-1 for Wt and A454S, respectively. For 
instance, a transient of the reaction between A454S is shown in Figure 3.4.11B.   
 
Figure 3.4.11: Interaction between actomyosin and ADP. (A) MantADP-dependence of the 
observed rate constants upon binding mantADP to Wt and A454S, respectively. Linear fit to the 
individual data sets define the second-order rate constants k+AD of 4.92±0.09 µM-1s-1 and k+AD 
=5.52±0.11 µM-1s-1 for Wt and A454S. The corresponding intercepts correspond to k
-AD = 
1.69±0.25 s-1 and k
-AD = 0.41±0.31 s-1 for WT and A454S. (B): Transient of the reaction between 
0.3 µM actomyosinA454S.mantADP with excess ATP at a total magnesium concentration of 
0.175 mM. The FRET signal was excited at 297 nm and the fluorescence decrease was detected 
after passage through a KV389 filter. The shown transient was fitted to a single-exponential 
function and comprises amplitude of -4.56% and an observed rate constant of 1.13 s-1. 
Calculation of the dissociation equilibrium constant of ADP binding to the 
actomyosin complex KAD from the ratio k-AD/k+AD gives constants of 0.34±0.06 
µM for Wt and 0.07±0.06 µM for A454S. All kinetic parameters of the interaction 
between myosin and actomyosin with ADP are listed in Table 26.  
3.4.4.7 Magnesium-sensitivity 
To further investigate the interaction between actomyosin and ADP, the effect of 
the concentration of free Mg2+ ions on the ADP-release kinetics from actomyosin 
was characterized for Wt and A454S. As depicted in Figure 3.4.12, the ADP 
release from actomyosin declines with increasing concentrations of free Mg2+. In 
case of Wt, increasing concentrations free Mg2+ in the concentration range 
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between 0.02 and 9.5 mM inhibits the actin-activated ADP release from 
5.77±0.37 s-1 to 2.07±0.19 s-1. For A454S, increasing concentrations of free Mg2+ 
between 0.02 mM and 19.5 mM reduces the ADP release kinetics from 
actomyosin ~3.3-fold from 1.30±0.12 s-1 to 0.42±0.03 s-1. The inhibitory constant 
lies at 0.45±0.09 mM and 1.17±0.39 mM free Mg2+ for Wt and A454S mutant, 
respectively. The point mutation A454S therefore drastically reduces the rate 
constant of ADP release without abolishing the magnesium-sensitive regulatory 
mechanism of NM2A. 
 
Figure 3.4.12: Magnesium-sensitivity. Increasing the free Mg2+ ion concentration reduces the 
actin-activated ADP release for Wt and A454S 2.8-3.3-fold. The inhibitory constant Ki lies with 
0.45±0.09 mM and 1.17±0.39 mM free Mg2+ for Wt and A454S mutant in the concentration range 
of physiological free Mg2+. This experiment was performed in collaboration with Dr. Sarah M. 
Heissler, BPC, MHH. 
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Table 26: Summarizes all kinetic constants of the interaction between actomyosin and myosin 
with ADP and free Mg2+.  
Parameter Signal or 
calculation 
NM2A-Wt NM2A-A454S NM2A(Kovacs 
et al, 2003) 
k+D [µM1s-1] mantADP  4.29±0.28 2.71±0.04 0.55±0.06 
k
-D [s-1] mantADP1 0.68±0.09 0.77±0.05 0.54±0.23 
 mantADP2 0.38±0.01 0.54±0.02 1.12±0.13 
 Tryptophan2 0.34±0.01 0.47±0.03 n.d. 
KD [µM]  k-D/k+D 0.16±0.03 0.28±0.02 1.5±0.4 
k
-+AD [µM-1 s-1] mantADP 4.92±0.09 5.52±0.11 2.72±0.16 
k
-AD [s-1] mantADP1  1.69±0.25 0.41±0.31 1.72±0.38 
 mantADP2 2.39±0.21 0.52±0.05 2.68±0.30 
Ki [Mg2+] (mM) mantADP2 0.45±0.09 1.17±0.39 n.d. 
KAD [µM] k-AD/k+AD 0.34±0.06 0.07±0.06 0.8±0.2 
1From the intercept of the kobs versus [mantADP] plot 
2From ATP chasing experiment 
 
The comparison of Wt nonmuscle myosin-2A and A454S indicate that the ADP 
kinetics in the absence of F-actin are not markedly changed. However, in the 
presence of F-actin, ADP release from A454S is ~5-fold reduced when compared 
with Wt, whereas the binding rate constants are comparable. This behavior leads 
to a ~5-fold increased ADP-affinity of A454S when compared to Wt NM2A. A ~5-
fold reduction in the actin-activated ADP release rates was also observed for 
murine Y439S myosin-5a, the corresponding switch-2 mutation in myosin-5a 
(Nagy et al, 2010).  
3.4.4.8 Interaction of Myosin and Myosin.ADP with F-actin 
The interaction between myosin and F-actin in the presence and absence of ADP 
was monitored from the fluorescence enhancement upon pyrene-actin binding to 
myosin according to the following scheme:   
 
k+DA
M·ADP+A* A·M·ADP
k
-DA
k+A
M+A* A·M
k-A In the scheme, A* represents the 
high fluorescent state of pyrene-
actin, and A the quenched state. 
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Experimentally, the pyrene fluorescence was excited at 365 nm and the time 
dependent change in fluorescence signal was monitored through a KV389 cut-off 
filter. The myosin:pyrene-actin concentrations were kept constant at a ratio of 1:5. 
Both, in the presence and absence of ADP (250 µM), the time courses follow 
double exponential functions. The slow phase presumably originates from photo-
bleaching and was neglected in the further analysis. The dependence of the fast 
phase as a function of the pyrene-actin concentration is depicted in Figure 3.4.13. 
In the absence of ADP, linear fit of the data sets gives the second order rate 
constants for F-actin binding k+A of 0.96±0.02 µM-1s-1 and k+A  of 1.03±0.23 µM-
1s-1 for WT and A454S, respectively (Figure 3.4.13A). In the presence of 
saturating ADP, rates of k+DA= 0.19±0.004 µM-1s-1 and 0.80±0.04 µM-1s-1 were 
obtained for Wt and A454S (Figure 3.4.13B).  
 
Figure 3.4.13: Interaction between myosin and myosin.ADP with F-actin. (A) F-actin dependence 
of the observed rate constants upon myosin binding to F-actin. Linear fit of the data sets for Wt 
and A454S define the second-order rate constants k+A = 0.96±0.02 µM-1s-1 and k+A =1.03±0.23 
µM-1s-1 for WT and A454S, respectively. Inset, representative transient upon mixing 0.75 µM Wt 
and 3.75 µM F-actin in a stopped–flow spectrophotometer. (B) F-actin dependence of the 
observed rate constants upon myosin.ADP binding to F-actin. Linear fit of the data sets for Wt 
and A454S define the second-order rate constants k+DA= 0.19±0.004 µM-1s-1 and k+DA =0.80±0.04  
µM-1s-1 for WT and A454S, respectively. 
F-actin release from the rigor complex was studied by mixing 0.75 µM pyrene-
labeled actomyosin with 20 µM F-actin in a stopped-flow apparatus. The time-
dependent fluorescence increase was fitted to double-exponentials (Figure 
3.4.14A). The rate constants of the fast phase reflects the rate constant of F-actin 
A B
Results 
 
135 
 
release k
-A to ~0.00019 s-1 and ~0.00024 s-1 for Wt and A454S. The slow phase 
was neglected in the following data analysis. The origin of the slow phase is 
presumable photobleaching and was further investigated in the present work. 
When performed the same assay in the presence of saturating ADP (100 µM), 
dissociation rate constants k
-DA of 0.04±0.002 s-1 and 0.07±0.004 s-1 were 
determined from the single exponential fits to the fluorescence increase for Wt 
and A454S, as depicted in Figure 3.4.14B. 
 
Figure 3.4.14: Determination of the F-actin release rate from Wt and A454S in the presence and 
absence of saturating ADP. (A) Single-exponential fit to the fluorescence transients gives k
-A  of 
~0.00019 s-1 and k
-A of ~0.00024 s-1 for Wt and A454S (inset), respectively. (B) F-actin release 
from NM2A. Single-exponential fit to the data set defines k
-DA  to 0.04±0.002 s-1. 
The calculation of the dissociation equilibrium constants for F-actin binding to 
myosin, KA, from the ratio of the dissociation and binding rate constants indicates 
values of ~0.0002 µM for Wt and A454S, respectively. In the presence of 
saturating ADP, values of ~0.21 µM and ~0.08 µM were calculated for the 
dissociation equilibrium constant of F-actin binding to Wt and A454S. All kinetic 
parameters of the interaction between myosin and F-actin in the presence and 
absence of nucleotide are summarized in Table 27.  
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Table 27: Kinetic parameters for the interaction between myosin and myosin.ADP with F-actin.   
Parameter Signal or 
calculation 
NM2A A454S NM2A(Kovacs 
et al, 2003)  
k+A [µM-1s-1] Pyrene-
actin 
0.96±0.02  1.03±0.23 0.73±0.03 
k
-A [s-1] Pyrene-
actin 
~0.00019 ~0.00024 <0.007 
(KA⋅k+A) 
KA [µM]  k-A/k+A   <0.01 
k+DA [µM-1s-
1]
 
Pyrene-
actin 
0.19±0.004  0.80±004  0.19±0.02 
k
-DA [s-1] Pyrene-
actin 
~0.04±0.002 ~0.07±0.004 ≈0.004 
(KDA⋅k+DA) 
KDA [µM]  k-DA/k+DA ~0.21 ~0.08 ≈0.02 
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4. Discussion 
4.1 Pentachloropseudilin as a Potent Class-1 Myosin Inhibitor 
Natural compounds, such as pseudilins have been identified as potent effectors 
of myosin motor activity (Martin et al, 2009a). Recently, Pentabromopseudilin 
(PBP) was reported as a potent inhibitor of myosin motor activity (Fedorov et al, 
2009). PBP has five bromine substitutions on its pseudilin backbone. The size of 
the bromine atoms is bigger than the chlorine atoms but the electronegativity of 
chlorines is much higher than the bromines. The size of the halogens is one of 
the key factors for the steric accommodation of the pseudilins in the allosteric 
binding pocket.  
 
Table 28: PClP-binding site and the contact residues for different myosin isoforms. Selected 
conserved and variable residues found in Dd myosin-1B, Rn myosin-1b, Rn myosin-1c, Oc 
myosin-2 and Dd myosin-5b structural models corresponding to selected residues in the crystal 
structure of Dd myosin-2 that interact with pentachloropseudilin are shown. The level of inhibition 
(IC50) is shown for each myosin isoform. Residues in the binding pocket are color-coded 
according to their polarity. Uncharged polar residues are shown in yellow, acidic residues in 
green, basic residues in red and non-polar residues in gray. 
Pentabromopseudilin (PBP), which was shown previously to be very potent 
against different myosin isoforms, especially against class-5 myosins (Fedorov et 
al, 2009), accommodates its bulkier substitutions better than PClP in the 
Myosin Conserved residues in the PClP-binding pocket 
Variable residues in the 
PClP-binding pocket 
IC50
 
(µM) 
Dd myosin-1B Lys186 Leu522 Asp520 Thr353 Asp356 Ser360 Lys560 1.0 ±0.5 
Rn myosin-1b Lys192 Leu534 Asp532 Asn355 Ser358 Ser362 Gln573 5.02±1.7 
Rn myosin-1c Lys189 Ile482 Asp480 Ala349 Ser352 Thr356 Tyr512 5.6±5.1 
Oc myosin-2 Lys273 Leu604 Asp602 Ala433 Glu436 Leu440 Leu653 91.2±26 
Dd myosin-5b Lys289 Ile620 Asp618 Phe452 Gly455 Asp459 Gln648 99.1±47.5 
Dd myosin-2 Lys265 Leu592 Asp590 Ala424 Gly427 Leu431 Gln633 126.6±21 
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allosteric binding pocket of Dd myosin-2. Pentachloropseudilin (PClP) on the 
other hand possess five chorines and this confers greater electronegativity to this 
pseudilin derivative. Compared to other myosin isoforms, class-1 myosins 
comprise a highly polar allosteric binding pocket (Table 28 and Figure 3.1.1.9). 
Thus, PClP being a more polar compound compared to PBP shows potent 
inhibition against class-1 myosins motor activity.  
4.1.1 Conformational Changes in the Allosteric Binding Pocket 
Myosin does not undergo any major conformational changes in the backbone 
atoms upon binding PClP. Indeed, the Cα atoms of the inhibitor-bound and 
unbound MgADPmetavanadate complexes superimpose with an r.m.s. 
deviation of 0.41 Å. Comparison of allosteric binding sites of PClP and PBP has 
shown significant local conformational changes. The average r.m.s. deviation for 
superimposed PClP and PBP molecules was 2.3 Å. Also, both the conformation 
of PClP and details of the interaction with myosin residues in the binding pocket 
differ from those observed with PBP. The planar anti-conformer of PClP binds to 
myosin (Figure 4.1). This differs from the binding mode of PBP, where the syn-
conformer is observed to bind with the phenyl and pyrrole ring systems bent 12º 
out of plane and twisted 20º against each other (Fedorov et al, 2009). Further 
analysis showed that the translation in the magnesium position is small (~0.2 - 
0.3 Å), when compared to unbound and bound PClP structures.  
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Figure 4.1: Dissimilarities in the allosteric binding site of PBP and PClP bound myosin motor 
domain structures.  (A) Close-up view of the superimposed binding site residues in the PClP 
structure (2XEL) and PBP structure (2JHR) in the pseudilin-binding pocket. (B) Close-up view of 
the superimposed PClP and PBP molecules in the allosteric binding pocket.  
4.1.2 PClP Induced Novel Allosteric Relay Mechanism 
Originally, allostery was defined as mere structural change between two states, 
which involves typical macromolecular conformational changes (Formaneck et al, 
2006; Gibriel & Doelle, 1975; Hope et al, 1975). Recently another mechanism of 
allostery surfaced that the plausible mechanism of allostery in some cases may 
operate by causing a shift of the protein to a different ensemble of conformations 
and this change may not be observable in an experimentally determined 3D 
structure (Cui & Karplus, 2008; Pan et al, 2000). A general model is presented in 
this work, whereby ligand-induced small changes in protein dynamics could 
produce allosteric communication between distinct binding sites, even in the 
absence of a macromolecular conformational change. In this study, Dd myosin-2 
does not undergo any major global conformational changes upon binding 
pentachloropseudilin. However, that does not rule the possibility of the presence 
of the allostery mechanism (Tsai et al, 2008). Allostery can be attributed to the 
scaffold shape, differences in electrostatic distribution and the presence & 
absence of catalytic water in the case of myosins (Figure 3.1.1.10 and 3.1.1.11). 
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Structural dissection of the pre-power stroke myosin structures in the presence 
and absence of PClP revealed the existence of a novel allosteric communication 
pathway between allosteric and nucleotide binding sites. A tight interaction 
network extended over a distance of 19 Å forming a direct link between PClP and 
the γ-phosphate position of ATP. Slight conformational changes observed in the 
rotamers of the allosteric relay path residues from the allosteric binding pocket, 
switch-1 and switch -2. However, the major difference between the PClP bound 
and unbound structures was the lack of catalytic water in the nucleotide-binding 
site. This catalytic water is present in the active site of the pre-power stroke state 
structures with bound ADP-VO3 (2JJ9), ATP-γ-S, (1MMG), ADP-AlF4 (1W9L), 
and mantADP-BeFx (1D1C) (Gulick et al, 2000; Gulick et al, 1997). Different 
theories have been proposed for the importance of this catalytic water as a 
nucleophile and γ-phosphate as the general base for the ATP hydrolysis (Li & 
Cui, 2004; Rayment et al, 1996). Hence, lack of catalytic water is coupled to the 
allosteric mechanism in the PClP bound structure. 
Further analysis of pseudilin bound structures revealed similar allosteric pathway 
in PBP bound (2JHR) and dichlorotribormospseudilin bound (2XO8) pre-power 
stroke state myosin motor domain structures. The major differences with the 
various pseudilin bound structures are the orientation of the allosteric effector in 
the binding pocket and also K265 conformational changes to interact with the 
pseudilin in the allosteric-binding pocket. The similarities comprise the same 
residues in the allosteric path as PClP and as a hallmark; catalytic water is 
absent in all these structures. 
In conclusion, allosteric effectors that target myosin motors with high affinity and 
specificity are key tools in cytoskeletal research. As described in the present 
work, the natural product PClP can be used as a potent and selective inhibitor of 
class-1 myosins in cell biological studies. The optical properties of the compound 
allow the direct observation of its binding interactions with myosins. Our detailed 
kinetic and structural analysis indicates that PClP is a non-competitive, reversible 
inhibitor of myosin motor activity that acts in part by reducing the coupling 
between the actin- and nucleotide-binding sites. Isoform-specific differences in 
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the potency of PClP-mediated inhibition can be rationalized by differences in the 
size and polarity of the allosteric binding pockets of myosin isoforms (Figure 4.1). 
In contrast to these differences in size and polarity, the residues involved in the 
relay pathway connecting the allosteric and active sites over a distance of 19 Å 
show a higher degree of conservation between myosin isoforms (Figure 4.2).  
Figure 4.2: Alignment of residues in the allosteric relay path in different myosin isoforms. This 
figure shows the residues in the allosteric path from PClP binding residues in helix 10 to the 
nucleotide-binding site. Residues colored in green are involved in the allosteric relay. Further, 
adjacent residues belonging to the same motif or secondary structure element are shown in grey 
color. 
This suggests that the same communication pathway plays an important role in 
coupling information between the actin-binding region and the nucleotide-binding 
site during normal, uninhibited catalytic ATP-turnover.  
4.2 Ammosamides as Allosteric Myosin Effectors 
Deep-sea sediments are rich sources of natural compounds. Ammosamides are 
one such compound isolated from the sediments of the deep sea.  Hughes et al. 
used a fluorescent-labeled probe, which is a conjugate of coupled ammosamide 
B with an acid, to verify the role of the ammosamides on cell cycle, cytokinesis 
and cell migration. Subsequent histological, confocal and mass-spectrometric 
studies indicated that marine compounds, such as ammosamides have profound 
role in inhibiting some of the class-2 myosins (Hughes et al, 2009a). However, 
these studies haven’t provided the details of the nature of inhibition and the mode 
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of binding to myosin.  
To carry forward, in this thesis, kinetic and structural studies on ammosamides 
were performed and the possible effect of ammosamides on Dd myosin-2 motor 
domain has been explained. Out of eight derivatives of ammosamides, only four 
of them have shown significant effect on myosin-2 motor domain. Steady-state 
ATPase assays with myosin motor domain in the presence of ammosamides 
have shown that the ammosamide 272 was more than 4 fold (IC50 = 17.2 µM) 
potent inhibitor compared to ammosamide B (IC50 = 72.4 µM). Similar results 
have been observed in the single-turnover experiments (Figure 3.1.2.3).  
In the absence of ammosamides, the time evolution of the reaction could be 
separated in three phases: an initial rise in mant fluorescence corresponding to 
binding of mantATP, a short, plateau phase determined by the rate of the 
conformational change that follows mantATP binding, and a drop in mant 
fluorescence corresponding to release and rebinding of mantADP (k
-4 + k+4). All 
three phases were extended in the presence of ammosamides. The extension of 
the plateau phase in the presence of ammosamides can be interpreted as the 
consequence of both slower mantATP hydrolysis and increased mantADP affinity.  
Crystallographic studies have shown that ammosamides preferentially bound to 
two allosteric sites in Dd myosin-2 motor domain. One of the binding sites of 
ammosamides is the pseudilin-binding site and the other one is adjacent to helix-
loop-helix. From crystallographic refinements, it was predicted that pseudilin-
binding site is the high affinity-binding site (occupancy 100 %) compared to the 
second binding site (occupancy 60-70 %). This different occupancy phenomenon 
was observed both in ammosamide 272 and ammosamide B crystal structures.  
However, the inhibiton of myosin motor activity possibly because of synergistic 
effect of the ammosamide in both binding sites.  
It was clear from the pseudilin bound myosin structures that an allosteric 
mechanism operates between the pseudilin binding site and the nucleotide-
binding site. As ammosamides bound in the same site, the possibility of allosteric 
relay mechanism can’t be ruled out (Chinthalapudi et al, 2011). The presence or 
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absence of the lytic water is crucial for the allosteric inhibitory relay path. 
However, the presence of ADP.VO4 in the crystallization trials not allowed any 
firm conclusions on the allosteric relay path as one of the oxygen from 
orthovanadate occupies the same position as the lytic water.   
Additionally, the presence of second binding pocket next to the helix-loop-helix 
and in close proximity to the relay helix may have an indirect effect on nucleotide 
binding and release kinetics (Figure 3.1.2.6). Single turnover experiments have 
shown that ammosamides may inhibit three phases of ATP binding, hydrolysis 
and ADP release kinetics of Dd myosin-2. Even though, the exact nature of the 
inhibition is not yet deciphered, it can be hypothesized that the synergistic action 
of ammosamides from two different allosteric binding sites in myosin motor 
domain is responsible for cumulative inhibitory effect on myosin motor activity. 
4.3 Pre-power Stroke State of Nonmuscle Myosin-2C 
This study has shown for the first time the crystal structure of “human” myosin 
motor domain. Comparison of the nonmuscle myosin isoforms: NM2A, NM2B 
and NM2C have shown >85 % sequence similarity in their motor domains. This 
indicates that nonmuscle myosin isoforms evolved from a common origin with 
alternative splicing as the major source of functional diversity (Kondrashov & 
Koonin, 2003). 
The pre-power stroke state of NM2C MD and its key features have been 
described in comparison with structures of chicken smooth muscle myosin 
(1BR4) and striated muscle myosin (1QVI) in the same conformational state. The 
main differences included the variation in the length of the surface loop-1, loop-2, 
loop-3 and Upper 50 kDa loops. In addition, the structural analysis showed 
striking conformational differences in the Upper-50 kDa loop and the structural 
elements of the Upper 50 kDa subdomain. Significant differences were described 
for loop-3 when compared to the conformations of other class-2 myosins, which 
can be attributed to both length and sequence composition. The loops mentioned 
above as well as the connecting secondary structures interact with each other 
and undergo coupled distortions. Highlighting a vast sequence variability and 
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composition among myosin isoforms and sequence variations in loop regions 
may likely allow kinetic tuning by altering the rates of transitions between kinetic 
states of the actomyosin ATPase cycle (Heissler et al, 2011; Kelley et al, 1993).  
To understand the kinetic and structural features of nonmuscle myosins is very 
important, not only in the viewpoint of molecular motors but also in the 
perspective of diseases, as NM2C was implicated in causing autosomal 
dominant hearing loss and other defects in auditive functions (Donaudy et al, 
2004). Also, other nonmuscle myosin-2 isoforms like NM2A and NM2B have 
been associated with giant-platelet disorders like May-Heggling anomaly and 
Fetchner syndrome (Althaus & Greinacher, 2009; Hu et al, 2002). Understanding 
the structural features of nonmuscle myosins and mapping their mutations 
specific to a particular disease will be of very significance in the future studies.  
4.4 Toxoplasma MHCs: MLCs Interaction  
TgMyoD is the smallest T.gondii MHC and is the closest relative to TgMyoA. It 
exhibits the same kinetic characteristics as TgMyoA (Herm-Gotz et al, 2006). 
These studies indicate that the orthologous proteins of apicomplexan MHCs or 
MLCs have similar kinetic features or structural features (Bosch et al, 2006). 
Hence, modeling and guiding the docking in the previously available 
experimental structural poses is very informative and reliable. Molecular docking 
studies predict that the MLC2 forms a tight clamp around the MyoD-tail helix and 
adopts a more closed and compact conformation than observed in the structures 
of other MLC–MHC complexes. Special features in both the light and heavy 
chains are contributing to this compactness and the uniqueness of the MLC2–
MyoD interface. The unique composition and the tight MLC2–MyoD interface 
make it an attractive target for the development of anti-coccidian drugs.  
Given the absence of the actin—myosin machinery in the human host and its 
remote homology to host myosin heavy chains, the myosin tail interacting protein 
(MTIP) in complex with the myosin heavy chain tail (Myosin-A/D-tail) is an 
attractive drug target. This is because human heavy myosins have distant 
homology, only 37 % identity, to apicomplexan myosin heavy chains. Also, this 
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holds true for MTIPs or MLCs of apicomplexans (27 % identity and 52 % 
similarity). Since, the MHCs (TgMyoD, TgMyoA and PfMyoA) are well conserved 
among apicomplexans (80 % to 85 % identity), it could also hypothesized to be a 
unique drug target in T.gondii or P.falciparum. In fact, recent studies indicated 
that apicomplexan MTIP-MHCs are suitable targets for drug discovery (Kortagere 
et al, 2011; Kortagere et al, 2010). Hence, small molecule compounds, which are 
designed to inhibit a specific protein–protein interaction, are expected to diminish 
the likelihood of acquired drug resistance by the parasite through permissible 
complementary mutations of interacting residues.  
4.5 Kinetic and Structural Characterization of Nonmuscle 
Myosin-2A Switch-2 Mutant A454S 
In the present work, the question how evolutionary conserved mutations within 
the conserved switch-2 region of class-2 myosins alter their kinetic properties 
was addressed. Therefore, human NM2A was chosen as a model system to 
study the effect of the A454S mutation on the kinetic properties of the enzyme. In 
vitro steady-state and transient-state kinetic techniques in combination with in 
silico modeling approaches were combined to interpret the obtained data. 
The kinetic parameters of the extensive kinetic analysis of both proteins are listed 
in Table 29. The comparison of the steady-state and transient kinetic features of 
NM2A Wt and A454S indicate, that A454S inhibits normal motor functions, as 
expected from the fact that the residue is not conserved among myosins and that 
serine occupies the analogue position in the switch-2 region of other myosins like 
Dd myosin-2 (Sasaki et al, 1998). Main kinetic difference between the two 
myosin motors is a reduced ATP turnover under steady-state conditions, both, in 
the absence and presence of F-actin. Interestingly, the extent to which F-actin 
can increase the basal ATPase activity under steady-state conditions, kbasal, is 
equal. These findings indicate, that the A454S comprises the intact capability to 
bind F-actin and hydrolyze ATP, even though neither the rates of nucleotide 
binding, hydrolysis nor product release are reduced (Nagy et al, 2010). 
Discussion 
 
146 
 
To further investigate which kinetic step in the ATPase cycle is influenced by the 
switch-2 mutation A454S, transient kinetic stopped-flow assays were performed.  
The kinetic parameters for ATP-binding to myosin and actomyosin indicate 
slightly elevated binding rate constants for A454S when compared to Wt. 
Mutation-induced changes were observed for the equilibrium constant for ATP-
binding (1/K1) and the ATP hydrolysis (k+3+k-3). Since the both kinetic steps, ATP 
binding and hydrolysis are much faster than the steady-state turnover, they do 
not rate-limit the steady-state cycling rate. 
ADP kinetics in the presence of F-actin implicate, that A454S binds the 
nucleotide with the same speed as the Wt, whereas the release rate is 4-5 times 
slower than in the Wt motor. The calculation of the dissociation equilibrium 
constants for ADP binding indicates that A454S exhibits a 5-fold increased ADP 
affinity than the native motor. Both, Wt and switch-2 mutant show a weak or no 
enhancement of the ADP release by F-actin (k
-AD/k-D). Correspondingly, the 
thermodynamic coupling constant KDA/KD is low and 10 decreased for A454S in 
comparison to Wt. The Mg2+-dependence of the actin-activated ADP release 
rates indicate, that both NM2A and A454S show a magnesium-sensitive product 
release as already described for NM2C (Heissler & Manstein, 2011).  
Previous studies of Rosenfeld et al. conclude that a fast release of Mg2+ implies 
an accelerated ADP release and that Mg2+ would leave the nucleotide-binding 
pocket prior to ADP (Rosenfeld2005). These findings are supported by structural 
studies on myosin-5, revealing a structure with ADP weakly bound and without 
magnesium bound in the nucleotide-binding pocket (Coureux et al, 2004; 
Rosenfeld et al, 2005).  
These findings support the structural analysis of the nucleotide-binding pocket of 
homology models of NM2A Wt and A454S in order to explain the decreased 
actin-activated ADP release rates of A454S and the magnesium-sensitivity of 
both myosin motors. Although the homology models represent the nucleotide-
binding pocket in the actin-detached state, it is assumed that the main features 
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resemble those of the actomyosin•ADP state from which ADP is released (Nagy 
2010).  
The structural analysis attributes the reduced ADP release rates in A454S to the 
formation of an ideal hydrogen bond between S454 with the backbone atoms of 
the residues S233 and F235 in the switch-1 loop. In addition, S233 coordinates 
to the Mg2+ ion. The additional hydrogen bonds might interfere with the coupling 
of switch-1 and switch-2 movements accompanying the Mg2+ release (Nagy 
2010). This hypothesis is supported by an accompanying paper from Fujita-
Becker et al (Fujita-Becker et al, 2005) suggesting that the interactions of the 
Y439, equivalent to S454 in NM2A, hydroxyl-moiety may be important for 
controlling Mg2+-dependent ADP release in myosin-1.  
This interference with the movement of switch-1 and -2 by the additional 
hydrogen bond in A454S results in reduced Mg2+ release rates which can be 
directly linked to a decreased nucleotide release rate and an increased ADP 
affinity. Since the Mg2+ coordination by the residues N231, T181 and S233 is 
equal in both nucleotide-binding pockets, the magnesium-sensitivity remains 
conserved in both motors. Hence, the decrease of the ADP release rate 
constants with increasing concentrations of Mg2+ can be directly explained by 
simple mass action (Heissler & Manstein, 2011).  
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Table 29: Summary of Hs NM2A and its switch-2 mutant kinetic analysis 
Parameter Signal or 
calculation 
NM2A-Wt NM2A-A454S 
Steady-state ATPase 
activity 
   
kbasal [s-1] NADH Assay 0.013±0.001 0.004±0.002 
vmax [s-1] NADH Assay1 0.11±0.01 0.04±0.004 
Kapp [µM] NADH Assay >140 >140 
vmax/ Kapp [µM-1s-1] vmax/ Kapp1 ~0.0008 ~0.0003 
ATP interaction    
K1k+2 [µM-1s-1] Tryptophan 0.39±0.01 0.77±0.03 
K1k+2 [µM-1s-1] mantATP 0.86±0.02 1.00±0.02 
1/K1 [µM] Tryptophan 78.09±10.08 167.04±17.72 
k+3+k-3 [s-1] Tryptophan 44.85±1.36 174.88±5.27 
K1k+2 [µM-1s-1] Pyrene-actin 0.26±0.04 0.24±0.04 
K1k+2 [µM-1s-1] mantATP 0.11±0.01 0.27±0.02 
1/K1 [µM] Pyrene-actin 643.68±126.95 502.76±112.09 
ADP interaction    
k+D [µM1s-1] mantADP  4.29±0.28 2.71±0.04 
k
-D [s-1] mantADP2 0.68±0.09 0.77±0.05 
 mantADP3 0.38±0.01 0.54±0.02 
 Tryptophan3 0.34±0.01 0.47±0.03 
KD [µM]  k-D/k+D 0.16±0.03 0.28±0.02 
k
-+AD [µM-1 s-1] mantADP 4.92±0.09 5.52±0.11 
k
-AD [s-1] mantADP2 1.69±0.25 0.41±0.31 
 mantADP3 2.39±0.21 0.52±0.05 
Ki [Mg2+] (mM) mantADP3 0.45±0.09 1.17±0.39 
KAD [µM] k-AD/k+AD 0.34±0.06 0.07±0.06 
Coupling KDA/KD ~2.1 ~0.25 
ADP release rate 
enhancement by F-actin 
k
-AD/k-D ~2.5-7 ~0.53-1.1 
F-Actin interaction    
k+A [µM-1s-1] Pyrene-actin 0.96±0.02  1.03±0.23 
k
-A [s-1] Pyrene-actin ~0.00019 ~0.00024 
KA [µM]  Pyrene-actin ~0.0002 ~0.0002 
k+DA [µM-1s-1] Pyrene-actin 0.19±0.004  0.80±0.04  
k
-DA [s-1] Pyrene-actin 0.04±0.002 ~0.07±0.004 
KDA [µM]  Pyrene-actin ~0.21 ~0.08 
1
 at 140 µM F-actin, the highest F-actin concentration that was experimentally accessible  
2
 From the intercept of the kobs versus mantADP plot 
3 From ATP chasing experiment
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